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General introduction and outline
INTRODUCTION
Diabetes mellitus and hypertension disease are important public health problems with a 
worldwide increasing prevalence. The global prevalence of diabetes rises from 2.8% in 2000 
to 4.4% in 2010 (1). Diabetes and hypertensive patients have a signifi cantly increased risk of 
cardiovascular disease like myocardial infarction, stroke and of cardiovascular death due to 
not totally unraveled pathophysiological mechanisms. Recent advances in knowledge have 
contributed to the understanding of the increased cardiovascular disease risk in these high 
risk populations by assigning a role for changes in the wall of the aorta (2,3).
The aorta is a complex organ originating from the heart and passing blood to all end-
organs. Importantly the aorta is an elastic tube with a capacity to distend and recoil in re-
sponse to high pulsatile fl ow resulting from cardiac contraction. Herewith, the aorta has the 
capacity to reduce cardiac afterload and to facilitate continuous perfusion of the end-organs.
Intrinsic aortic wall abnormalities have been described in diabetes due to high glucose 
levels resulting in formation of advanced glycation end products which crosslink to collagen 
in the aortic vessel wall (4). In patients with hypertension, continuous hemodynamic stress 
at the aortic wall leads to structural and functional changes in the arterial wall (5). Possibly, 
arterial stiff ness and endothelial dysfunction precede the presence of clinical hypertension 
(6). Infl ammatory mechanisms and formation of atherosclerosis also play an important role in 
aortic wall changes in diabetes and hypertension (2). These complex heterogeneous mecha-
nisms result in degeneration of the aortic vessel wall, leading to reduced aortic elasticity.
Stiff ening of the aorta may initiate a negative cascade aff ecting the heart and all other 
end-organs. As a consequence of aortic stiff ness, cardiac remodeling, compromised perfu-
sion of the coronary arteries, and subsequently diastolic and systolic cardiac dysfunction 
may occur, which may ultimately lead to heart failure and cardiac death (7). Furthermore, 
stiff ness of the central large arteries results in a defi cient absorption of the pulse wave and 
an increase in central pulse pressure. This high pulsatile fl ow is transmitted from the aorta 
to all end-organs like the brain and kidneys causing damage to the endothelial and smooth 
muscle cells, disrupting the cerebral and renal arterioles. Also, aortic stiff ness may represent 
systemic endothelial dysfunction or wall thickening caused by shared underlying mecha-
nisms. Numerous recent reports emphasize the importance of aortic stiff ness as a prognostic 
indicator for future cardiovascular disease and mortality in diabetes (8,9) and hypertensive 
patients (10).
Aortic stiff ness can be assessed by means of pulse wave velocity (PWV) measurements (11). 
PWV is defi ned as the velocity of the systolic pulse wave front propagating through the aorta, 
refl ecting the elastic properties of the aortic vessel wall. During the last decades, Magnetic 
Resonance Imaging (MRI) has emerged as a reliable, accurate, ionizing radiation-free modal-
ity for a general evaluation of anatomy and function of the heart, brain and vessels. MRI has 
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also been established as a non-invasive accurate tool for assessment of aortic stiff ness by 
measuring aortic PWV (12).
In this thesis, subclinical end-organ damage of the heart, brain and kidneys and their 
relationship with aortic stiff ness will be assessed using a comprehensive MRI evaluation in 
diabetes mellitus and hypertensive patients.
Furthermore, new developments in high magnetic fi eld MRI, with the introduction of hu-
man 7 Tesla MRI scanners, potentially contribute to imaging of end-organ damage at early 
stages of disease. In the fi nal two chapters of this thesis, development of coronary magnetic 
resonance angiography (MRA) at high fi eld 7 Tesla MRI is described, relevant for studying 
coronary artery disease with subsequent myocardial ischemic and functional end-organ 
damage. Coronary artery disease remains the leading cause of death for men and women in 
the Western world (13). The technique of coronary MRA, most commonly applied at 1.5 Tesla 
MRI, remains challenging due to the small diameter of the coronary arteries and cardiac and 
respiratory motion, and is not yet routinely applicable as a clinical diagnostic tool.
The current gold standard for the diagnosis of hemodynamically signifi cant coronary 
artery disease is x-ray coronary angiography. X-ray coronary angiography, however, has a few 
disadvantages. A small but signifi cant risk of complications has been reported and these are 
related to the invasive nature of the procedure, radiation exposure and the use of iodinated 
contrast agents (14). In addition, up to 40% of patients who undergo invasive x-ray coronary 
angiography are found to have no signifi cant coronary artery lumen stenosis (15). For these 
reasons, there is a strong need for an alternative technique that is noninvasive, more cost 
eff ective, and which can provide not only information about the vessel lumen but also about 
the vessel wall and myocardial condition, without the need for ionizing radiation and neph-
rotoxic contrast agents.
MRI systems with higher fi eld strengths enable imaging with increased signal-to-noise 
ratio, allowing improved spatial resolution, improved temporal resolution and/or reduced 
scanning times (16-18). Individually or in combination, these improvements are likely to result 
in improved image quality, and ultimately better access to small diameter and branching ves-
sels. High fi eld coronary MRA is therefore a promising tool for the non-invasive identifi cation 
of signifi cant proximal coronary artery disease without the use of ionizing radiation (19,20).
Because of the large resonance frequency increase going from low 1.5 and 3 Tesla to high 7 
Tesla magnetic fi eld strength MR, considerable technical challenges are expected for cardio-
vascular studies at 7 Tesla to account for the increased magnetic fi eld inhomogeneities. In the 
studies performed for this thesis, we show the implementation and the benefi ts of imaging 
coronary MRA at 7 Tesla.
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OUTLINE OF THIS THESIS 
This thesis evaluates MRI assessed end-organ damage, and the role of aortic pulse wave ve-
locity in diabetes and hypertensive patients. In addition, the application and implementation 
of innovative MR techniques will be discussed.
Chapter 2 studies the independent and contributive eff ect of diabetes mellitus and hyper-
tension on aortic pulse wave velocity. In chapter 3 the infl uence of aortic pulse wave velocity 
on cardiac and cerebral MR fi ndings is evaluated in hypertensive patients. In chapter 4 a 
similar evaluation regarding the eff ect of aortic pulse wave velocity on cardiac and cerebral 
MR fi ndings is assessed in type 1 diabetes mellitus patients. Chapter 5 describes a role of 
aortic pulse wave velocity in renal function of type 1 diabetes mellitus.  Chapter 6 shows two 
separate vascular mechanisms; cerebral perfusion and aortic pulse wave velocity, being re-
lated to white matter brain atrophy in type 1 diabetes mellitus. Chapter 7 reports accelerated 
progression of brain atrophy with cognitive consequences in elderly type 2 diabetes mellitus 
patients. Chapter 8 evaluates the metabolic eff ect of diabetes mellitus on the skeletal muscle 
in patients carrying a mitochondrial mutation, present in approximately 1% of all diabetes 
patients, using the MR Phosphorus-Spectroscopy technique. Chapter 9 shows feasibility of 
imaging techniques to perform coronary imaging at 7 Tesla MR fi eld strength. In chapter 
10 a fi rst comparison study of coronary MR angiography at 7 Tesla in healthy volunteers is 
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The aim of our study was to investigate in type 1 diabetes mellitus (DM) patients the role of 
hypertension and of type 1 DM itself on aortic stiff ness by using magnetic resonance (MR) 
imaging.
Materials and Methods 
Consecutive patients from the diabetes and hypertension outpatient clinic and healthy 
volunteers were included in our study. Subjects were divided into four groups: 32 healthy 
volunteers (mean age: 54.5 ± 6.8 years), 20 type 1 DM patients (mean age: 48.3 ± 5.9 years), 31 
hypertensive patients (mean age: 59.9 ± 7.2 years) and 28 patients with both type 1 DM and 
hypertension (mean age: 50.1 ± 6.2 years). Aortic stiff ness was measured by means of pulse 
wave velocity (PWV) using velocity-encoded MR imaging. Analysis of variance (ANOVA), uni- 
and multivariable regression models and the Bonferroni-test for multiple testing, were used 
for statistical analyses.
Results
Mean aortic PWV was 5.7 ± 1.2 m/s in healthy volunteers, 5.9 ± 1.2 m/s in type 1 DM patients 
without hypertension, 7.3 ± 1.2 m/s in hypertensive patients and 7.3 ± 1.3 m/s in type 1 DM 
patients with hypertension. Compared to healthy control subjects, aortic PWV was signifi -
cantly higher in patients with hypertension (p<0.001) and in type 1 DM patients with hyper-
tension (p<0.001), whereas aortic PWV was not increased in patients having type 1 DM alone. 
Furthermore, aortic PWV was signifi cantly higher in type 1 DM patients with hypertension 
than in patients with type 1 DM alone (p=0.002). These fi ndings remained after adjustment 
for confounding factors.
Conclusion
Hypertension has a predominant contributive eff ect on aortic stiff ness in type 1 DM patients 
whereas the direct diabetic eff ect on aortic stiff ness is small.
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INTRODUCTION 
Increased aortic stiff ness is an important risk factor for adverse cardiovascular outcome in 
various disease states including diabetes mellitus (DM) (1-3). Studies have demonstrated that 
aortic stiff ness is increased in patients with particularly type 2 DM (1,4). However, type 2 DM 
is commonly associated with other classical risk factors such as obesity, abnormal lipid status 
and hypertension that also may aff ect aortic stiff ness (1,5-7). 
Cardiovascular risk profi les in patients with type 1 DM usually diff er from that in patients 
with type 2 DM, but similar fi ndings with respect to increased aortic stiff ness have been found 
(3,8-13). A magnetic resonance (MR) imaging study has recently shown that aortic stiff ness is 
associated with cerebrovascular and cardiovascular end-organ damage in type 1 DM patients 
(3). In these type 1 DM patient studies, the increase in aortic stiff ness was relatively minor as 
compared to other patient groups, such as in patients with type 2 DM and in patients with 
hypertension (2,3,14,15). Also, in type 1 DM patients increased aortic stiff ness has been mea-
sured in young type 1 DM patients or in type 1 DM patients with microvascular complications 
(2,8-13). Therefore, it is conceivable that like in type 2 DM patients, confounding factors may 
play a dominant role in aortic stiff ness of type 1 DM patients as well.
A recent systematic review on aortic stiff ness risk factors has demonstrated that age and 
hypertension are major and independent risk factors for aortic stiff ness, while the associa-
tion between DM (particularly type 2 DM), obesity and abnormal lipid profi les with aortic 
stiff ness were found moderate (16). The hypothesis of our study is that hypertension also 
has a predominant eff ect on aortic stiff ness in type 1 DM patients. To what extent type 1 DM 
itself independently adds to aortic stiff ness remains to be established. Having knowledge of 
dominant factors aff ecting aortic stiff ness in type 1 DM patients may be of value in guiding 
therapy, which is relevant considering the increased cardiovascular risk status in type 1 DM 
patients with increased aortic stiff ness. 
A widely used parameter expressing aortic stiff ness is the pulse wave velocity (PWV), which 
is defi ned as the propagation speed of the pressure or fl ow wave front traveling along the 
aorta (17). PWV is estimated by dividing the distance between anatomical locations in the 
aorta  by the time diff erence between the fl ow waves at the two locations that can be ac-
curately measured with MR imaging (18).
The purpose of our study was to investigate in type 1 DM patients the role of hypertension 





This study was approved by the local medical ethics committee and all subjects gave in-
formed consent to participate in the study. Consecutive patients, diagnosed with type 1 
DM and essential hypertension, from the diabetes and hypertension outpatient clinic were 
eligible in our study. Healthy volunteers were also eligible and recruited by advertisement in 
local newspapers. All subjects were within the age range of 40-70 years and underwent MR 
imaging of the aorta between January 2005 and October 2009. 
Subjects were divided into 4 subgroups based on the following criteria: group 1, healthy 
volunteers (n=32); group 2, patients with type 1 DM (n=20); group 3, patients with hyperten-
sion (n=27); group 4, patients with both type 1 DM and hypertension (n=28). The eff ect of 
type 1 DM and hypertension on aortic stiff ness was investigated by comparing aortic PWV 
measurements between the groups. 
Type 1 DM was defi ned as fasting blood glucose ≥ 7.0 mmol/l according to WHO criteria 
(19). Hypertension was defi ned as: systolic blood pressure > 140 mmHg and/or diastolic 
blood pressure > 90 mmHg, on repeated physical examination before antihypertensive 
therapy was instituted and according to criteria of the European Society of Hypertension 
(ESH) (20), or blood pressure above 140/90 mmHg at time of MR imaging. All diabetic pa-
tients were on treatment with insulin and all hypertensive patients were on treatment with 
antihypertensive medication. Blood pressure was measured at the time of MR imaging using 
a semi-automated sphygmomanometer (Dinamap, Critikon, Tampa, Florida, USA). Pulse pres-
sure was defi ned as: systolic blood pressure–diastolic blood pressure. Furthermore, smoking 
status (i.e. non-smoker or current smoker), body mass index (BMI), glycated hemoglobin 
(HbA1c), total cholesterol, the cholesterol to high-density lipoprotein (Cholesterol/HDL) 
ratio, triglycerides and C-reactive protein were determined. Blood was drawn in the morning 
after an overnight fast within two weeks before MR imaging. The albumin excretion ratio was 
calculated using the microalbumin and creatinin concentrations in the urine. 
Healthy volunteers underwent similar work-up as type 1 DM or hypertensive patients. 
Healthy volunteers did not comprise subjects with type 1 DM, hypertension, cardiovascular 
disease, left ventricular hypertrophy as evaluated by means of electrocardiography or MR 
imaging or any systemic disease.
Exclusion criteria comprised of known history of cardiovascular disease, evidence of aortic 
valve stenosis or insuffi  ciency, as evaluated by means of physical examination and velocity-
encoded MR imaging, Marfan syndrome, aortic coarctation or any aortic disease, known 
history of other systemic diseases than type 1 DM or hypertension and general contraindica-
tions to MR imaging. 
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MR imaging protocol
Aortic PWV was assessed using a 1.5-T MR imaging scanner (NT 15 Gyroscan Intera; Philips 
Medical Systems, Best, the Netherlands) as previously described (18). In short, fi rst a longi-
tudinal image of the aorta was acquired during a breath-hold using a segmented gradient-
echo sequence. Scan parameters were: repetition time (TR) 4.0ms, echo time (TE) 1.05ms, 
fl ip angle (FA) 30o, fi eld-of-view (FOV) 450mm, 128×128 acquisition matrix, reconstructed 
to 256×256, slice thickness 15mm and 2 number of signal averaged (NSA) using a fi ve-
element phased array cardiac surface coil. Then, a retrospectively electrocardiographic-gated 
gradient-echo sequence with velocity encoding perpendicular to the aorta was applied to 
measure through-plane fl ow at two predefi ned levels: 1) at the level of the ascending aorta 2) 
at the level of the distal abdominal aorta. Scan parameters were: TR 5.0 ms, TE 2.9 ms, FA 20o, 
FOV 300 mm, 128×115 acquisition matrix, reconstructed to 256×256, slice thickness 8mm 
with maximal number of phases reconstructed ensuring high (6-10 ms) temporal resolution. 
Maximum velocity encoding (Venc) was set to 150 cm/s at the ascending aorta level and 100 
cm/s at the abdominal aorta level, respectively.
Image analysis
PWV was calculated using the following formula: Δx/Δt (m/s), where Δx describes the 
distance between the ascending aorta and the distal abdominal aorta and Δt describes 
the transit time between the arrival of the pulse wave at these respective sites. The aortic 
path length between the measurements sites was determined from a centerline manually 
positioned along the aorta using the software package MASS (Medis) (21). Aortic velocity 
maps were analyzed using the in-house developed software package FLOW (Medis) (21). The 
onset of the systolic wave front was automatically determined from the resulting fl ow graph 
by the intersection point of the constant diastolic fl ow and upslope of the systolic wave front, 
modeled by linear regression along the steepest part of the upslope. 
Manual contour drawing in the aorta velocity maps was performed by two researchers 
(A.B. and S.v.E, both 3 year experience in cardiac MR imaging) and supervised by a senior 
researcher (J.W. 15 years experience in cardiac MR imaging), all unaware of the subjects’ 
conditions. 
Statistical analysis
Statistical analysis was performed using SPSS for Windows (version 17.0; SPSS, Chicago, Il-
linois, USA). Data are expressed as mean ± standard deviation (sd) unless stated otherwise. 
Aortic PWV data were non-normally distributed and further analyses were performed using 
the log-transformed PWV data. Analyses of variance (ANOVA) were used to calculate the 
diff erences between the groups concerning aortic PWV and continuous variables. The chi-
square test was used to calculate the diff erence in dichotomous variables between groups. 
Pearson and Spearman correlation analyses were performed to analyze the association 
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between aortic PWV and continuous and dichotomous variables, respectively. Pearson or 
Spearman correlation coeffi  cients (r) and p-values are reported.
Univariable and multivariable regression models were used to correct for possible con-
founding factors. Age and sex were considered as standard confounding factors. Further-
more, clinical and laboratory variables that were statistically signifi cantly diff erent between 
groups (i.e. with ANOVA) and were related to outcome (i.e. with aortic PWV in Pearson or 
Spearman correlation analyses) were considered as confounding factors. 
To estimate the eff ect of type 1 DM, hypertension, and type 1 DM with hypertension on 
aortic PWV, healthy volunteers were used as the reference category. To estimate the addi-
tional eff ect of type 1 DM or hypertension on aortic PWV, type 1 DM patients with hyperten-
sion were used as the reference category. Overall p-values and mean ± standard errors (se) 
are reported. The Bonferroni-test was used to correct for multiple testing.  A p < 0.05 was 
considered statistically signifi cant.
RESULTS
Clinical characteristics
Table 1 describes the clinical characteristics of the study population per subgroup. Age was 
signifi cantly higher in healthy volunteers and in patients with hypertension as compared to 











Age (years) 54.5 ± 6.8 48.3 ± 5.9 59.9 ± 7.2 50.1 ± 6.2 <0.001
Male gender, n (%) 24 (75) 8 (40) 10 (37) 15 (54) ns
Systolic blood pressure 
(mmHg)
118 ± 11 120 ± 10 165 ± 18 141 ± 19 <0.001
Diastolic blood pressure 
(mmHg)
76 ± 9 69 ± 7 96 ± 13 76 ± 10 <0.001
Pulse pressure (mmHg) 42 ± 12 51 ± 9 69 ± 19 64 ± 15 <0.001
Smoking yes, n (%) 4 (13) 2 (10) 5 (19) 5 (18) ns
Body mass index (kg/m2) 26.9 ± 3.0 24.4 ± 2.1 26.0 ± 4.7 26.5 ± 3.4 ns
HbA1c (%) 5.4 ± 0.2 7.0 ± 1.0 5.2 ± 0.3 7.8 ± 1.0 <0.001
Cholesterol (mmol/l) 5.3 ± 0.9 4.5 ± 0.7 5.6 ± 1.0 4.9 ± 1.0 0.001
Cholesterol/HDL ratio 
(mmol/l)
3.7 ± 1.0 2.8 ± 0.6 3.7 ± 1.1 3.2 ± 1.0 0.003
Triglycerides (mmol/l) 1.1 ± 0.5 0.9 ± 0.3 1.4 ± 0.4 1.6 ± 1.0 <0.001
C-reactive protein (mg/l) 1.9 ± 1.8 1.6 ± 1.5 2.4 ± 2.7 2.7 ± 3.7 ns
Microalbuminuria (mg/l) 1.5 ± 2.1 1.0 ± 1.5 2.3 ± 4.4 1.8 ± 3.2 ns
Values are mean ± SD or n (%) or data are numbers of patients and numbers in parentheses are percentages. 
DM1: type-1 diabetes mellitus patients; HbA1c: Glycated hemoglobin; HDL: high density lipoprotein. ns: non-
signifi cant.
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type 1 DM patients with and without hypertension. The group of healthy volunteers com-
prised of a higher male/female ratio than the other groups. Systolic blood pressure, diastolic 
blood pressure and pulse pressure were inherently increased in the hypertensive groups. 
HbA1c was inherently higher in the groups including type 1 DM patients. Furthermore, lipid 
profi les were diff erent between groups.
Association between aortic PWV and clinical and laboratory parameters 
Aortic PWV was signifi cantly associated with age (r=0.4, p<0.001), systolic blood pressure 
(r=0.5, p<0.001), diastolic blood pressure (r=0.3, p=0.002), pulse pressure (r=0.4, p<0.001) 
and triglycerides (r=0.2, p=0.012). As pulse pressure is a resultant of systolic blood pressure 
minus diastolic blood pressure, pulse pressure was considered as a confounding factor, 
whereas systolic and diastolic blood pressure were not. Sex, smoking status, BMI, HbA1c, lipid 
status, C-reactive protein and microalbuminuria did not correlate with aortic PWV. 
Independent and combined eff ect of type 1 DM and hypertension on aortic PWV
Mean aortic PWV was 5.7 ± 1.2 m/s in healthy subjects, 5.9 ± 1.2 m/s in type 1 DM patients, 7.3 
± 1.2 m/s in hypertensive patients without DM and 7.3 ± 1.3 m/s in type 1 DM patients with 
hypertension. Table 2 describes the uni- and multivariable regression models for assessment 
of the independent and combined eff ect of type 1 DM and hypertension on aortic stiff ness, 
before and after correction for confounding factors.
Table 2. Diff erence in aortic PWV between subgroups before and after correction for confounding factors
Uncorrected model Model corrected for 
age and sex
Model corrected for 
age, sex,
pulse pressure and 
triglycerides
Reference category Subgroup p-value p-value p-value
a. Healthy volunteers
DM1 patients 0.528 0.058 0.198
Hypertensive patients < 0.001* < 0.001* <0.001*
DM1 patients with 
hypertension 
< 0.001* < 0.001* <0.001*
b. DM1 patients with 
hypertension 
Hypertensive patients 0.665 0.668 0.668
DM1 patients 0.002* 0.030* 0.228
a. healthy volunteers serve as the reference category b. DM1 patients with hypertension serve as the reference 
category. DM1: type-1 diabetes mellitus patients. * p-value < 0.05.
Without correction for confounding factors, aortic PWV was statistically signifi cant higher 
in patients with hypertension (p<0.001) and in patients with both type 1 DM and hyperten-
sion (p<0.001), but not in patients having only type 1 DM (p=0.528) as compared to healthy 
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volunteers (Table 2a). Furthermore, aortic PWV was statistically signifi cantly higher in type 1 
DM patients with hypertension as compared to type 1 DM patients (p=0.002), whereas aortic 
PWV was not statistically signifi cantly diff erent between type 1 DM patients with hyperten-
sion and hypertensive patients (Table 2b). 
After correction for standard confounding factors age and sex, the diff erences in aortic 
PWV remained comparable between groups (Table 2). Mean aortic PWV was 5.4 ± 1.0 m/s in 
healthy subjects, 6.3 ± 1.1 m/s in type 1 DM patients, 7.2 ± 1.0 m/s in hypertensive patients and 
7.3 ± 1.0 m/s in type 1 DM patients with hypertension. Figure 1 shows the diff erence between 
the groups regarding aortic PWV corrected for age and sex; having type 1 DM alone does not 
statistically signifi cant aff ect aortic PWV as compared to healthy volunteers, although a slight 
trend for increased aortic PWV in type 1 DM patients as compared to healthy volunteers can 
be observed. Conversely, hypertension has a major eff ect in increasing aortic PWV (Figure 1). 
After correction for age, gender, pulse pressure and triglycerides mean aortic PWV was 5.6 
± 1.1 m/s in healthy subjects, 6.4 ± 1.1 m/s in type 1 DM patients, 7.1 ± 1.0 m/s in hypertensive 
patients without diabetes and 7.2 ± 1.0 m/s in type 1 DM patients with hypertension. Ad-
ditionally correcting for pulse pressure and triglycerides as confounding factors, had eff ect 
on the diff erence in aortic PWV between type 1 DM patients with hypertension and patients 
having only type 1 DM, which was no longer statistically signifi cant diff erent from each 
other (Table 2b). This was expected because pulse pressure and triglycerides are inherently 
increased in subgroups with type 1 DM and hypertension; by correcting for these confound-
ers group outcomes were equalized. 



































Abbreviations: V : Healthy volunteers; DM1: type-1 diabetes mellitus patients; HT: hypertensive patients; DM1HT: 
type-1 diabetes mellitus patients with hypertension. Means ± se per subgroup are given and p-values between 
subgroups are presented below. ns: non-signifi cant.
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DISCUSSION
We investigated the independent and combined eff ect of type 1 DM and hypertension on 
aortic stiff ness by comparing four subgroups including type 1 DM patients with and without 
hypertension, hypertensive patients and healthy volunteers by using MR imaging. The main 
fi nding was that the independent eff ect of type 1 DM on aortic PWV was minor; aortic PWV 
was not signifi cantly diff erent between healthy volunteers and type 1 DM patients. In addi-
tion, no diff erences were found in aortic PWV between type 1 DM patients with hyperten-
sion and hypertensive patients that remained after correction for confounding factors age, 
gender, pulse pressure and triglycerides. Secondly, the independent eff ect of hypertension 
on aortic PWV was major; aortic PWV was signifi cantly higher in hypertensive patients than 
in healthy volunteers. In addition, the combination of type 1 DM and hypertension resulted 
in increased aortic stiff ness, and was signifi cantly higher than in patients having type 1 DM 
alone, that remained after correction for age and sex. 
Previous studies have demonstrated increased aortic stiff ness in type 1 DM patients with 
microvascular complications including microalbuminuria or hypertension as compared to 
healthy volunteers (2,8-13). Age and hypertension are well-established risk factors of aortic 
stiff ness and hypertension is often present in type 1 DM. It is therefore conceivable that 
multiple factors may contribute to aortic stiff ness in type 1 DM patients. We investigated 
the eff ect of type 1 DM itself on aortic PWV by evaluating a fairly well-controlled, uncom-
plicated type 1 DM patient group with an age range between 40-70 years old. In type 1 DM 
patients, aortic stiff ness was not signifi cantly diff erent from healthy volunteers although a 
trend towards increased aortic stiff ness was observed after correction for age and sex. When 
comparing subgroups, triglycerides and pulse pressure were inherently increased in patients 
with hypertension. Therefore, after additional correction for triglycerides and pulse pressure, 
diff erences between type 1 DM patients with hypertension and patients having type 1 DM 
alone became non-signifi cant, that was explained by equalizing subgroups.
Hypertension is a well-known major and independent risk factor for aortic stiff ness (16,22), 
that was also found in our study. Investigating the hypertensive contribution on aortic stiff -
ness in patients with type 1 DM is relevant for cardiovascular risk assessment, as type 1 DM is 
often associated with hypertension, especially in the elderly (2,16). Age and blood pressure 
have consistently been shown to be independently associated with PWV (16). The impact of 
hypertension on aortic stiff ening may be twofold: 1. mechanistic stretching of the arterial 
wall may result in aortic stiff ening; 2. structural changes of the arterial wall due to cyclic 
stress, resulting in stress fracturing of elastin and consequent stiff ening (16,23). In contrast 
to the predominant eff ect of hypertension on aortic stiff ening, only weak correlations have 
been shown with diabetes, accounting for a mean of 5% of the variation in PWV (16). It is 
generally believed that increased aortic stiff ness plays an important role in the pathway link-
ing various diseases, including type 1 DM, with their increased cardiovascular risk (1,2). We 
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have now demonstrated that aortic stiff ness in type 1 DM patients mainly depends on having 
additional hypertension, and not on type 1 DM alone. Thus, identifi cation of hypertension in 
patients with type 1 DM is of importance for risk stratifi cation and may be used for stratifying 
therapy as to improve cardiovascular outcome.
Some study limitations are addressed. This study has a cross-sectional design. Therefore, 
direct causative mechanisms of the eff ect of type 1 DM itself and of hypertension cannot 
be determined. Follow-up studies are required for further evaluation of the role of type 1 
DM and hypertension on aortic stiff ness. From our study design with four subgroups it was 
diffi  cult to exactly age- and gender match all patients and volunteers. Therefore, multivari-
able regression models were used to account for possible confounding factors, including 
age. After correction for age and sex the diff erences in aortic PWV remained comparable 
between subgroups. 
In conclusion, hypertension has a predominant contributive eff ect on aortic stiff ness in 
type 1 DM patients whereas the direct diabetic eff ect on aortic stiff ness is small. As aortic 
stiff ness and type 1 DM are highly associated with adverse cardiovascular outcome, identify-
ing hypertension in type 1 DM patients seems highly relevant for risk stratifi cation. 
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Association of aortic arch pulse wave 
velocity with left ventricular mass 
and lacunar brain infarcts in hypertensive 
patients: assessment by MR imaging
A Brandts, SGC van Elderen, JJM Westenberg, J van der Grond, 






To assess the possible association between aortic arch stiff ness, which may cause hyperten-
sive cardiovascular disease, and cardiac and cerebral end-organ damage in patients with 
hypertension by using magnetic resonance (MR) imaging. 
Materials and Methods 
Approval from the local institutional review board was obtained, and patients gave informed 
consent. Fifty patients with hypertension (31 women and 19 men; mean age ± standard de-
viation, 49.2 ± 12.7 years; mean systolic blood pressure, 152.1 ± 22.3 mmHg; mean diastolic 
blood pressure, 88.0 ± 13.1 mmHg), compliant for treatment with antihypertensive medica-
tion, were prospectively enrolled for MR examinations of the aorta, heart, and brain with 
standard pulse sequences. Aortic arch pulse wave velocity (PWV), left ventricular (LV) mass, 
LV systolic and diastolic function, lacunar brain infarcts, and periventricular and deep white 
matter hyperintensities (WMHs) were assessed. Univariable and multiple linear and logistic 
regression analyses were used for statistical analyses. 
Results
Mean aortic arch PWV was 7.3 ± 2.5 m/s. Aortic arch PWV was statistically signifi cantly associ-
ated with LV mass (r = 0.30, p = .03, β = 1.73); indexes of systolic function, including ejection 
fraction (r = −0.38, p = .01, β = −1.12); indexes of diastolic function, including the ratio of early 
diastolic to atrial contraction peak fi lling rates (r = −0.44, p < .01, β = −0.11); lacunar brain 
infarcts (odds ratio [OR] = 1.8, p < .01); and periventricular (OR = 1.5, p = .01) and deep (OR = 
1.6, p = .01) WMHs. Aortic arch PWV was statistically signifi cantly associated with LV mass (r = 
0.37, p = .03, β = 2.11) and lacunar brain infarcts (OR = 1.8, p = .04), independent of age, sex 
and hypertension duration, but not with indexes of diastolic and systolic function and WMHs.
Conclusion
Aortic arch stiff ness is associated with LV mass and lacunar brain infarcts in hypertensive 
patients, independent of age, sex, and hypertension duration; these manifestations of end-
organ damage may help to risk stratify hypertensive patients.
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INTRODUCTION
Hypertension has a high prevalence in the general population and is one of the major risk 
factors for cardiovascular disease that may aff ect both the heart and the brain (1,2). The elas-
tic properties of the aortic wall play an important role in the pathogenesis of hypertensive 
cardiovascular disease (3,4). Owing to continuous stress at the aortic wall, structural and 
functional changes in the arterial wall may occur, leading to increased aortic stiff ness (3–8). 
Aortic stiff ness, as measured by means of ultrasonography (US), is an independent predictor 
of adverse cardiovascular outcome in hypertensive patients (9,10). Increased aortic stiff ness 
may aff ect the heart by producing an extra workload on the left ventricle (LV) (11). As a 
consequence, LV hypertrophy, compromised coronary perfusion, and subsequently diastolic 
and systolic dysfunction may occur, which may ultimately lead to heart failure and cardiac 
death (11,12).
Aortic stiff ness may also lead to impaired absorption of the pulse wave and an increase in 
central pulse pressure, which may augment small vessel disease in the brain (13). Lacunar 
brain infarcts and white matter hyperintensities (WMHs) have been described as early mani-
festations of cerebral small vessel disease by using magnetic resonance (MR) imaging (14). 
Both lacunar brain infarcts and WMHs are associated with dementia (15,16) and stroke (17).
The proximal part of the aorta and its fi rst branches (i.e., the more elastic part of the aorta) 
act as a conduit delivering blood from the LV, primarily to the myocardium and the cerebrum 
(3,11,13). The hypothesis is that stiff ness of the aortic arch is involved in cardiac and cerebral 
damage in patients with hypertension.
Aortic stiff ness can be assessed by means of pulse wave velocity (PWV) measurements 
(18,19). A number of studies have shown that MR imaging is well suited to accurately assess 
PWV (18–22), LV function (23,24) and brain abnormalities (25,26). Furthermore, MR imaging 
allows for assessment of local PWV, also in the aortic arch (3,18), whereas US measurements 
estimate the stiff ness of the entire aorta (7,11).
However, to our knowledge, the association between aortic arch stiff ness and cardiac and 
cerebral damage in hypertensive patients has not been comprehensively studied by using 
MR imaging.
Accordingly, the purpose of the present study was to assess the possible association 
between aortic arch stiff ness and cardiac and cerebral end-organ damage in hypertensive 





This study was approved by the local institutional review board. Consecutive patients from 
the hypertension outpatient clinic in whom there was a diagnosis of essential hyperten-
sion were prospectively included for the study. Between October 2007 and May 2008, 69 
patients were considered for participation in our study. All patients were older than 18 years 
and were undergoing treatment with antihypertensive medication. Treatment compliance 
was verifi ed. Exclusion criteria were evidence of aortic valve stenosis or insuffi  ciency, as 
evaluated by means of physical examination and velocity-encoded MR imaging, and general 
contraindications to MR imaging. In total, 50 hypertensive patients (19 men and 31 women; 
mean age ± standard deviation, 47.1 ± 14.6 years and 50.5 ± 11.5 years, respectively; overall 
mean age, 49.2 ± 12.7 years) gave written informed consent to participate in the study, and 
19 patients were excluded for this study (six patients had general contraindications for MR, 
six did not fulfi ll the selection criteria, fi ve were claustrophobic, and two had a diagnosis of 
aortic valvular disease).
Hypertension was defi ned as systolic and/or diastolic blood pressure of greater than or 
equal to 140 mmHg and/or greater than 90 mmHg, respectively, at repeated physical ex-
amination before antihypertensive therapy was instituted and according to criteria of the 
European Society of Hypertension (2). Blood pressure was measured by using a semiauto-
mated sphygmomanometer (Dinamap, Critikon, Tampa, Fla). The duration of hypertension 
was estimated as the time (in years) passed since the reported age of diagnosis until MR 
examination. Pulse pressure was defi ned as systolic minus diastolic blood pressure. Body 
mass index (i.e., the patient’s body weight in kilograms during MR imaging divided by the 
square root of the height of the patient in centimeters), smoking status (nonsmoker, cur-
rent smoker, or former smoker), diabetes mellitus (i.e., fasting blood glucose ≥ 7.0 mmol/L 
or current use of oral antidiabetic agents) and lipid profi les (total cholesterol, high-density 
lipoprotein, and triglycerides) were determined. Blood was drawn in the morning after an 
overnight fast within 2 weeks before MR imaging.
Table 1 describes the characteristics of the 50 hypertensive patients. Mean systolic blood 
pressure was 152.1 ± 22.3 mmHg and mean diastolic blood pressure was 88.0 ± 13.1 mmHg, 
despite antihypertensive medication. Fourteen patients were current smokers, six patients 
were former smokers, and nine patients had a diagnosis of diabetes mellitus.
MR imaging protocol
Aortic arch PWV imaging and cardiac imaging were performed by using a 1.5-T MR imager 
(NT 15 Gyroscan Intera; Philips Medical Systems, Best, the Netherlands) (25 patients) or a 3.0-T 
MR imager (Achieva; Philips Medical Systems) (25 patients) with similar protocols (27). All 
brain examinations were performed with the 3.0-T system. Diastolic function fi ndings were 
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not obtained in nine patients owing to technical problems with valvular fl ow measurements 
at 3.0-T MR during the start of the study. Total study duration, to complete all examinations 
and including the time between cardiovascular and brain examination, was 60 minutes. 
Table 1. Characteristics of the study population
Characteristics Patients with essential hypertension (n=50)
Male gender, n (%) 19 (38)
Age (years) 49.2 ± 12.7
Hypertension duration (years) 7.9 ± 8.3
Systolic blood pressure (mmHg)        152.1 ± 22.3
Diastolic blood pressure (mmHg)  88.0 ± 13.1
Pulse pressure (mmHg) 64.1 ± 19.0
Heart rate (beats per minute) 68.2 ± 11.3
BMI (kg/m2) 25.5 ± 3.0
Smoking
No, n (%) 30 (60)
Yes, n (%) 14 (28)
Former smoker, n (%) 6 (12)
Diabetes yes, n (%) 9 (18)
Total cholesterol (mmol/l) 5.2 ± 1.3
HDL (mmol/l) 1.5 ± 0.5
Triglycerides (mmol/l) 1.6 ± 1.2
Data are presented as mean and standard deviations or n (%). BMI: body mass index; HDL: high-density 
lipoprotein.
Aortic arch PWV
Aortic arch PWV was determined as described in the literature (18–22). Figure 1 demonstrates 
assessment of aortic arch PWV between the ascending and the proximal descending aorta. 
A retrospectively electrocardiographically gated gradient-echo sequence with maximum ve-
locity encoding perpendicular to the ascending aorta was performed to assess the fl ow in the 
ascending and proximal descending aorta. This imaging plane (Figure 1a) was determined 
from coronal and oblique sagittal views of the aortic arch. Examination parameters for both 
1.5- and 3-T MR imaging are included in Table 2. For both 1.5- and 3-T MR, a maximal number 
of phases was reconstructed ensuring high (6–10 msec) temporal resolution. Maximum 
velocity encoding was set to 150 cm/sec. The aortic arch PWV sequence took 3–4 minutes 
when measured for a mean heart rate of 65 beats per minute and was acquired during free 
breathing. A fi ve-element phased-array cardiac coil was used for data acquisition.
Aortic arch velocity maps were analyzed by using the previously validated in-house de-
veloped software package FLOW (Figure 1c) (28). Aortic arch PWV was calculated as Δx/
Δt (in meters per second), where Δx is the distance between the ascending and proximal 
descending aorta (measured along the centerline in the oblique sagittal view of the aortic 
arch by using the previously validated in-house developed software package MASS) (Figure 
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1a) (28) and Δt is the transit time between the arrival of the pulse wave at the ascending 
and the proximal descending aorta, respectively (19). Manual contour drawing in the aorta 
velocity maps was performed by one researcher (A.B., with 1 year of experience in cardiac MR 
imaging) and was supervised by a senior researcher (J.J.M.W., with 13 years of experience in 
cardiac MR imaging).
LV function and mass
For assessment of LV systolic function and LV mass, the entire heart was imaged in short-axis 
orientation by using electrocardiographically gated breath-hold segmented gradient-echo 
imaging with steady-state free-precession, as described previously (23,29). Examination 
parameters for both 1.5- and 3-T MR imaging are described in Table 2. Ten to 12 consecutive 
sections without gap were imaged with one signal acquired and a minimum of 30 recon-
structed phases. Arrhythmia rejection was used with an acceptance window of 10%.
To determine LV volumes, end-systolic and end-diastolic endocardial and epicardial bor-
ders were manually traced on short-axis cine images by using the software package MASS 
(28). Papillary muscles were considered to be part of the myocardium and excluded from the 
blood pool. LV end-systolic volume, LV end-diastolic volume, ejection fraction, and LV mass 
were assessed. The LV end-diastolic mass was obtained from the volume of the LV muscle 
Figure 1. Aortic arch PWV determination with MR imaging. (a) Sagittal gradient-echo image of aorta in 
41-year-old woman. Black line represents the acquisition plane for velocity-encoded MR and is perpendic-
ular to the aorta at the level of the pulmonary trunk. Δx = path length of aortic arch along centerline of the 
aortic arch. (b) Phase (left) and magnitude (right) images acquired with an electrocardiographically gated 
gradient-echo sequence with velocity encoding at the acquisition sites in the ascending aorta (AO Asc) 
and proximal descending aorta (AO Desc). (c) Flow curves of ascending and proximal descending aorta. Δt 
= transit time of arrival of proximal fl ow wave. Aortic PWV is defi ned as Δx/Δt (in meters per second).
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tissue including the interventricular septum, multiplied with the specifi c weight of muscle 
tissue, which is 1.04 g/cm3 (30). Volumes and mass were indexed for body surface area (31).
For assessment of LV diastolic function, an electrocardiographically gated gradient-echo 
sequence with maximum velocity encoding was performed to measure blood fl ow across the 
mitral valve (32,33). Table 2 describes parameters for both 1.5- and 3-T MR. For both 1.5- and 
3-T MR, 40 phases were reconstructed to ensure a high temporal resolution. Furthermore, 
a maximum velocity encoding of 150 cm/sec was used (34). In each cardiac phase, the area 
of the mitral valve was traced manually by using the software package FLOW (28). Flow at 
early diastole and at atrial contraction were assessed from the fl ow graph. The early peak 
fi lling rate, the atrial peak fi lling rate, and the early diastolic to atrial contraction peak fi lling 
rate (E/Apeak) ratio were assessed. Furthermore, the early diastolic peak deceleration gradients 
were calculated automatically (24). Moreover, LV fi lling pressures were estimated by the early 
Table 2. MR imaging parameters for assessment of aortic arch PWV and LV systolic and diastolic function
1.5 T MRI 3 T MRI
Aortic arch PWV
TR (ms) 5.0 4.9
TE (ms) 2.9 3.0
FA (0) 20 10
Acquisition matrix 128 x 115 128 x 104
Acquired voxel size (mm3) 2.3 x 2.3 x 8.0 2.5 x 2.5 x 8.0
Reconstructed number of phases maximum maximum
Venc (cm/s) 150 150
LV systolic function
TR (ms) 3.3 4.4
TE (ms) 1.7 2.2
FA (0) 50 45
Acquisition matrix 256 x 194 128 x 104
Acquired voxel size (mm3) 1.7 x 1.7 x 10.0 1.3 x 1.7 x 10.0
NSA 1 1
Reconstructed number of phases 40 30
LV diastolic function
TR (ms) 14 5.2
TE (ms) 4.8 3.2
FA (0) 20 10
Acquisition matrix 128 x 104 128 x 104
Acquired voxel size (mm3) 2.7 x 3.4 x 8.0 2.5 x 2.5 x 8.0
Reconstructed number of phases 40 40
Venc (cm/s) 150 150
Aortic arch PWV: aortic arch pulse wave velocity; LV systolic function: left ventricular systolic function; LV diastolic 
function: left ventricular diastolic function; TR: repetition time; TE: echo time; FA: fl ip angle; Venc: maximum 
velocity encoding; NSA: number of signal averaged. 
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peak fi lling rate–to–early diastolic peak wall velocity ratio to correct for possible pseudo-
normalization (35).
Contour segmentation was performed by one observer (A.B., with 1 year of experience in 
cardiac MR imaging) and was supervised by a radiologist (L.J.M.K., 12 years of experience in 
cardiac MR imaging).
Cerebral lesions
Brain MR imaging consisted of spin-echo T2-weighted and fl uid-attenuated inversion 
recovery (FLAIR) sequences. Acquisition parameters for T2-weighted imaging were as fol-
lows: repetition time msec/echo time msec, 3951/80; fl ip angle, 90°; fi eld of view, 224 mm; 
acquisition matrix, 448 × 448; reconstruction matrix, 1024 × 1024; section thickness, 3.6 mm; 
40 sections without gap; and turbo-spin-echo factor, 16. The acquisition time was 2 minutes 
46 seconds. Acquisition parameters for the FLAIR sequence were as follows: repetition time 
msec/echo time msec/inversion time msec, 10 000/100/2800; fl ip angle, 90°; fi eld of view, 224 
mm; acquisition matrix, 224 × 224; reconstruction matrix, 448 × 448; section thickness, 3.6 
mm; and 40 sections without gap, with an acquisition time of 3 minutes 20 seconds.
Lacunar brain infarcts were defi ned as cavities within and not extending to the outer 
contours of the brain, with signal intensity similar to that of cerebrospinal fl uid for all pulse 
sequences, surrounded by an area of parenchyma with a high signal intensity on T2-weighted 
and FLAIR images (14,25,36). WMHs were defi ned as areas of brain parenchyma with increased 
signal intensity on T2-weighted and FLAIR images and without mass eff ect. WMHs were sub-
divided into periventricular WMHs and deep WMHs and were classifi ed according to Fazekas 
(26). Fazekas scores of 0 and 1 were considered normal, a score of 2 was considered abnormal 
below the age of 75 years, and a score of 3 was considered abnormal in any age group.
Lacunar brain infarcts and WMHs were visually scored by consensus reading by a researcher 
(A.B., with 1 year of experience in neuroradiology) and two experienced observers (M.A.v.B. 
and J.v.d.G., both with 15 years of experience in neuroradiology). 
Statistical analysis
Statistical analysis was performed by using SPSS for Windows (version 14.0; SPSS, Chicago, Ill). 
Data are expressed as mean ± standard deviation unless stated otherwise. Univariable linear 
regression analyses were performed to analyze the association between aortic arch PWV and 
continuous data. Pearson correlation coeffi  cients (r), p-values, and β regression coeffi  cients 
are reported. Univariable logistic regression analyses were performed to analyze the asso-
ciation between aortic arch PWV and dichotomous data. Odds ratios (ORs), 95% confi dence 
intervals (CIs), and p-values are reported. Multiple linear and logistic regression analyses 
were performed to identify variables that were independently associated with cardiac as well 
as cerebral indexes and to adjust for confounders. Age, sex, hypertension duration, and MR 
imager type were considered as confounders.
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RESULTS
Aortic arch PWV
Mean aortic arch PWV was 7.3 ± 2.5 m/s, indicating increased aortic arch stiff ness in com-
parison with normal MR imaging values from the literature (i.e., 5.7 ± 1.1 m/s for healthy 
volunteers (21)). Aortic arch PWV was statistically signifi cantly associated with age (r = 0.53, 
p < .01, β = 2.67) and systolic blood pressure (r = 0.30, p = .04, β = 2.55). Sex, diastolic blood 
pressure, pulse pressure, heart rate, body mass index, smoking status, diabetes mellitus, and 
lipid status did not correlate with aortic arch PWV.
Association between aortic arch PWV and LV function and mass
Aortic arch PWV was statistically signifi cantly associated with end-systolic LV volume indexed 
for body surface area (r = 0.34, p = .02, β = 1.21), ejection fraction (r = −0.38, p = .01, β = 
−1.12), LV mass index (r = 0.30, p = .03, β = 1.73), early peak fi lling rate (r = −0.37, p = .02, β = 
−0.14), atrial peak fi lling rate (r = 0.42, p = .01, β = 20.10), and E/Apeak ratio (r = −0.44, p < .01, β 
= −0.11) (Table 3). Mean ratio of early peak fi lling rate to early diastolic peak wall velocity was 
4.2 ± 1.7, indicating that the patients had a normal LV fi lling pressure (35).
Table 3. Association between aortic arch PWV and LV function and mass
aortic arch PWV
n mean ± sd r p-value ß
LVEDV-I (ml/m2) 50 79.7 ± 12.2 0.12 0.43 0.56
LVESV-I (ml/m2) 50 31.0 ± 9.2 0.34 0.02 1.21
LV ejection fraction (%) 50 61.3 ± 7.5 -0.38 0.01 -1.12
LVEDM-I (g/m2) 50 60.4 ± 14.5 0.30 0.03 1.73
Early peak fi lling rate (ml/s) 41 507.7 ± 160.5 -0.37 0.02 -0.14
Early deceleration peak (ml/s2) 41 -4.6 ± 2.0 0.29 0.06 0.23
Early deceleration mean (ml/s2) 41 -2.6 ± 1.2 0.16 0.31 0.08
Early deceleration time (ms) 41 194.0 ± 77.9 -0.20 0.21 -6.11
Atrial peak fi lling rate (ml/s) 41 138.5 ± 121.9 0.42 0.01 20.10
E/A-peak ratio 41 1.5 ± 0.6 -0.44 <0.01 -0.11
Data are expressed as mean and standard deviations (sd) and Pearson correlation coeffi  cients (r), p-values and β 
regression coeffi  cients (β). 
LVEDV-I: left ventricular end-diastolic volume corrected for body surface area, LVESV-I: left ventricular end-
systolic volume corrected for body surface area, LVEDM-I: left ventricular end-diastolic LV mass corrected for 
body surface area, LV ejection fraction: left ventricular ejection fraction. E/A-peak ratio: Early diastolic to Atrial 
contraction peak fi lling rate ratio.
After adjustment for age, sex, and hypertension duration, aortic arch PWV was statistically 
signifi cantly associated with LV mass index (r = 0.37, p = .03, β = 2.11). Aortic arch PWV was 
not statistically signifi cantly associated with other indexes of LV diastolic, including E/Apeak 
ratio, and systolic function, including ejection fraction, after adjustment for age, sex, and 
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hypertension duration. Imager type was not statistically signifi cantly associated with cardiac 
parameters (data not shown).
Association between aortic arch PWV and cerebral lesions
Lacunar brain infarcts were diagnosed in eight patients. Fazekas grade 2 or 3 periventricular 
WMHs were diagnosed in 12 patients. Fazekas grade 2 or 3 deep WMHs were diagnosed in 14 
patients (Table 4).
Table 4. Association between aortic arch PWV and lacunar brain infarcts and periventricular and deep white 
matter hyperintensities
aortic arch PWV
n OR 95% CI p-value
Lacunar brain infarcts 1.8 (1.2-2.5) <0.01
No 42
Yes 8
Periventricular WMHs 1.5 (1.1-2.1) 0.01
No 38
Yes 12
Deep WMHs 1.6 (1.1-2.1) 0.01
No 36
Yes 14
Data are expressed as Odds ratios (OR) and 95% confi dence intervals (CI) and p-values.
PWV: pulse wave velocity; WMHs: white matter hyperintensities
Univariable logistic regression analyses showed that aortic arch PWV was associated with 
lacunar brain infarcts (OR = 1.8; 95% CI: 1.2, 2.5; p < .01), Fazekas grade 2 or 3 periventricular 
WMHs (OR = 1.5; 95% CI: 1.1, 2.1; p = .01), and Fazekas grade 2 or 3 deep WMHs (OR = 1.6; 95% 
CI: 1.1, 2.1; p = .01) (Table 4).
After adjustment for age, sex, and hypertension duration, aortic arch PWV was statistically 
signifi cantly associated with lacunar brain infarcts (OR = 1.8; 95% CI: 1.0, 3.0; p = .04). Aortic 
arch PWV was not statistically signifi cantly associated with periventricular and deep WMHs 
after adjustment for age, sex, and hypertension duration. MR imager type was not statistically 
signifi cantly associated with cerebral parameters (data not shown).
In Figure 2, aortic arch PWV in hypertensive patients with and those without lacunar brain 
infarcts is presented in a box plot that shows higher aortic arch PWV in patients with lacunar 
brain infarcts compared with patients without lacunar brain infarcts.
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DISCUSSION
We demonstrated that aortic arch PWV is statistically signifi cantly associated with LV mass, as 
well as lacunar brain infarcts, in patients with hypertension, independently of age, sex, and 
hypertension duration. 
We found that local stiff ness of the aortic arch is related to early changes in LV mass, in 
the absence of overt cardiac failure. In our study most patients were adequately treated 
with mildly elevated systolic blood pressure, possibly explaining the mild degree of cardiac 
dysfunction. Our observations are in accordance with previous US studies that showed that 
aortic PWV is associated with LV hypertrophy (37–40). To our knowledge, only one previous 
study used MR imaging to demonstrate an association between decreased aortic distensibil-
ity and LV mass in 20 hypertensive patients (41).
In the current study, no associations between aortic arch stiff ness and indexes of LV diastolic 
function (including E/Apeak ratio) and LV systolic function (including ejection fraction) were 
observed after correction for confounding factors of age, sex, and hypertension duration. 
Previous studies have shown that LV diastolic dysfunction occurs in hypertensive patients with 
increased aortic stiff ness and preserved LV systolic function (42,43). In our study, LV systolic and 
diastolic function were still preserved, which is likely related to the less advanced stage of hy-
pertensive heart disease. Furthermore, measurement of LV diastolic function was not obtained 
in nine patients, owing to technical problems. This could have aff ected the precision with 
which the association between aortic arch stiff ness and LV diastolic function was determined.
Figure 2. Box plot for aortic arch PWV in hypertensive patients with and those without lacunar brain infarcts. 
Median, 25th and 75th quartiles, and the range in aortic arch PWV measurements are shown. The OR, 95% 
































Our study also reveals that aortic arch PWV in hypertensive patients is independently as-
sociated with lacunar brain infarcts, after correction for confounding factors of age, sex, and 
hypertension duration, whereas no signifi cant association between aortic arch PWV and peri-
ventricular and deep WMHs is found after correction for confounding factors. These results 
are in line with a previous US study that assessed the relationship between brachial-ankle 
PWV and the risk of cerebral small vessel disease in 196 elderly patients with hypertension 
(44). These authors found a signifi cant association between aortic PWV and lacunar brain 
infarcts but no relationship between the severity of periventricular WMHs and PWV after 
controlling for age (44).
The association between aortic stiff ness and cerebral damage may be indirect through 
shared vascular risk factors or may be causative in nature (10,13,44,45). One possible mecha-
nism is that increased aortic stiff ness leads to a defi cient absorption of the pulse wave and 
an increase in central pulse pressure, which may augment small vessel disease of the brain 
through high pulsatile fl ow (10,13,44). We hypothesize that large vessel disease of the aortic 
arch contributes to the occurrence of cerebral damage.
Although WMHs and lacunar brain infarcts share underlying risk factors, our results 
demonstrate that MR imaging–measured aortic arch PWV is not associated with WMHs after 
controlling for age, sex, and hypertension duration. It is plausible that aging has more eff ect 
on arteriosclerosis of the medullary arteries than on perforating arteries in hypertensive 
patients (44). Recent studies have suggested diff erent pathogenic mechanisms between 
lacunar brain infarcts or WMHs (43,46).
Current recommendations for the care of hypertensive patients stress the importance of 
assessing early end-organ damage, allowing for better risk stratifi cation with more thera-
peutic options and better follow-up. Increased PWV is an independent predictor of adverse 
cardiovascular events in various clinical settings (7,9,47,48). Of note, assessment of aortic 
PWV is not part of clinical routine in hypertensive patients. The results of our study suggest 
that aortic arch PWV could provide additional cardiovascular risk prediction beyond classical 
risk factors in hypertensive patients.
Our study had some limitations. First, this was a cross-sectional study, and therefore caus-
ative mechanisms cannot be determined. Outcome studies are required to assess the clinical 
signifi cance of the relationship between aortic arch stiff ness and LV mass and lacunar brain 
infarcts found in this study. Furthermore, no age-matched healthy subjects were included 
to serve as controls. However, the primary purpose of this study was to assess the possible 
relationship between aortic arch PWV and cardiac and cerebral end-organ damage in hyper-
tensive patients.
In conclusion, aortic arch PWV is statistically signifi cantly associated with LV mass index 
and lacunar brain infarcts in hypertensive patients, independent of age, sex, and hyperten-
sion duration. Further studies are required to assess the prognostic importance of these 
fi ndings for risk stratifi cation and optimization of therapy.
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Aortic stiff ness is associated with cardiac 
function and cerebral small vessel disease 
in patients with type 1 diabetes mellitus: 
assessment by MR imaging
SGC van Elderen, A Brandts, JJM Westenberg, J van der Grond, JT Tamsma, 






To evaluate, with the use of magnetic resonance imaging (MRI), whether aortic pulse wave 
velocity (PWV) is associated with cardiac left ventricular (LV) function and mass as well as 
with cerebral small vessel disease in patients with type 1 diabetes mellitus (DM).
Ma terials and Methods 
We included 86 consecutive type 1 DM patients (49 male, mean age 46.9 ± 11.7 years) in a 
prospective, cross-sectional study. Exclusion criteria included aortic/heart disease and gen-
eral MRI contra-indications. MRI of the aorta, heart and brain was performed for assessment 
of aortic PWV, as a marker of aortic stiff ness, systolic LV function and mass, as well as for the 
presence of cerebral white matter hyperintensities (WMHs), microbleeds and lacunar infarcts. 
Multivariate linear or logistic regression was performed to analyse the association between 
aortic PWV and outcome parameters, with covariates defi ned as age, gender, mean arterial 
pressure, heart rate, BMI, smoking, DM duration and hypertension.
Results 
Mean aortic PWV was 7.1 ± 2.5 m/s. Aortic PWV was independently associated with LV ejec-
tion fraction (ß=-0.406, p=0.006), LV stroke volume (ß=-0.407, p=0.001), LV cardiac output (ß 
=-0.458, p=0.001), and with cerebral WMHs (p<0.05). There were no independent associa-
tions between aortic stiff ness and LV mass, cerebral microbleeds or lacunar infarcts.
Conclusion   
Aortic stiff ness is independently associated with systolic LV function and cerebral WMHs in 
patients with type 1 DM.
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INTRODUCTION 
Type 1 diabetes mellitus (DM) patients show functional and structural alterations of the arte-
rial vessel wall, resulting in arterial stiff ness (1,2). Arterial stiff ening has been described as 
an early phenomenon in subjects with type 1 DM, already apparent before clinical onset of 
cardiovascular (CV) complications, and also as an independent predictor of overt CV disease 
and mortality (3). Therefore, arterial stiff ening may be related to the pathogenesis of CV com-
plications in type 1 DM. This notion could be substantiated if an independent relationship 
could be established between arterial stiff ness and cardiac function in type 1 DM. Further-
more, CV complications in type 1 DM also involve small vessel disease in the brain, and if a 
relationship between arterial stiff ness and cerebral small vessel disease could be established 
as well, this would support the importance of arterial stiff ness in CV complications in type 
1 DM. An integrated study investigating the relationship between arterial stiff ness, cardiac 
function and cerebral small vessel disease has not been performed in type 1 DM so far. 
Stiff ening of the aorta aff ects cardiac function by increasing the cardiac afterload and re-
ducing diastolic coronary artery perfusion (4). Myocardial perfusion might fail to compensate 
for the increased metabolic energy demand, resulting in an impaired myocardial contractility 
function (5). Furthermore, stiff ness of the central large arteries results in defi cient absorption 
of the pulse wave. This high pulsatile fl ow is transmitted from the aorta to the brain causing 
damage to the endothelial and smooth muscle cells, disrupting the cerebral small vessels 
(6,7). Also, aortic stiff ness may represent coronary and cerebral endothelial dysfunction or 
wall thickening caused by shared underlying mechanisms. 
As aortic function plays a central role in maintaining adequate perfusion of both the heart 
and the brain, we hypothesized that aortic stiff ness is associated with cardiac function as well 
as with cerebral small vessel disease in DM patients. To our knowledge, no previous magnetic 
resonance imaging (MRI) studies have evaluated the relationship between aortic function, 
cardiac function and cerebral small vessel disease in one comprehensive protocol. MRI is a 
non-invasive tool for the accurate assessment of aortic pulse wave velocity (PWV) (8) as a 
marker of aortic stiff ness (9). Notably, MRI is not dependent on geometric assumptions about 
the aortic path length unlike ultrasound techniques (10). Furthermore, MRI is well suited 
to assess cardiac LV function (11). Moreover, MRI is a validated technique for the detection 
of cerebral small vessel disease manifesting as white matter hyperintensities (WMHs) (12), 
microbleeds (13) and lacunar infarcts (14).
Therefore, the purpose of the present study was to use a comprehensive MRI protocol to 
evaluate whether aortic PWV is associated with cardiac LV function and mass as well as with 





Between February 2008 and February 2009, consecutive patients with type 1 DM were 
recruited from our local outpatient clinic of the university medical centre. For inclusion, pa-
tients had to be older than 18 years and diagnosed with type 1 DM. A total of 86 patients (49 
men, 37 women; mean age 46.9 ± 11.7 years) gave written informed consent to participate 
in the study and were prospectively included. Exclusion criteria included congenital aortic/
heart disease, evidence of aortic or heart disease as evaluated by means of cardiac ausculta-
tion and ECG, and standard contra-indications to MRI such as claustrophobia, pacemaker and 
metal implantations. 
Information about patient characteristics was obtained by means of a standardized in-
terview and physical and laboratory examinations. Diabetes duration was estimated as the 
time passed between the reported age of diagnosis and the MRI examination. Body mass 
index (BMI) was calculated from body length and mass at the time of MRI. Blood pressure and 
heart rate were measured after MRI using a semi-automated sphygmomanometer (Dinamap, 
Critikon, Tampa, FL, USA, validated to ANSI/AAMI SP10 criteria). Pulse pressure was defi ned 
as the diff erence between systolic and diastolic blood pressure. Mean arterial pressure (MAP) 
was calculated by adding diastolic blood pressure to one-third of the pulse pressure. Smok-
ing was defi ned as non-smoker or a current smoker. Hypertension was defi ned as the use 
of anti-hypertensive medication. Glycated hemoglobin (HbA1c), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), total cholesterol, triglycerides and C-reactive protein 
were determined. The albumin excretion ratio was calculated using the microalbumin and 
creatinine concentrations in the urine. 
The study was approved by the local medical ethics committee, and the study was con-
ducted according to the principles in the Declaration of Helsinki. 
MR  imaging protocol
Aortic and cardiac imaging was performed using 1.5 Tesla MRI (NT 15 Gyroscan Intera; Philips 
Medical Systems, Best, the Netherlands). All brain examinations were performed on 3.0 Tesla 
MRI (Achieva; Philips Medical Systems, Best, the Netherlands). 
For the evaluation of aortic stiff ness, aortic PWV was determined using a previously de-
scribed protocol (15). In short, a scout view of the aorta was performed. Two velocity-encoded 
images were obtained: one perpendicular to the aorta at the level of the pulmonary trunk, 
and one at the level of the abdominal descending aorta 7.5 cm beneath the diaphragm. This 
resulted in through-plane fl ow measurements of the ascending and descending aorta at 
those levels. Aortic PWV was calculated for the aorta as Δx/Δt, where Δx is the aortic path 
length between the two measurement sites and Δt is the time delay between the arrivals 
of the foot of the pulse wave at the respective measurement sites. Data were analyzed with 
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MASS/FLOW (Medis, Leiden, the Netherlands) by a single observer (S.v.E., 2 years of experi-
ence in cardiac MRI) supervised by a senior researcher (J.W., 13 years of experience in cardiac 
MRI). 
For the assessment of systolic LV function and LV mass, the entire heart was imaged in 
short-axis orientation as described previously (11). Endocardial and epicardial LV borders 
were manually traced on short-axis cine images using the software package MASS. Ejection 
fraction (EF), stroke volume (SV), cardiac output (CO), LV end-diastolic volume (LV ED volume), 
LV end-systolic volume (LV ES volume) and LV end-diastolic mass (LV ED mass) were assessed. 
Volumes and mass were indexed (i) for body surface area (BSA). All manual contour drawings 
were performed by a researcher (S.v.E., 2 years of experience in cardiac MRI), with supervision 
of a radiologist (L.K., 12 years of experience in cardiac MRI). 
For evaluation of cerebral small vessel disease a spin-echo T2-weighted image, a fl uid-
attenuated inversion recovery (FLAIR) image and a T2*-weighted gradient echo sequence 
were assessed. WMHs were defi ned as areas of brain parenchyma with increased signal on 
T2-weighted and FLAIR images without mass eff ect. WMHs were distinguished as either 
periventricular (pv) WMHs or subcortical (sc) WMHs because of the diff erent pathogenesis 
involved (16). WMHs were classifi ed according to Fazekas et al. (16). For statistical analysis 
subjects were divided into those with normal [0] versus abnormal [1] amounts of pv and sc 
WMHs. Figure 1 demonstrates a case example with presence of pv and sc WMHs on a FLAIR 
Figure 1. A 66-year-old male patient with type 1 diabetes mellitus with abnormal white matter 
hyperintensities (WMHs) on a FLAIR sequence and high aortic pulse wave velocity of 8.9 m/s. The four 
arrows point to periventricular WMHs, the arrowhead indicates an example of a subcortical WMH.
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sequence. Microbleeds were defi ned as focal, nodular areas of signal loss in brain parenchyma 
on T2* images that are invisible or smaller on T2-weighted spin echo images (17). Micro-
bleeds were scored as absent [0] or present [1]. Lacunar brain infarcts were defi ned as small 
(but >3 mm in size) cavities within the brain parenchyma, with similar signal intensity to that 
of cerebrospinal fl uid on all pulse sequences, surrounded by an area of high signal intensity 
on T2 and FLAIR images (18,19). Their presence was defi ned on a binary scale: absent [0] or 
present [1]. WMHs, microbleeds and lacunar infarcts were visually scored by consensus read-
ing by a researcher (S.v.E., 1 year of experience in neuroradiology) and a senior neuroscientist 
(J.v.d.G., 15 years of experience in neuroradiology) or a neuroradiologist (M.v.B., 15 years of 
experience in neuroradiology).
Statistic al analysis
Statistical analysis was performed using SPSS for Windows (version 16.0; SPSS, Chicago, Il-
linois, USA). Data are expressed as mean ± standard deviation, unless stated otherwise. Aortic 
PWV values were non-normally distributed (Kolmogorov-Smirnov test of normality, p=0.002). 
Spearman correlation analysis was performed to analyse the association between aortic PWV 
and continuous outcome parameters. Spearman correlation coeffi  cients (r) and p values are 
reported. Univariate logistic regression was performed to analyse the association between 
aortic PWV and dichotomous outcome parameters. Odds ratios (OR), 95% confi dence inter-
vals (CI) and p values were reported. For adjustment of confounding factors, defi ned as age, 
gender, MAP, heart rate, BMI, smoking, DM duration and hypertension these covariates were 
entered into a multivariate linear or logistic regression model. Associations between cardiac 
parameters indexed for BSA were not corrected for BMI.
RESULTS
The characteristics of the study population are described in Table  1. All MRI examinations 
were successfully performed without any adverse events. Eighty-six patients with type 1 DM 
were included, with a mean age of 46.9 ± 11.7 years. The mean HbA1c values were 7.7 ± 1.0 %.
Mean aortic PWV wa s 7.11 ± 2.51 m/s. Aortic PWV was signifi cantly associated with age 
(r=0.674, p<0.001), DM duration (r=0.299, p=0.006), BMI (r=0.317, p=0.003), systolic blood 
pressure (r=0.484, p<0.001), pulse pressure (r=0.509, p<0.001), MAP (r=0.339, p=0.001) and 
use of antihypertensive medication (OR=1.278, p=0.017). There were no statistically signifi -
cant associations between aortic PWV and laboratory markers (Table 1).
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Associations betwe en aortic PWV and cardiac LV function and mass
The mean values of cardiac LV parameters and the associations with aortic PWV are sum-
marised in Table 2. After statistical correction for confounder’s age, gender, MAP, heart rate, 
BMI, smoking, DM duration and hypertension, aortic PWV was found to be signifi cantly as-
sociated with systolic LV parameters: LV EF (ß=-0.402, p=0.006), LV SVi (ß=-0.407, p=0.001) 
and LV COi (ß=-0.458, p=0.001). The inverse association between aortic PWV and LV SVi is 
illustrated in Figure 2. There was no statistically signifi cant association between aortic PWV 
and LV mass.
Assoc iations between aortic PWV and cerebral small vessel disease
According to their Fazekas score, 16 (18.6%) patients showed pv WMHs and 38 (44.2%) pa-
tients were diagnosed with sc WMHs. In 7 (8.1%) DM patients, microbleeds were detected. 
Two patients (2.3%) showed lacunar infarcts on brain MRI. The associations between aortic 
PWV and parameters of cerebral small vessel disease are summarized in Table 2. Univariate 
logistic regression analysis showed that aortic PWV was signifi cantly associated with all MRI 
parameters of cerebral small vessel disease. 
Table 1. Patient characteristics
Patients (n=86) Association with
aortic PWV
Characteristics
Male gender, n (%) 49 (57) p=0.586
Age (years) 46.9 ± 11.7 r=0.674, p<0.001*
Diabetes duration (years) 23.8 ± 11.0 r=0.299, p=0.006*
BMI (kg/m2) 25.7 ± 3.4 r=0.317, p=0.003*
Systolic blood pressure (mmHg) 132 ± 18 r=0.484, p<0.001*
Diastolic blood pressure (mmHg) 74 ± 9 p=0.164
Pulse pressure (mmHg) 58 ± 16 r=0.509, p<0.001*
Mean arterial pressure (mmHg) 93 ± 11 r=0.339, p=0.001*
Heart rate (beats/min) 71 ± 10 p=0.286
Current smokers, n (%) 10 (12) p=0.867
Use of antihypertensive medication, n (%) 31 (36) OR=1.278, p=0.017*
Laboratory markers
HbA1c (%) 7.7 ± 1.0 p=0.597
HDL cholesterol (mmol/l) 1.6 ± 0.5 p=0.905
LDL cholesterol (mmol/l) 2.8 ± 0.9 p=0.154
Total cholesterol (mmol/l) 4.7 ± 1.0 p=0.050
Triglycerides (mmol/l) 1.2 ± 0.8 p=0.193
C-reactive protein (mg/l) 2.1 ± 2.1 p=0.549
Microalbumin/creatinine ratio (μg/μmol) 1.2 ± 2.5 p=0.145
Data are presented as mean ± standard deviation or n (%). Spearman rho (r) and p-values are presented. 
*p-value < 0.05, PWV: Pulse wave velocity; BMI: body mass index; HbA1c: glycated hemoglobin; HDL: high-density 
lipoprotein; LDL: low-density lipoprotein
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Table 2. Aortic PWV and the associations with MRI parameters
Univariate analysis Multivariate analysis
Cardiac MRI parameters mean ± sd r p-value ß p-value
Aortic PWV (m/s) 7.11 ± 2.51
LV EF (%) 59.7 ± 6.1 0.201 -0.409 0.006*
LV SV (i) (ml/m2) 46.7 ± 8.1 -0.376 <0.001* -0.407 0.001*
LV CO (i) (ml/m2) 3100 ± 542 -0.416 <0.001* -0.457 0.001*
LV ED volume (i) (ml/m2) 78.4 ± 12.7 -0.310 0.004* 0.066
LV ES volume (i) (ml/m2) 31.6 ± 7.8 0.327 0.349
LV ED mass (i) (g/m2) 47.4 ± 9.7 0.848 0.666
Brain MRI parameters n (%) OR p-value OR p-value
Periventricular WMHs 16 (18.6) 1.452 0.002* 1.426 0.048*
Subcortical WMHs 38 (44.2) 1.408 0.004* 1.479 0.020*
Microbleeds 7 (8.1) 1.301 0.042* 0.976
Lacunar infarct 2 (2.3) 1.492 0.036* 0.997
Data are presented as mean ± standard deviations or n (%). Spearman’s rho (r), standardised ß values, odds ratios 
(OR) and p-values are reported for the association with aortic PWV, in univariate analysis or multivariate analysis 
with the covariates age, gender, MAP, heart rate, BMI, smoking, DM duration and hypertension. *p-value<0.05 
PWV: Pulse wave velocity; MRI: magnetic resonance imaging; LV: left ventricular; EF: ejection fraction; SV: stroke 
volume; CO: cardiac output; ED: end-diastolic; ES: end-systolic; i: indexed for body surface area; WMHs: white 
matter hyperintensities
Figure 2. There is an inverse relation between aortic pulse wave velocity and systolic left ventricular (LV) 
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After statistical adjustment for confounding factors, aortic PWV was signifi cantly associ-
ated with pv WMHs (OR=1.425, 95% CI=1.003–2.026, p<0.05) and sc WMHs (OR=1.479, 95% 
CI=1.063–2.058, p=0.02). In Figure 3, aortic PWV in patients with type 1 DM with and without 
pv WMHs is presented in boxplots showing higher aortic PWV in patients with pv WMHs 
compared with patients without pv WMHs.
DISCUSS ION
The purpose of the present study was to evaluate whether aortic PWV is associated with 
cardiac LV function and mass as well as with cerebral small vessel disease in patients with 
type 1 DM using a comprehensive MRI protocol. 
The main fi ndings of our study are that aortic stiff ness in patients with type 1 DM is inversely 
associated with systolic LV function and is associated with cerebral WMHs, independently of 
age, gender, MAP, heart rate, BMI, smoking, DM duration and hypertension. No independent 
association between aortic stiff ness and LV mass, cerebral microbleeds or lacunar infarcts 
was found. 
This study is the fi rst to report an integrated approach for detecting the relationship among 
arterial stiff ness, cardiac function and cerebral small vessel disease. Indeed, in this cohort of 
Figure 3. These boxplots show that type 1 diabetes mellitus patients with periventricular white matter 
hyperintensities in the brain have higher aortic pulse wave velocity values compared with those without 


























relatively young type 1 DM patients, aortic stiff ness was found to be inversely associated with 
systolic LV function and with WMHs. Patients with type 1 DM are at increased risk of develop-
ing systolic LV dysfunction, with subsequent progressive heart failure and premature death 
(20). In addition, it is known that WMHs may progress and become manifest over time (21,22) 
but also that individuals with WMHs benefi t from secondary stroke prevention therapies (23). 
We hypothesized that PWV as measured in the aorta by MRI may be a marker or risk factor for 
generalized vascular disease that might potentially be treated. Interestingly, this association 
between PWV and MRI manifestations of cardiac function and cerebral small vessel disease 
was independent of many major risk factors such as age and hypertension, suggesting that 
aortic stiff ness might have an independent pathophysiological mechanism. 
The present MRI data show that in type 1 DM patients aortic stiff ness was inversely re-
lated to systolic LV function. To our knowledge, this is the fi rst study to report a relationship 
between systolic LV function and aortic stiff ness in a type 1 DM population. In our study 
population, the LV ejection fraction was in the normal range (24), which might emphasize an 
important role of aortic stiff ness in cardiac function already manifesting before occurrence of 
cardiac dysfunction or failure and compensatory remodeling. High blood pressure is strongly 
associated with LV hypertrophy (25). However, in type 1 DM patients the presence of LV hy-
pertrophy is not a well-known phenomenon (26,27). Therefore it is more likely that in patients 
with hypertension increased aortic stiff ness is associated with LV hypertrophy (28,29). Our 
study on type 1 DM patients is in line with these fi ndings; no relationship between aortic 
PWV and LV mass was found in a relatively young type 1 DM population with well-treated 
hypertension. Furthermore, a statistical correction for hypertension was performed.
In the present study, aortic PWV was independently associated with pv and sc WMHs. 
Although increased arterial stiff ness in DM was related to microvascular complications of the 
kidneys and the retina in a previous study (3), the current study is the fi rst to report on the 
potential relation between aortic stiff ness and small vessel disease in the brain in patients 
with type 1 DM. Interestingly, this relationship between aortic stiff ness and WMHs was inde-
pendent of hypertension, a fi nding that has been reported recently (30), and independent of 
age as described before (31), suggesting an independent pathophysiological mechanism for 
aortic stiff ness and WMHs in patients with type 1 DM. 
No independent relationship was found between aortic stiff ness and microbleeds. It is 
plausible that instead of a haemodynamic eff ect, other mechanisms including altered glu-
coregulation and microvascular changes by advanced glycation end products are involved 
in the development of microbleeds in DM patients (32,33). The low prevalence of lacunar 
infarcts (n=2) in our study population may have hampered the statistical analyses.
In addition to arterial stiff ness being a predictor of (fatal) myocardial infarction and stroke 
(3), our study results show that aortic stiff ness is associated with reduced cardiac function 
and cerebral small vessel disease as shown by MRI. Of note, assessment of aortic PWV is cur-
rently not part of the clinical routine assessment in DM patients. Our study results suggest 
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that aortic PWV could be useful in the cardiovascular risk screening of patients with type 
1 DM, if longitudinal studies confi rm our initial observations and establish their prognostic 
implications in patients with type 1 DM. 
As the study design is cross-sectional, a causal relationship between aortic PWV and sys-
tolic LV function or WMHs cannot be determined. However, the present study reveals that 
aortic stiff ness refl ects both cardiac function and cerebral small vessel disease. In our study 
design, we chose to measure aortic PWV with some distance of the aortic bifurcation to avoid 
wave refl ections from the aortic bifurcation, which can corrupt the observer-independent 
automatic assessment of the PWV (34). However, more refi ned analysis of thoracic and ab-
dominal aortic segments may allow local identifi cation of aortic vessel wall condition, and its 
relationship with cardiac function and cerebral small vessel disease. A possible limitation of 
this study is the lack of a healthy control group. However, the main purpose of this study was 
to investigate the possible relationship between aortic PWV and cardiac function and mass 
as well as cerebral small vessel disease in type 1 DM patients.
In conclusion, this study shows that in patients with type 1 DM stiff ness of the aorta is 
independently associated with systolic LV function as well as with cerebral WMHs. By docu-
menting that aortic stiff ness refl ects stages of both cardiac function and cerebral small vessel 
disease, our study results suggest that aortic PWV assessment might be a useful marker of 
cardiac and cerebrovascular disease in patients with type 1 DM. Future studies are needed to 
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Arterial stiff ness is an important predictor of cardiovascular disease in type 1 diabetes mel-
litus (DM). The study purpose was 1. to investigate whether type 1 DM is associated with 
increased aortic stiff ness measured by magnetic resonance imaging (MRI), independent of 
renal dysfunction; 2. to evaluate the relationship between aortic stiff ness and renal function 
within the normal range in type 1 DM.
Materials and Methods
We included 77 type 1 DM patients (mean age 46 ± 12 years) and 36 healthy controls matched 
for age and renal function, in a cross-sectional study. Exclusion criteria consisted of micro-
albuminuria, renal impairment, aortic valve disease and standard MRI contra-indications. 
Aortic pulse wave velocity (PWV), a marker of aortic stiff ness, was assessed by MRI. Renal 
function was expressed as estimated glomerular fi ltration rate (eGFR). Mann-Whitney U-test 
and Spearman correlation analysis were performed. Stepwise multivariable logarithmic 
regressions with forward entry analysis for eGFR were performed to study the relation with 
aortic PWV using interaction terms for type 1 DM.
Results
Type 1 DM patients without microalbuminuria or renal impairment show increased aortic 
PWV compared to controls (p<0.05). There was a statistically signifi cant correlation between 
eGFR and aortic PWV in type 1 DM patients (p<0.001, r=-.427) and controls (p=0.002, r=-.502) 
with aortic PWV being increased in type 1 DM patients for each given eGFR within normal 
range (p<0.001). The decrease in eGFR per increase in aortic PWV was similar for type 1 DM 
patients and controls (p=ns).
Conclusion
Our data show that aortic stiff ness, measured by MRI, is increased and inversely related to 
renal function in type 1 DM patients with normoalbuminuria and normal eGFR.
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INTRODUCTION 
Type 1 diabetes mellitus (DM) leads to functional and structural arterial vessel wall alterations, 
resulting in stiff ening of the arterial system (1,2). In turn, increased arterial wall stiff ness is an 
important predictor of cardiovascular disease in type 1 DM (3). A close relationship has been 
established between indices of arterial stiff ening and progressive microvascular damage in 
the kidneys leading to renal failure (4). The mechanism of this relationship is complex, as a 
decrease in aortic wall elasticity may contribute to renal dysfunction by transmission of high 
pulsatile fl ow to the kidneys, but vice versa renal dysfunction may also contribute to increased 
aortic stiff ness (5). Most of the studies reporting on arterial stiff ness and the kidneys have been 
conducted in patients with chronic kidney disease (6), and similar fi ndings have been noted in 
DM patients with microalbuminuria (7). However, whether type 1 DM per se is associated with 
increased aortic stiff ness, independent of renal dysfunction has not been studied in detail be-
fore. Therefore, we selected type 1 DM patients with normal renal function to avoid the possible 
confounding eff ect of renal dysfunction that may aggravate reduction in vascular elasticity. On 
the other hand, diabetic nephropathy is one of the major complications of type 1 DM (8) and 
a gradual progressive process of aortic stiff ening, renal damage and their interaction can be 
assumed in the chronic type 1 DM disease, appearing before onset of clinically detectable renal 
damage. This notion could be substantiated if an independent relationship can be established 
between aortic stiff ness and renal function within the normal range in type 1 DM.
Velocity-encoded magnetic resonance imaging (MRI) is well-suited to assess aortic stiff -
ness independent of geometric assumptions unlike other methods frequently used in clini-
cal studies like tonometry and ultrasound (9). Furthermore, MRI-based pulse wave velocity 
measurements have been well-validated in comparison to invasive pressure recordings (10).
Accordingly, the purpose of the present study was twofold: 1. to investigate whether type 1 
DM per se is associated with increased aortic stiff ness measured by MRI, independent of renal 
dysfunction; 2. to evaluate the relationship between aortic stiff ness and renal function within 
the normal range in type 1 DM patients.
MATERIALS AND METHODS
Study participants 
Between February 2008 and July 2009, 77 consecutive adult type 1 DM patients (mean dura-
tion of type 1 DM 24.3 ± 11.2 years) from our local outpatient clinic of the university medi-
cal centre participated in our study. Between March 2009 and September 2009 36 healthy 
controls (no history or clinical evidence of DM, hypertension and cardiovascular disease) 
similar in age and renal function were included. A retrospective subgroup analysis of a pre-
vious prospectively acquired population was performed. The type 1 DM patients included 
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for this study partly overlap with participants of a study described before (sixty-nine type 
1 DM patients overlap with the formerly published study, and 8 type 1 DM patients were 
newly recruited because of the ongoing study design) (11). All type 1 DM patients were on 
insulin treatment. Study subjects were included if they had preserved renal function defi ned 
as estimated glomerular fi ltration rate (eGFR) ≥ 60 ml/min/1.73m2 (12) and the presence of 
normoalbuminuria (i.e. <30 mg/24h microalbuminuria or microalbumuria/creatinine ratio < 
2.5 mg/mmol for men or <3.5 mg/mmol for women). Renal function was calculated with the 
Modifi cation of Diet in Renal Diseases (MDRD) equation providing accurate GFR estimates 
using serum creatinine (13). Exclusion criteria included aortic valve stenosis or insuffi  ciency 
and standard MRI contra-indications. 
Blood pressure was measured after MRI using a semi-automated sphygmomanometer. 
Hypertension was diagnosed after repeated blood pressure measurements according to 
guidelines of the European Society of Hypertension (14). The study was approved by the 
local medical ethics committee, and conducted according to the principles in the Declaration 
of Helsinki. All study participants signed informed consent.
MR imaging evaluation of aortic stiff ness
For the evaluation of aortic stiff ness all participants underwent MRI scanning on a 1.5 Tesla 
whole-body MR scanner (Philips Medical Systems, Best, the Netherlands) using a fi ve-ele-
ment phased-array cardiac coil for data acquisition. Aortic pulse wave velocity (PWV, i.e. the 
propagation speed of systolic wave front through the aorta) was assessed with a validated 
technique (10) as previously described in detail (15). First, coronal and oblique sagittal scout 
views of the aorta were obtained. In these scout scans, two imaging planes; one perpendicu-
lar to the ascending aorta at the level of the pulmonary trunk and one perpendicular to the 
abdominal descending aorta 7.5 cm beneath the diaphragm were determined (Figure 1A). 
At those levels retrospectively electrocardiographically gated gradient-echo sequences with 
maximum velocity encoding were subsequently obtained during free breathing to assess the 
fl ow in the ascending and abdominal descending aorta. A maximal number of phases was 
reconstructed to ensure high (6–10 msec) temporal resolution. Maximum velocity encoding 
was set to 150 cm/sec in the ascending aorta and 100 cm/sec in the abdominal descend-
ing aorta. Aortic PWV was defi ned as the aortic path length (Δx) divided by the transit time 
(Δt) of the systolic wave front between the respective measurement sites. Δx is the distance 
between the ascending and abdominal descending aorta, measured along the centerline in 
the oblique sagittal aortic scout view. Δt is the time delay between arrival of the foot of the 
pulse wave at the ascending, respectively abdominal descending aorta (Figure 1B). Manual 
contour drawing in the aorta velocity maps was performed by a single observer (S.v.E., 3 
years of experience in cardiac MRI) supervised by a senior researcher (J.W., 14 years of experi-
ence in cardiac MRI) using in-house developed software packages MASS and FLOW (Leiden 
University Medical Center, Leiden, The Netherlands).
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Statistical analysis
Data are expressed as mean ± standard deviation. Only aortic PWV values, because of non-
normal distribution, were expressed as median (interquartile range). To compare clinical 
characteristics between type 1 DM and healthy controls independent samples t-test for con-
tinuous variables and Chi-Square test for dichotomous variables were used. Mann-Whitney 
U test was used to test aortic PWV values between type 1 DM and healthy subjects. The 
correlation between eGFR and aortic PWV was tested by the Spearman correlation analysis 
separate for type 1 DM and healthy controls. Stepwise multivariable logarithmic regressions 
with forward entry analysis for eGFR were performed to study the relation with aortic PWV 
using interaction terms for the presence of type 1 DM. To investigate the possible confound-
ing eff ect of age, hypertension (14), heart rate, body mass index (BMI), smoking, DM duration 
and HbA1c multivariable logarithmic regression analysis was performed for the association 
between aortic PWV and eGFR in type 1 DM, using eGFR values uncorrected for age. P value 
< 0.05 was considered statistically signifi cant. We used SPSS for Windows (version 16.0; SPSS, 
Chicago, Illinois, USA) for statistical analysis.
Figure 1. Assessment of aortic pulse wave velocity
In Panel A, an oblique sagittal scout view of the aorta is shown. An oblique transverse pre-saturation slab in the 
ascending aorta and another pre-saturation slab perpendicular to the abdominal aorta result in black lines in the 
image. Velocity mapping was subsequently obtained at the same level of these lines in order to assess the fl ow 
graphs in the ascending and abdominal aorta. The aortic path length (Δx) between both levels was measured, 
indicated by the dashed line following the centerline of the aorta.
In Panel B, the fl ow curves in the ascending and abdominal aorta are illustrated. The horizontal lines represent the 
mean constant diastolic fl ow at the corresponding site in the aorta. The line following the upstroke is determined 
by linear regression between 20% and 80% of the range between diastolic fl ow and peak systolic fl ow. Time 
point of intersection between the upstroke and the baseline of the fl ow curve was considered being the arrival 
time of the pulse wave. The transit time (Δt) between arrival of the pulse wave at the ascending and respectively 




In all enrolled subjects, MRI scanning was completed and PWV was successfully obtained and 
interpreted. The clinical characteristics of the study population are shown in Table 1. There 
were no diff erences between type 1 DM patients and healthy controls with respect to renal 
function, age, gender, BMI, systolic blood pressure, smoking and HDL-cholesterol.
Type 1 DM patients showed signifi cantly increased aortic PWV (p<0.05), lower diastolic 
blood pressure (p=0.026), a higher pulse pressure (p<0.001), increased HbA1c (p<0.001) and 
lower total cholesterol levels (p=0.010) compared to healthy controls.
Table 1. Clinical characteristics and MRI results of the study population
Parameter Diabetes mellitus (n=77) Healthy controls (n=36) p- value
Clinical characteristics
Male gender, n (%) 39 (51) 23 (64) 0.2
Age (years) 46 ± 12 46 ± 16 0.9
DM duration (years) 24.3 ± 11.2 - na
Body mass index (kg/m2) 25.2 ± 3.2 25.7 ± 3.9 0.5
Systolic blood pressure (mmHg) 130 ± 17 124 ± 18 0.1
Diastolic blood pressure (mmHg) 73 ± 9 78 ± 11 0.026
Pulse pressure (mmHg) 57 ± 13 46 ± 15 <0.001
Current smoker, n (%) 10 (13) 4 (11) 0.7
HbA1c (%) 7.6 ± 1.0 5.0 ± 0.3 (n=10) <0.001
Fasting plasma glucose (mmol/l) - 4.9 ± 0.6 na
Total cholesterol (mmol/l) 4.7 ± 1.0 5.2 ± 1.0 0.010
HDL cholesterol (mmol/l) 1.6 ± 0.4 1.6 ± 0.4 0.7
Use of statin, n (%) 26 (34) 0 (0) na
Use of antihypertensive drug, n (%) 23 (30) 0 (0) na
Renal function
Estimated GFR (ml/min/1.73m2) 94 ± 16 89 ± 13 0.1
Aortic stiff ness
Aortic pulse wave velocity (m/s) 6.2 (5.4-7.8) 5.8 (4.4-7.1) <0.05
Data are means ± SD, number (%) or median (interquartile range). DM: diabetes mellitus; GFR: glomerular 
fi ltration rate; HbA1c: glycosylated haemoglobin; HDL: high density lipoprotein
Aortic pulse wave velocity and renal function
There was a statistically signifi cant correlation between eGFR and aortic PWV in both type 
1 DM patients (p<0.001, r=-.427, corresponding regression line; eGFR=-23×ln(aortic PWV) 
+ 137) and healthy controls (p=0.002, r=-.502, corresponding regression line; eGFR=-
24×ln(aortic PWV) + 130), which are shown in Figure 2. Interaction analyses showed that the 
association between eGFR and aortic PWV was signifi cantly diff erent between type 1 DM 
and healthy controls: 1. Type 1 DM patients show a higher aortic PWV than healthy controls 
for each given eGFR (p<0.001); 2. The decrease in eGFR per increase in aortic PWV was not 
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signifi cantly diff erent between type 1 DM patients and healthy controls (p=ns). The inverse 
association between eGFR and aortic PWV in type 1 DM patients was independent of age, 
hypertension, heart rate, BMI, smoking, DM duration and HbA1c level (p=0.026, Beta=-0.392).
Figure 2. Figure showing the inverse relationship between eGFR and aortic PWV in type 1 DM patients and 
in healthy controls
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The table illustrates the linear regression analysis eGFR=A× ln(aortic PWV) + B for type 1 DM and for healthy 
controls. P-values are reported from Interaction analysis, showing: 1. Increased aortic PWV in type 1 DM patients 
compared to healthy controls for each given eGFR (p<0.001); 2. The rate of decrease of eGFR per increase in 
aortic PWV did not statistically diff er between type 1 DM patients and healthy controls (p=0.919).
DISCUSSION
The purpose of the present study was to investigate whether type 1 DM per se is associated 
with increased aortic stiff ness measured by MRI, independent of renal dysfunction, and to 
evaluate the relationship between aortic stiff ness and renal function within the normal range 
in type 1 DM patients. The main fi ndings of our cross-sectional study are: 1. Type 1 DM patients 
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without microalbuminuria or renal impairment show increased aortic stiff ness compared to 
matched healthy controls; 2. An inverse association between eGFR and aortic PWV was found 
in both type 1 DM patients and in healthy controls; aortic stiff ness was increased for each 
given eGFR within normal range in type 1 DM, and the decrease in renal function per increase 
in aortic stiff ness was similar for type 1 DM patients and healthy controls.
We found increased aortic stiff ness in type 1 DM patients without microalbuminuria and re-
nal impairment. The present fi nding of increased aortic PWV in type 1 DM patients compared 
to healthy controls extends the observations in previous studies showing augmentation of 
aortic stiff ening in type 1 DM (2,16,17). Our fi ndings confi rm the hypothesis of an associa-
tion between type 1 DM per se and increased aortic stiff ness, irrespective of the potential 
detrimental eff ect on vascular elasticity of frequently present renal dysfunction. 
Secondly, we showed a signifi cant decrease in renal function within the normal range per 
increase in aortic stiff ness which was similar for type 1 DM patients and healthy controls, but 
with an increased aortic stiff ness for each given eGFR in type 1 DM (Figure 1). Our fi ndings are 
consistent with earlier studies showing the signifi cant relationship between eGFR values and 
arterial stiff ness in a community population with normal renal function (18,19). However, in 
these studies the infl uence of type 1 DM was not reported. Interestingly, although aortic stiff -
ness was increased in type 1 DM patients selected in our study, the increase in aortic stiff ness 
itself did not show an additional deteriorative eff ect on renal function; the rate of decrease in 
eGFR per increase in aortic stiff ness remained similar with healthy controls. A consequence 
of an increased aortic stiff ness is that pulse waves propagate faster into peripheral arteries 
and therefore may induce early return of refl ected waves, as manifested by the increased 
brachial pulse pressure shown by our data. Transmission of high pulsatile pressure is known 
to lead to renal microvascular damage (20). Apparently, the interaction between pulse wave 
velocity and renal function is also operational in presumed healthy subjects, indicating that 
this phenomenon may be physiological to some extent.
Of note, in our study aortic stiff ness was associated with renal function in type 1 DM pa-
tients independent of other risk factors including age, hypertension and smoking or type 1 
DM duration and glucose regulation. In contrast to our data, a previous study did not fi nd 
this independent relationship between eGFR and aortic PWV in DM (21). These diff erences 
may be explained by their inclusion of both type 1 DM and type 2 DM patients. Risk profi les 
in patients with type 1 DM are usually diff erent than in patients with type 2 DM. Type 2 DM 
is commonly associated with a high prevalence of other classical risk factors, such as obesity, 
abnormal lipid status and hypertension that also may aff ect aortic stiff ness (22) and subse-
quently confound the relationship between aortic stiff ness and renal function, as analyzed in 
our study independent of BMI and hypertension in type 1 DM patients. Another explanation 
for the diff erence in study outcome may be the methodology used for measuring aortic stiff -
ness. In our study aortic PWV was assessed using velocity encoded MRI, a validated modality 
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which is not dependent on geometric estimations unlike applanation tonometry as used in 
the before mentioned study. 
In perspective, MRI assessment of aortic PWV is currently not part of clinical routine in 
type 1 DM patients. However, our data show increased aortic stiff ness in type 1 DM patients 
without microalbuminuria, whereas microalbuminuria is currently one of the most frequently 
used screening tools for the early detection of cardiovascular disease (23) in medical practice. 
Furthermore, arterial stiff ness has been described as an independent predictor of cardio-
vascular disease and mortality in type 1 DM (3). Importantly, besides MRI assessed aortic 
stiff ness being a marker of renal function in our current study, earlier studies have shown 
MRI assessed aortic stiff ness to be an integrated marker of both cardiac function and cerebral 
small vessel disease (11) in type 1 DM patients. The results of our cross-sectional study and 
of earlier studies suggest that MRI assessment of aortic PWV could function as an integrated 
non-invasive screening tool for the detection of multi-organ cardiovascular complications in 
type 1 DM beyond classical risk factors. However, longitudinal studies are required to confi rm 
a clinical role of aortic PWV in cardiovascular risk stratifi cation and optimization of therapy.
In conclusion, this cross-sectional study demonstrates that aortic stiff ness is increased 
in type 1 DM patients independent of renal dysfunction. Moreover, an inverse relation was 
found between aortic stiff ness and renal function within the normal range in type 1 DM 
patients as well as in healthy controls. Longitudinal studies are needed to provide additional 
insight into the mechanisms of interaction between aortic stiff ening and renal failure as a se-
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Cerebral perfusion and aortic 
stiff ness are independent predictors 
of white matter brain atrophy 
in type 1 diabetes mellitus patients: 
assessment by MR imaging
SGC van Elderen, A Brandts, J van der Grond, JJM Westenberg, 






To identify vascular mechanisms of brain atrophy in type 1 diabetes mellitus (DM) patients 
by investigating the relationship between brain volumes and cerebral perfusion and aortic 
stiff ness using magnetic resonance imaging (MRI).
Materials and Methods
Approval from the local institutional review board was obtained and patients gave informed 
consent. Fifty-one type 1 DM patients (30 men; mean age 44 ± 11 years; mean DM duration 
23 ± 12 years) and 34 age and gender matched healthy controls, were prospectively enrolled. 
Exclusion criteria comprised hypertension, stroke, aortic disease and standard MRI contra-
indications. White matter (WM) and grey matter (GM) brain volumes, total cerebral blood fl ow 
(tCBF), total brain perfusion and aortic pulse wave velocity (PWV) were assessed using MRI. 
Multivariable linear regression analysis was used for statistics, with co-variates age, gender, 
mean arterial pressure, body mass index, smoking, heart rate, DM duration and HbA1c.
Results
Both WM and GM brain volumes were decreased in type 1 DM patients compared to controls 
(WM: p=0.04; resp. GM: p=0.03). Total brain perfusion was increased in type 1 DM compared 
to controls (Beta= -0.219, p<0.05). Total CBF and aortic PWV predicted WM brain volume 
(Beta=0.352, p=0.024 for tCBF, resp. Beta=-0.458, p=0.016 for aortic PWV) in type 1 DM. Age 
was the independent predictor of GM brain volume (Beta=-0.695, p<0.001).
Conclusion
Type 1 DM patients without hypertension showed WM and GM volume loss compared to 
controls concomitant with a relative increased brain perfusion. Total CBF and stiff ness of the 
aorta independently predicted WM brain atrophy in type 1 DM. Age only was predicting GM 
brain atrophy.
75
Vascular mechanisms of brain atrophy in type 1 diabetes
INTRODUCTION 
In type 1 diabetes mellitus (DM) patients, early development of brain atrophy (1,2) which 
may aff ect cognitive functioning (3,4) has been demonstrated. Multiple pathophysiological 
mechanisms like repeated hypoglycemic episodes (5), chronic hyperglycemia (6) and altera-
tions in insulin metabolism and associated insulin use (7) are suggested to be involved in the 
development of cerebral complications in type 1 DM. Although cerebral atrophy is common in 
neurodegenerative processes, decreased brain volumes have been associated with vascular 
risk factors (3,8), suggesting vascular mechanisms contributing to the development of brain 
atrophy. Indeed, the hyperglycemic state of DM induces structural changes and endothelial 
dysfunction of the macro- and microvasculature (9). Impaired cerebrovascular reactivity in 
type 1 DM has been demonstrated recently (10) and cerebral perfusion abnormalities have 
been found in type 1 DM patients in earlier studies (11,12). The cerebral circulation plays an 
important role in the maintenance of neuronal cell integrity, and therewith potentially in the 
development of brain atrophy.
Furthermore, arterial stiff ening has shown to occur in type 1 DM, being an independent pre-
dictor of cardiovascular outcome (13). The elastic aorta is the predominant site of pathologic 
arterial stiff ening. Aortic stiff ening increases pulse wave velocity (PWV) and pulse pressure 
(PP), placing considerable pulsatile stress on the peripheral circulation. The brain is a high 
fl ow organ and therewith particularly susceptible to pulsatile stress. Therefore, it is conceiv-
able that aortic stiff ness is contributing to the pathogenesis of brain atrophy in type 1 DM.
Although the associations between type 1 DM and cerebral perfusion or arterial stiff ening 
have been described, their relationship with brain volumes in this patient group, to investi-
gate potential vascular mechanisms causing brain atrophy has not been assessed until so far.
Quantitative measurements of brain volumes can be accurately evaluated on scans 
obtained by magnetic resonance imaging (MRI) (14). MRI using phase-contrast is a reliable 
method for estimating total cerebral blood fl ow (tCBF) (15) as well as for evaluating aortic 
stiff ness by means of PWV (16). 
Accordingly, the purpose of the current study was to identify potential underlying vascular 
mechanisms of brain atrophy in type 1 DM patients by investigating the relationship between 
brain volumes and cerebral perfusion and aortic stiff ness in this patient group using MRI.
METHODS
Study participants
Between February 2008 and January 2010, in total 51 consecutive type 1 DM patients from 
the local outpatient clinic of the Leiden university medical center and 34 age and gender 
matched healthy controls recruited by advertisement in local newspapers participated in 
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the study. Healthy controls did not have a history or clinical evidence of DM, hypertension 
or cardiovascular disease. Exclusion criteria for all participants included a clinical history or 
diagnosis of hypertension according to the guidelines of the European Society of Cardiology, 
stroke, aortic valve stenosis or insuffi  ciency as evaluated by means of cardiac auscultation 
and velocity-encoded MR imaging, Marfan syndrome, and standard MRI contra-indications 
like claustrophobia, pacemaker and metal implantations.
Information about type 1 DM and healthy control characteristics was obtained by standard-
ized interviews and physical and laboratory examinations. Type 1 DM duration was estimated 
as the time passed between the reported age of diagnosis and the MRI examination. Body 
mass index (BMI) was calculated from body length and mass at the time of MRI. Blood pressure 
(BP) and heart rate were measured after MRI using a semi-automated sphygmomanometer 
(Dinamap, Critikon, Tampa, FL, USA, validated to ANSI/AAMI SP10 criteria). Pulse pressure was 
defi ned as the diff erence between systolic and diastolic BP. Mean arterial pressure (MAP) was 
calculated by adding diastolic BP to one-third of the PP. Smoking was defi ned as non-smoker 
or a current smoker. Retinopathy was recognized on fundoscopy. Monofi lament testing was 
used to diagnose peripheral neuropathies. Microalbuminuria was defi ned as 30-300 mg 
albumin/24h urine collection or microalbumuria/creatinine ratio > 2.5 mg/mmol for men or 
>3.5 mg/mmol for women. Glycated hemoglobin (HbA1c) in type 1 DM, fasting glucose in 
healthy controls, high-density lipoprotein (HDL), total cholesterol, triglycerides and creati-
nine were furthermore determined. 
The study was approved by the local medical ethics committee, and conducted according 
to the principles in the Declaration of Helsinki. All study participants signed informed consent.
MR imaging protocol
All brain examinations were performed on a 3.0 Tesla MRI (Achieva; Philips Medical Systems, 
Best, the Netherlands). Aortic imaging was performed using 1.5 Tesla MRI (NT 15 Gyroscan 
Intera; Philips Medical Systems, Best, the Netherlands).
Brain MR imaging consisted of a 3-dimensional T1 sequence for brain volume assessment 
and a 2-dimensional phase contrast scan at the level of the skull base for fl ow measurements 
in the internal carotid arteries and basilar artery.
For the evaluation of white matter (WM) and grey matter (GM) brain volumes the 3D T1 
image (repetition time (TR) 9.8 msec, echo time (TE) 4.6 msec, fl ip angle (FA) 8˚, fi eld of view 
(FOV) 224 mm, 192x152 acquisition matrix, 256x256 reconstruction matrix, slice thickness 
1.2 mm, 120 slices, no slice gap) was obtained. Software package SIENAX automatically 
segments brain from non-brain matter, calculates white, grey and total brain volume, and 
applies a normalization factor to correct for skull size (14). To avoid confounding brain vol-
ume measurements because not all scans included the full brain, the SIENAX analyses were 
restricted to a pre-specifi ed interval along the z-axis, ranging from 75 to -52 mm in standard 
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MNI152 space. SIENAX is part of the FMRIB Software Library (FSL). All SIENAX analyses were 
performed using FSL version 2.6.
Total CBF was calculated from the electrocardiographic-triggered 2D phase contrast images 
(TR 13 msec, TE 8.3 msec, FA 10˚, FOV 150 mm, 128x88 acquisition matrix, 256x256 reconstruc-
tion matrix, slice thickness 5 mm, no slice gap, velocity sensitivity 140 cm/s) using the software 
package FLOW (Leiden University Medical Center, Leiden, the Netherlands). An experienced 
researcher drew manual regions of interest closely around the vessel lumen of the internal 
carotid arteries and the basilar artery (S.v.E., 3 year of experience in neuroradiology). The fl ow 
through the three arteries was summed and multiplied by the individual’s heart rate during 
MR scanning to calculate the tCBF (in ml/min). In three subjects (two type 1 DM patients, one 
healthy control) tCBF could not be obtained due to incorrect positioning of the phase-contrast 
imaging plane. Total brain perfusion (in ml/min per 100ml) was assessed by dividing tCBF (ml/
min) by each individual’s total brain volume (ml) and multiplying the obtained result by 100. 
For the evaluation of aortic stiff ness, aortic PWV was determined using a previously described 
protocol (16). In short, a scout view of the aorta was performed. Next, a velocity encoded im-
age perpendicular to the ascending aorta at the level of the pulmonary trunk was assessed. 
This resulted in through-plane fl ow measurements of the ascending and proximal descend-
ing aorta at those levels. Linear regression between 20% and 80% of the range between 
diastolic fl ow and peak systolic fl ow determines the line following the upstroke. Time point of 
intersection between the upstroke and the baseline of the fl ow curve was considered being 
the arrival time of the foot of the pulse wave. Aortic PWV was subsequently calculated for 
the aorta as Δx/Δt, where Δx is the aortic path length between the two measurement sites 
measured in the aortic scout view and Δt is the time delay between the arrivals of the foot 
of the pulse wave at the respective measurement sites. Data were analyzed using MASS and 
FLOW (Leiden University Medical Center, Leiden, the Netherlands) by two observers (S.v.E. 
and A.B., both 4 years of experience in cardiac MRI) supervised by a senior researcher (J.W., 15 
years of experience in cardiac MRI).
Statistical analysis
Data are expressed as mean ± standard deviation. To compare clinical characteristics be-
tween type 1 DM and healthy controls independent samples t-test for continuous variables 
and Chi-Square test for dichotomous variables were used. Kolmogorov-Smirnov test showed 
that aortic PWV was non-normally distributed (p<0.001). Therefore, a log transformation of 
aortic PWV values was used in the analyses. To compare MR fi ndings between type 1 DM and 
healthy controls linear regression analysis with covariates age, gender and MAP was applied.
In type 1 DM multivariable linear regression analysis was performed to study the associa-
tion between brain volumes and tCBF and aortic PWV, independent of potential confounders 
defi ned as age, gender, MAP, BMI, smoking, heart rate, DM duration and HbA1c. P value < 
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0.05 was considered statistically signifi cant. We used SPSS for Windows (version 16.0; SPSS, 
Chicago, Illinois, USA) for statistical analysis.
RESULTS
The characteristics of the study population are described in Table 1. Fifty-one type 1 DM 
patients (30 male, 21 female, mean age 44 ± 11 years, mean type 1 DM duration 23 ± 12 years) 
and 34 healthy controls were included. All type 1 DM patients were on insulin treatment. Type 
Table 1. Clinical characteristics and MRI parameters of type 1 DM patients and healthy controls
Type 1 DM patients 
(n=51)
Healthy controls (n=34) p-value
Characteristics
Age, years 44 ± 11 46 ± 14 0.46
Male gender, n (%) 30 (59) 17 (50) 0.42
Body mass index, kg/m2 25.0 ± 3.2 26.2 ± 3.9 0.18
Systolic blood pressure, mmHg 126 ±18 128 ± 15 0.62
Diastolic blood pressure, mmHg 74 ± 10 80 ± 11 <0.01*
Pulse pressure, mmHg 52 ± 13 47 ± 13 0.11
Mean arterial pressure, mmHg 91 ± 11 96 ± 11 0.04*
Heart rate, beats/min 65 ± 10 61 ± 10 0.05
Current smoker, n (%) 8 (16) 2 (6) 0.17
Alcohol use yes, n (%) 33 (64) 26 (77) 0.30
Laboratory markers
HbA1c, % 7.6 ± 1.0 na na
Fasting glucose level, mmol/l na 4.9 ± 0.6 na
HDL-cholesterol, mmol/l 1.7 ± 0.5 1.6 ± 0.4 0.34
Total cholesterol, mmol/l 4.7 ± 0.9 5.3 ± 1.2* 0.01*
Triglycerides, mmol/l 1.1 ± 0.6 1.4 ± 0.7* 0.04*
Creatinine, μmol/l 74 ± 11 77 ± 17 0.32
MRI fi ndings
Aortic PWV, m/s 5.3 (4.7 - 6.1) 5.7 (4.6 - 7.6) 0.21
Total cerebral blood fl ow, mL/min 466 ± 131 424 ± 111 0.27
Total brain perfusion, mL/min per 100 mL brain 
tissue
41.3 ± 11.0 36.4 ± 9.0 <0.05#
White matter brain volume, mL 567 ± 72 583 ± 70 0.04#
Grey matter brain volume, mL 565 ± 59 584 ± 54 0.03#
Total brain volume, mL 1132 ± 124 1167 ± 117 <0.01#
* signifi cantly diff erent between groups using independent samples t-test, p<0.05
# signifi cantly diff erent between groups, in multivariable linear regression analysis correcting for age, gender and 
MAP, p<0.05
Abbreviations: DM: diabetes mellitus; HbA1c: glycated hemoglobin, HDL: high density lipoprotein; PWV: pulse 
wave velocity
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1 DM and healthy controls were comparable in age, gender, BMI, systolic BP, PP, heart rate, 
current smokers, HDL-cholesterol and creatinine. Type 1 DM patients showed lower diastolic 
BP (p<0.01), lower total cholesterol (p=0.01) and lower triglyceride levels (p=0.04). Twelve 
type 1 DM patients used statins, whereas none of the healthy volunteers did. One out of the 
fi fty-one type 1 DM patient used an ACE-inhibitor and an angiotensin II-antagonist for the 
presence of microalbuminuria. None of the type 1 DM patients were on bèta-blocker use. 
None of the volunteers used antihypertensive medication.
WM brain volumes and GM brain volumes, normalized for skull size, were decreased in type 
1 DM patients compared to healthy controls (p=0.04 for WM; resp. p=0.03 for GM brain vol-
ume). Total brain perfusion was signifi cantly increased in type 1 DM compared to healthy 
controls presenting with similar systolic blood pressures and corrected for age, gender and 
MAP (Beta= -0.219, p<0.05). Aortic PWV values were in the normal range in type 1 DM patient 
and healthy controls (p=0.21). 
Table 2 shows the results of multivariable linear regression analyses to assess independent 
predictors for WM and GM brain volume in type 1 DM. Both tCBF and aortic PWV were inde-
pendent predictors of WM brain volume (Beta=0.352, p=0.024 for tCBF, resp. Beta=-0.458, 
p=0.016 for aortic PWV) in type 1 DM patients in a model including co-variates age, gender, 
MAP, BMI, smoking, heart rate, DM duration and HbA1c. In a similar multivariable linear 
regression model for GM brain volume age was a signifi cant predictor (Beta=-0.695, p<0.001) 
and tCBF and aortic PWV were not. Both total CBF and aortic PWV did not independently 
predict WM or GM brain volumes in healthy controls.
Table 2. Results of multivariable linear regression analyses performed in type 1 DM patients to assess 
independent predictors of WM and respectively GM brain volumes
WM brain volume GM brain volume
Beta p-value Beta p-value
Age, years 0.13 0.56 -0.70 <0.001
Male gender (n=30) -0.27 0.06 0.14 0.21
Mean arterial pressure, mmHg -0.04 0.80 -0.10 0.45
Body mass index, kg/m2 0.20 0.15 -0.03 0.77
Current smoker (n=8) 0.06 0.68 0.12 0.28
DM duration, years -0.18 0.35 0.02 0.91
HbA1c, % -0.04 0.83 0.23 0.08
Aortic PWV, m/s -0.46 0.02 0.07 0.62
Total cerebral blood fl ow, ml/min 0.35 0.02 0.11 0.36





The purpose of the current study was to assess the possible association between brain vol-
umes and cerebral perfusion and aortic stiff ness in type 1 DM patients without hypertension 
by using MRI. The main fi ndings of our study were: 1. Type 1 DM patients showed WM and 
GM volume loss compared to healthy controls concomitant with a relative increased brain 
perfusion. 2. Total CBF and stiff ness of the aorta independently predicted WM brain atrophy; 
3. Age was the only independent predictor of GM brain atrophy, whereas tCBF and aortic 
PWV were not.
Our fi ndings of cortical and subcortical atrophy in type 1 DM are in line with previous stud-
ies reporting mild cerebral atrophy in type 1 DM compared to controls (1,2). Furthermore, we 
found concomitant hyperperfusion of the brain. Impaired echo Doppler measured cerebro-
vascular reactivity has been described before in type 1 DM in accordance with our fi ndings 
(10,17). The Framingham heart study reported the exposure of cardiovascular disease risk 
factors, like DM, associated with high resting arterial fl ow and impaired vasoreactivity (18). 
The vasodilatory eff ect of persistent hyperinsulinemia was mentioned as a possible mecha-
nism of the high resting arterial blood fl ow (19). 
Furthermore, in our current study tCBF and aortic stiff ness were both predictors of WM 
brain atrophy. Recently, two large cohort studies were the fi rst to investigate and report as-
sociations between CBF and brain volumes (20,21). An elevation in CBF, particularly in the 
presence of factors that stiff en the aorta, may allow additional pulsatility to penetrate into 
and damage the microcirculation with subsequent cerebral tissue loss. A similar mechanism 
is a well known phenomenon in the kidneys; renal hyperperfusion is present in the earliest 
stages of type 1 DM and considered to contribute to renal injury and the progression to clini-
cal nephropathy (22). It has been suggested that the brain and the kidneys, both high fl ow 
organs with low impedance vascular beds, present a common and unique vascular reactivity 
mechanism on blood pressure and fl ow fl uctuations.
We found aortic stiff ness as an independent predictor of WM brain atrophy. To the best of 
our knowledge, no studies investigated this relationship before. Measurements of aortic PWV 
represent propagation speed of the pulse pressure which is infl uenced by both functional 
and structural changes of the arterial vessel wall. An earlier study found a positive correlation 
between MR parameters of brain atrophy and wall thickness of the internal carotid artery as 
well as a diagnosis of DM and the current use of insulin in community-dwelling elderly (3), 
which is in congruence with our fi ndings. Because vascular resistance in the brain is very low, 
pulsations can extend well into the microvascular cerebral bed. It is remarkable that the aor-
tic PWV was still in the normal range without statistical signifi cant diff erence as compared to 
that in healthy controls. We speculate that the brain of type 1 DM patients may be susceptible 
to small changes in aortic PWV, even when PWV appears to be relative normal. Moreover, 
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aortic stiff ness may be a marker of arterial function and infl ammatory processes manifesting 
in cerebral arteries and arterioles. 
Of note, the association between aortic PWV and WM brain volume was found indepen-
dent of tCBF suggesting two separate vascular mechanisms operating on WM brain atrophy. 
The associations between WM brain volumes and tCBF as well as aortic PWV could not be 
shown for GM brain volumes. It is known that the blood fl ow in the GM is substantially higher 
to the amount of blood fl ow in the WM because of high metabolic activity in the GM (23). 
Subtle fl uctuation in arterial blood fl ow or function may therefore spare GM brain volume 
in contrast to the vulnerable end-arterioles penetrating the WM. An earlier study suggested 
that persistent hyperglycemia and acute severe hypoglycemic events have an impact on 
early subtle alterations in GM structure in type 1 DM patients (24). In our study age was the 
only and strong predictor of GM brain atrophy, confi rming the theory of accelerated brain 
ageing in DM.
Our results may have important implications. First, our study results reveal further insight 
into the pathophysiology of brain atrophy in type 1 DM. Our fi ndings suggest two separate 
vascular mechanisms, namely tCBF and aortic stiff ness, being involved in WM brain atrophy 
in type 1 DM patients, independent of glucose regulation. Second, our fi ndings may have 
prognostic implications. Assessment of aortic PWV may have prognostic implications, even 
when values fall into the normal range, possibly due to increased brain susceptibility in DM 
patients. Furthermore, the arterial system is known to stiff en with older age and high blood 
pressure (25). When patients with type 1 DM become older or develop hypertension increased 
aortic stiff ening may occur with subsequent adverse changes in WM brain volumes. On the 
other hand, methods likely to detect subtle changes in the brain are essential for evaluating 
the eff ects of type 1 DM on the brain since the gradual progress of cerebral changes may 
make them diffi  cult to detect until years after onset of type 1 DM. Earlier detection of brain 
structural changes may increase the likelihood that treatment interventions can slow down 
the progression of these impairment. However, longitudinal studies are required to confi rm 
our results and to investigate the clinical implications of our fi ndings.
In conclusion, type 1 DM patients without hypertension showed WM and GM volume loss 
compared to healthy controls concomitant with a relative increased brain perfusion. Total 
CBF and stiff ness of the aorta independently predicted WM brain atrophy in type 1 DM pa-
tients. Age only predicted GM brain atrophy. Future prospective studies are needed to assess 




 1.  Lunetta M, Damanti AR, Fabbri G, Lombardo M, Di Mauro M, Mughini L. Evidence by magnetic 
resonance imaging of cerebral alterations of atrophy type in young insulin-dependent diabetic 
patients. J Endocrinol Invest 1994;17(4):241-245.
 2.  Northam EA, Rankins D, Lin A, et al. Central nervous system function in youth with type 1 diabetes 
12 years after disease onset. Diabetes Care 2009;32(3):445-450.
 3.  Longstreth WT, Jr., Arnold AM, Manolio TA, et al. Clinical correlates of ventricular and sulcal size 
on cranial magnetic resonance imaging of 3,301 elderly people. The Cardiovascular Health Study. 
Collaborative Research Group. Neuroepidemiology 2000;19(1):30-42.
 4.  Brands AM, Kessels RP, Hoogma RP, et al. Cognitive performance, psychological well-
being, and brain magnetic resonance imaging in older patients with type 1 diabetes. Diabetes 
2006;55(6):1800-1806.
 5.  Perros P, Deary IJ, Sellar RJ, Best JJ, Frier BM. Brain abnormalities demonstrated by magnetic 
resonance imaging in adult IDDM patients with and without a history of recurrent severe hypo-
glycemia. Diabetes Care 1997;20(6):1013-1018.
 6.  Wessels AM, Scheltens P, Barkhof F, Heine RJ. Hyperglycaemia as a determinant of cognitive 
decline in patients with type 1 diabetes. Eur J Pharmacol 2008;585(1):88-96.
 7.  Brands AM, Kessels RP, de Haan EH, Kappelle LJ, Biessels GJ. Cerebral dysfunction in type 1 diabe-
tes: eff ects of insulin, vascular risk factors and blood-glucose levels. Eur J Pharmacol 2004;490(1-
3):159-168.
 8.  Heijer T, Skoog I, Oudkerk M, et al. Association between blood pressure levels over time and brain 
atrophy in the elderly. Neurobiol Aging 2003;24(2):307-313.
 9.  Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 
2008;45:1-16.
 10.  Kozera GM, Wolnik B, Kunicka KB, et al. Cerebrovascular reactivity, intima-media thickness, and 
nephropathy presence in patients with type 1 diabetes. Diabetes Care 2009;32(5):878-882.
 11.  Quirce R, Carril JM, Jimenez-Bonilla JF, et al. Semi-quantitative assessment of cerebral blood fl ow 
with 99mTc-HMPAO SPET in type I diabetic patients with no clinical history of cerebrovascular 
disease. Eur J Nucl Med 1997;24(12):1507-1513.
 12.  Salem MA, Matta LF, Tantawy AA, Hussein M, Gad GI. Single photon emission tomography (SPECT) 
study of regional cerebral blood fl ow in normoalbuminuric children and adolescents with type 1 
diabetes. Pediatr Diabetes 2002;3(3):155-162.
 13.  Schram MT, Chaturvedi N, Fuller JH, Stehouwer CD. Pulse pressure is associated with age and 
cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J Hy-
pertens 2003;21(11):2035-2044.
 14.  Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-
sectional brain change analysis. Neuroimage 2002;17(1):479-489.
 15.  Spilt A, Box FM, van der Geest RJ, et al. Reproducibility of total cerebral blood fl ow measurements 
using phase contrast magnetic resonance imaging. J Magn Reson Imaging 2002;16(1):1-5.
83
Vascular mechanisms of brain atrophy in type 1 diabetes
 16.  Grotenhuis HB, Westenberg JJ, Steendijk P, et al. Validation and reproducibility of aortic pulse 
wave velocity as assessed with velocity-encoded MRI. J Magn Reson Imaging 2009;30(3):521-526.
 17.  Fulesdi B, Limburg M, Bereczki D, et al. Impairment of cerebrovascular reactivity in long-term type 
1 diabetes. Diabetes 1997;46(11):1840-1845.
 18.  Mitchell GF, Vita JA, Larson MG, et al. Cross-sectional relations of peripheral microvascular 
function, cardiovascular disease risk factors, and aortic stiff ness: the Framingham Heart Study. 
Circulation 2005;112(24):3722-3728.
 19.  Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood fl ow. A possible link 
between insulin resistance and blood pressure. Hypertension 1993;21(2):129-135.
 20.  Muller M, van der Graaf Y, Visseren FL, Vlek AL, Mali WP, Geerlings MI. Blood pressure, cerebral 
blood fl ow, and brain volumes. The SMART-MR study. J Hypertens 2010;28(7):1498-1505.
 21.  van Es AC, van der Grond J, ten Dam VH, et al. Associations between total cerebral blood fl ow and 
age related changes of the brain. PLoS One 2010;5(3):e9825.
 22.  Mogensen CE. Early glomerular hyperfi ltration in insulin-dependent diabetics and late nephropa-
thy. Scand J Clin Lab Invest 1986;46(3):201-206.
 23.  Catafau AM, Lomena FJ, Pavia J, et al. Regional cerebral blood fl ow pattern in normal young and 
aged volunteers: a 99mTc-HMPAO SPET study. Eur J Nucl Med 1996;23(10):1329-1337.
 24.  Musen G, Lyoo IK, Sparks CR, et al. Eff ects of type 1 diabetes on gray matter density as measured 
by voxel-based morphometry. Diabetes 2006;55(2):326-333.
 25.  Benetos A, Waeber B, Izzo J, et al. Infl uence of age, risk factors, and cardiovascular and renal 
disease on arterial stiff ness: clinical applications. Am J Hypertens 2002;15(12):1101-1108.

Chap ter 7
Progression of brain atrophy 
and cognitive decline in diabetes mellitus, 
a 3 year follow-up
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To investigate progression of magnetic resonance imaging (MRI) assessed manifestations 
of cerebral degeneration related to cognitive changes in a population of elderly diabetes 
mellitus (DM) patients compared to age-matched control subjects.
Materials and Methods
From a randomized controlled trial (PROSPER-study) a study sample of 89 DM patients and 
438 non-DM control subjects, aged 70-82 years, were included for brain MRI scanning and 
cognitive function testing at baseline and re-examination after 3-years. Changes in brain 
atrophy, white matter hyperintensities (WMHs), number of infarctions and cognitive function 
test results were determined in DM and non-DM subjects. Linear regression analysis was 
performed with correction for age, gender, hypertension, pravastatin treatment, educational 
level and baseline test results. In DM patients, baseline MRI parameters were correlated with 
change in cognitive function test result using linear regression analysis with covariates age 
and gender.
Results
DM patients showed increased progression of brain atrophy (p<0.01) after follow-up com-
pared to control subjects. No diff erence in progression of WMH volume or infarctions was 
found. DM patients showed increased decline in cognitive performance on Stroop (p=0.04) 
and Picture Learning Test (PLT) (p=0.03). Furthermore, in DM patients change in PLT was as-
sociated with baseline brain atrophy (p<0.02).
Conclusion
Our data show that non-demented elderly DM patients have accelerated progression of 
brain atrophy with signifi cant consequences in cognition compared to non-DM subjects. Our 
fi ndings add further evidence to the hypothesis that diabetes exerts deleterious eff ects on 
neuronal integrity.
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INTRODUCTION 
Diabetes Mellitus (DM) is associated with cerebral atrophy, white matter hyperintensities 
(WMHs) and infarctions, observed on Magnetic Resonance Imaging (MRI) scans of the brain 
(1-4). In general the presence of these cerebral alterations is also associated with cognitive 
impairment (5-7) and dementia (8-10), and indeed previous studies have shown a higher 
prevalence of brain atrophy (11,12), WMHs (13,14) and infarctions (13), as well as a diminished 
cognitive function in DM patients compared to control subjects (14-18). For DM patients, 
little is known however about the progression in time of cerebral degeneration on MRI. Until 
now, only few longitudinal studies have investigated DM as possible risk factor for MRI as-
sessed brain atrophy and WMHs, reporting confl icting results. Some studies reported DM as 
a risk factor for brain atrophy, WMH progression and new infarctions (1,19,20) while other 
studies did not fi nd DM as a risk factor (3,21). Moreover, the potential predictive value of MRI 
parameters for cerebral degeneration for cognitive decline over time has not been studied 
before in DM.
The purpose of the present study was to investigate diff erences in progression rate of 
neurodegenerative changes (cerebral degeneration on MRI and cognitive function) between 
DM and non-DM subjects. Furthermore, we investigated whether MRI assessed brain atrophy, 
WMH volume and infarctions at baseline were associated with cognitive decline in DM after 
3 year follow-up duration.
METHODS
Study participants 
All study participants originated from the PROspective Study of Pravastatin in the Elderly at 
Risk (PROSPER) study (22), a large randomized controlled trial assessing the benefi ts of 40 
mg pravastatin daily on vascular endpoints. Inclusion and exclusion criteria of the PROSPER 
study and extensive defi nition of PROSPER study endpoints have been described in detail 
elsewhere (22). In short, men and women between 70 and 82 years old with either pre-ex-
isting coronary (physician diagnosed stable angina, myocardial infarction), cerebral (stroke, 
transient ischemic attack) or peripheral vascular disease (physician diagnosed intermittent 
claudication, arterial surgery or amputation for vascular disease >6 months before study 
entry), or with increased risk of vascular disease because of smoking, hypertension (defi ned 
as currently receiving antihypertensive drug treatment) or DM (known diabetes mellitus) 
were enrolled. Individuals with pre-existing poor cognitive function, defi ned as a minimal 
mental state examination (MMSE) score of less than 24, or abnormal laboratory fi ndings were 
excluded at baseline. Additional exclusion criteria for this MRI sub-study were general MRI 
contra-indications (pacemaker, metal implantations, claustrophobia). From the 1100 Dutch 
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participants in the PROSPER study, 646 participants consented for the MRI sub-study. Forty of 
the 646 original study participants died during the 3 year follow-up period. From the remain-
ing 606 study subjects, MRI data and cognitive function test results at baseline and at end of 
follow-up were available from in total 527 participants. Reasons for exclusion of follow-up 
examination were claustrophobia or illness during MRI (n=41), technical problems of the MRI 
(n=2), MRI contra-indications (n=3), artifacts on MRI (n=27), and 6 withdrew their informed 
consent. Compared with the follow up participants, those who dropped out had higher base-
line total WMH volumes and performed worse on the Stroop and Letter-Digit Coding Test 
(LDCT). All participating study subjects experienced MRI scanning and cognitive function 
testing at the same day. In total 89 of the 527 participants were DM patients. All participants 
gave their written informed consent according to the Declaration of Helsinki. Our local ethics 
committee approved the study protocol.
MRI scanning
Similar MRI protocols were performed on a 1.5 T MR system (Philips Medical Systems, Best, 
the Netherlands) at baseline and at follow-up. The MRI protocol included dual fast spin 
echo (TR/TE1/TE2= 3000/27/120ms; fl ip angle 90˚, echo train length 10; 48 continuous 3mm 
slices; matrix 256x256; FOV 220mm) and fl uid-attenuated inversion recovery (FLAIR) (TR/TE= 
8000/100ms; 48 continuous 3mm slices; matrix 256x256; FOV=220mm) sequences.
Automatic quantifi cation of intracranial volume, brain parenchyma volume and WMH 
volume was performed on T2-weighted and FLAIR images using Software for Neuro-Image 
Processing in Experimental Research (SNIPER) (23). A measure refl ecting acquired brain 
volume loss was calculated using the equation: brain atrophy (%) = [(intracranial volume – 
parenchymal volume)/intracranial volume] x 100% (24). Hyperintensities connected to the 
lateral ventricles were labeled as periventricular WMHs. Hyperintensities not connected to 
the lateral ventricles were labeled as deep WMH (25). The volume of periventricular WMH and 
deep WMH was calculated automatically. Brain infarctions included symptomatic and silent 
(lacunar) infarctions. Infarction was defi ned as a parenchyma defect (>3 mm in size) seen on 
a FLAIR scan with the same signal intensity as cerebrospinal fl uid and corresponding focal 
hyperintensity on T2-weighted images. The total number of infarctions for each patient was 
visually scored by a neuroradiologist with more then 15 years of experience in neuroradiology.
Cognitive function testing
For the assessment of cognition, three diff erent cognitive function tests refl ecting the main 
cognitive domains aff ected in DM (26,27) were performed at baseline and subsequently 
repeated at end of follow-up, including Stroop test, LDCT and Picture Learning Test (PLT). 
Since the MMSE is not suitable for longitudinal research because of learning and ceiling 
eff ects, MMSE scores are not reported here. The third part of the Stroop test was used for 
the evaluation of selective attention (28). In this study an abbreviated version of the Stroop 
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Color-Word test was used in which the stimuli were reduced from 100 to 40 items, which is a 
very reliable estimate of the performance on the complete test (29). The LDCT was performed 
to measure speed of processing of general information, which tests visual scanning, percep-
tion, visual memory, visuoconstruction and motor functions. The PLT consists of 12 pictures 
which subjects should recall in any order after the pictures has been shown to them, to test 
recent memory. The PLT performed comprised an immediate and a 20 minute delayed recall.
Statistical analysis
Statistical analysis was performed using the SPSS-16.0.2 statistical software package (SPSS 
Inc., Chicago, IL). Baseline diff erences between DM and control subjects in demographic 
variables, MRI parameters and cognitive function test results were analyzed using regression 
analysis, adjusting for age and gender. We calculated change in scores for each subject fi nal 
visit (change in score (Δ) = follow-up value minus baseline value) for each MRI parameter 
and cognitive function test result, respectively defi ned as Δ Atrophy, Δ WMH, Δ infarction, Δ 
Stroop, Δ LDCT and Δ PLT. Diff erences between DM and control subjects in Δ MRI parameters 
and Δ cognitive function test results were tested using linear regression models. Age, gender, 
hypertension, pravastatin treatment and corresponding baseline test result were defi ned 
as possible confounders and entered as co-variates in the multivariate regression model. 
Educational level (age left school) was added as a co-variate in the linear regression analysis 
for Δ cognitive function tests. A potential predictive role of MRI assessed brain atrophy, WMH 
volume and infarction for cognitive decline over time in DM was investigated by correlating 
baseline MRI parameters with Δ cognitive function test scores, which were signifi cantly in-
creased for DM versus non-DM subjects. For this analysis linear regression analysis was used 
with correction for age and gender. A p-value ≤ 0.05 was considered signifi cant.
RESULTS
The demographic characteristics of the study population are shown in Table 1. At baseline, 
there were no diff erences in age, gender, pravastatin use, MMSE score and educational level 
between the DM and control subjects. The DM patients showed higher body mass index (BMI) 
(p=0.01), higher glucose level after overnight fasting (p<0.01), less hypertension (p<0.01) but 
with similar systolic blood pressure levels, and a slightly better cholesterol profi le (p<0.05) 
compared to control subjects. There was no diff erence in use of drugs with an eff ect on cog-
nition between groups including the use of anitcholinergics, antipsychotics, antiepileptics 
and benzodiazepines. Out of the 89 DM patients, 11 (12.4%) DM patients were on insulin 
treatment, 56 (62.8%) DM patients used oral glucose lowering drugs, two (2.2%) DM patients 
used both insulin treatment and an oral glucose lowering drug and 24 (27.0%) DM patients 
did not receive medical treatment for their DM (lifestyle interventions).
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Table 1. Baseline characteristics of the study population
DM patients 
(n = 89)
Control subjects (n = 438) p-value
Age, years 74.7 ± 3.1 75.0 ± 3.2 0.39
Male gender, n (%) 53 (60) 244 (56) 0.51
MMSE, total test score 28.1 ± 1.4 28.2 ± 1.5 0.55
Education level, age in years left school 15.3 ± 2.80 15.5 ± 2.89 0.41
BMI, kg/m2 27.6 ± 3.8 26.5 ± 3.6 0.01*
Systolic blood pressure, mmHg 161 ± 21 157 ± 22 0.09
Diastolic blood pressure, mmHg 84 ± 12 86 ± 11 0.19
Pravastatin treatment, n (%) 41 (46) 218 (50) 0.52
Current smoker, n (%) 14 (16) 97 (22) 0.18
Hypertension, n (%) 43 (48) 290 (66) <0.01*
TIA or stroke, n (%) 9 (10) 72 (16) 0.13
Myocardial infarction, n (%) 14 (16) 51 (12) 0.29
Peripheral vascular disease, n (%) 29 (33) 194 (44) 0.03*
Fasting glucose, mmol/l 8.32 ± 2.39 5.26 ± 0.69 <0.01*
Total cholesterol, mmol/l 5.56 ± 0.78 5.80 ± 0.87 0.02*
LDL cholesterol, mmol/l 3.76 ± 0.70 3.95 ± 0.76 0.03*
HDL cholesterol, mmol/l 1.19 ± 0.30 1.25 ± 0.32 0.13
Triglycerides, mmol/l 1.57 ± 0.67 1.49 ± 0.68 0.30
Use of anticholinergicum, n (%) 6 (6.7) 16 (3.7) 0.30
Use of antiepilepticum, n (%) 0 (0) 0 (0) na
Use of antipsychoticum, n (%) 1 (1.1) 1 (0.1) 0.31
Use of benzodiazepine, n (%) 5 (5.6) 16 (3.7) 0.38
Data are expressed as mean ± standard deviation or number of subjects with numbers in parentheses being 
percentages. List of abbreviations: DM: diabetes mellitus; MMSE: mini mental state examination; BMI: body 
mass index; TIA: transient ischemic attack; LDL: low-density lipid; HDL: high density lipid; *signifi cant diff erence 
between DM and control subjects corrected for age and gender, p<0.05
The average time period (± SD) between baseline and follow up visit was 33 ± 1.4 months. 
Follow-up duration was slightly shorter in DM patients compared to control subjects (p<0.05).
MRI parameters of DM and control subjects at baseline, and change between follow-up and 
baseline (Δ) MRI parameters are shown in Table 2. At baseline DM patients had more brain 
atrophy compared to control subjects (p=0.02). No diff erence in baseline WMH volume and 
number of infarctions per patient was found between DM patients and control subjects. DM 
patients showed increased progression of total brain atrophy (p<0.01, Beta=0.136) compared 
to control subjects, after correction for age, gender, hypertension, pravastatin treatment and 
baseline level of atrophy. DM subjects did not show increased progression of total, periven-
tricular or subcortical WMHs or infarctions compared to control subjects.
In addition, a linear regression analysis was performed to investigate the possible role 
of hyperglycemia or insulin use on the progression of atrophy (Δ atrophy as a dependent 
variable and age, gender, hypertension, pravastatin treatment, baseline level of atrophy and 
fasting glucose respectively insulin treatment entered as co-variates). There was a signifi cant 
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association between Δ atrophy and fasting glucose levels (p=0.003, Beta=0.127), and be-
tween Δ atrophy and insulin treatment (p=0.002, Beta=0.131).






Time between follow-up and baseline visit, wks (SD) 170 ± 14 173 ± 13 0.03*
MRI fi ndings
Baseline total brain atrophy, % 26.9 ± 0.37 26.1 ± 0.14 0.02*
Baseline total WMH volume, cc 4.19 ± 0.82 5.34 ± 0.48 0.31
Baseline periventricular WMH volume, cc 3.29 ± 0.69 4.19 ± 0.42 0.36
Baseline subcortical WMH volume, cc 0.90 ± 0.16 1.15 ± 0.08 0.20
Baseline infarction, number per patient 1.39 ± 3.02 0.98 ± 1.84 0.53
Δ total brain atrophy, % 1.57 ± 0.26 0.96 ± 0.10 <0.01†
Δ total WMH volume, cc 1.78 ± 0.29 2.21 ± 0.17 0.41
Δ periventricular WMH volume, cc 1.38 ± 0.24 1.78 ± 0.16 0.32
Δ subcortical WMH volume, cc 0.39 ± 0.12 0.44 ± 0.05 0.87
Δ infarction, number per patient 0.40 ± 1.23 0.19 ± 0.68 0.07
Cognitive function test
Baseline Stroop time, sec 59.0 ± 1.94 54.1 ± 0.84 0.02*
Baseline LDCT score, digits/min 26.6 ± 0.76 28.0 ± 0.34 0.09
Baseline PLT immediate, recalled pictures 9.70 ± 0.18 10.23 ± 0.08 0.01*
Baseline PLT delayed, recalled pictures 10.67 ± 0.30 11.31 ± 0.12 0.04*
Δ Stroop time, sec 3.8 ± 2.48 0.6 ± 0.65 0.04†
Δ LDCT score, digits/min -1.9 ± 0.37 -1.3 ± 0.21 0.06
Δ PLT immediate, recalled pictures -0.16 ± 0.16 0.07 ± 0.09 0.03†
Δ PLT delayed, recalled pictures -0.15 ± 0.27 -0.04 ± 0.12 0.12
Data are expressed as mean ± standard error unless stated otherwise. List of abbreviations: DM: diabetes 
mellitus; MRI: magnetic resonance imaging; WMH: white matter hyperintensity; LDCT: letter digit coding test; PLT: 
picture learning test
Δ: change in test score between baseline and follow-up
*Signifi cant diff erence (p<0.05) between DM and control subjects adjusted for age and gender
†Signifi cant diff erence (p<0.05) between DM and control subjects adjusted for age, gender, hypertension, 
pravastatin treatment, educational level and corresponding baseline test results
Cognitive function test results of DM and control subjects at baseline, and change between 
follow-up and baseline (Δ) cognitive function test results are shown in Table 2. At baseline, 
DM patients showed worse performance on Stroop testing (p=0.02) and immediate and 
delayed PLT scores (p<0.05) compared to control subjects. No diff erence in LDCT test results 
between the DM and the control subjects were found at baseline. After follow-up, DM sub-
jects showed worse decline in cognitive function test results on Stroop (p=0.04, Beta=-0.090) 
and PLT immediate (p=0.03, Beta=-0.090) compared to control subjects, corrected for age, 
gender, hypertension, pravastatin treatment, educational level and respective baseline test 
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result. No independent signifi cant association was found between DM and change in LDCT 
and PLT delayed test score. 
In the DM group, change in immediate PLT scores was correlated with baseline brain 
atrophy (p=0.01, r=-0.292). Changes in Stroop did not show a signifi cant association with 
baseline MRI parameters of cerebral degeneration in patients with DM.
DISCUSSION
The main fi ndings of our study are an accelerated progression of total brain atrophy in 
non-demented elderly DM patients compared to control subjects. In addition, DM patients 
showed accelerated decline in cognitive performance on Stroop and immediate PLT com-
pared to control subjects. Moreover, change in immediate recall was associated with baseline 
brain atrophy in DM patients.
We investigated the progression of MRI assessed manifestations of cerebral degeneration 
in DM and we found accelerated progression of brain atrophy, but not of WMHs or infarctions 
in DM compared to control subjects. Although many cross-sectional studies have reported 
an association between DM and brain atrophy (2,12,30-32), to our knowledge only two longi-
tudinal studies have reported on this (3,19). Our fi nding on accelerated progression of brain 
atrophy in DM compared to control subjects is in line with one of these studies (19), which 
showed that DM subjects had a high rate of brain atrophy after a 6-year follow-up period. 
Our results are in contrast with an earlier published study (3) which did not fi nd DM as a risk 
factor of progression in brain atrophy. In our study, DM patients did not have accelerated 
progression of WMHs, which is supported by previous studies in which hypertension (33), 
high blood pressure and smoking (21) were determinants of WMH progression, whereas DM 
was not. On the contrary, others have found that DM is a risk factor for WMH progression 
within a comparable follow-up period of 3 years (1). The confl icting results in the latter study 
compared to our results may be explained by the diff erence in methodological approach. 
In our study semiautomated quantifi cation of WMHs was performed, whereas WMHs were 
visually rated in the latter study. This rating method may be less sensitive compared to abso-
lute measurements in studying longitudinal white matter changes (34). The fi nding that the 
number of new infarctions during follow-up in DM patients was not diff erent from control 
subjects is in line with earlier longitudinal studies investigating risk factors of incidental brain 
infarcts which reported no association with DM (1,21).
A possible explanation for accelerated progression of brain atrophy and not of WMHs 
and infarctions in DM patients could be due to diff erences in underlying pathofysiological 
mechanisms. Our results indicate that the increased progression of brain atrophy in DM is 
mediated mostly by mechanisms other then hemodynamic causes, since there was a low 
prevalence of hypertension in the DM group compared to the control group. In this respect, 
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a direct neurotoxic eff ect of hyperglycemia or hyperinsulinaemia as proposed in previous 
studies (31,35,36) could be important determinants of brain atrophy in DM. Importantly, 
additional analyses showed a signifi cant role for glucose levels and for the use of insulin on 
brain atrophy progression.
Another important fi nding in our study is that DM subjects demonstrated an accelerated 
decline in selective attention and immediate recall. This fi nding is in line with previous stud-
ies reporting an association between DM and increased decline in cognitive function test 
scores (15-18), including the cognitive domains of attention and memory. In contrast to our 
fi ndings, one study did not fi nd an accelerated cognitive decline in DM (37). However, in this 
study the oldest old beyond the age of 85 were investigated, compared to a mean age of 
75 years in our study. Although we found a progressive decline in cognitive functioning in 
DM, the changes in cognitive function test scores were relatively small (Δ Stroop: 3.8 sec, Δ 
PLT immediate: -0.16 recalled pictures). Still, in daily practice patients can already experience 
subtle inconvenience from this cognitive decline, for instance being in stressful situations. 
Importantly, DM can be well treated and elderly DM patients on oral hypoglycemic therapy 
have been shown to perform comparable on cognitive function tests over time to subjects 
without DM (38).
In the current longitudinal study we reported the predictive value of cerebral degeneration 
on cognitive decline over time in DM. Our study results show that brain atrophy at baseline 
is a predictor of verbal memory loss in DM implying a causative mechanism of loss of brain 
volume on impaired memory. Previous cross-sectional studies reported brain atrophy and 
WMHs observed on MRI scans of elderly DM patients to be associated with several domains 
of cognitive impairment including memory (13,39). However, to our knowledge, there are no 
previous studies specifi cally addressing the longitudinal relation between brain MRI abnor-
malities and cognitive functioning in DM patients.
A strength of our study is the large number of DM patients investigated. Although a limita-
tion of the present study is the relatively short follow-up duration, it should be noted that 
even in a relatively small follow-up period of three years accelerated progression of brain 
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of skeletal muscle in maternally 
inherited diabetes and deafness A3243G 
mitochondrial mutation carriers
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To investigate high-energy phosphate metabolism in striated skeletal muscle of patients with 
Maternally Inherited Diabetes and Deafness (MIDD) syndrome.
Materials and Methods 
In 11 patients with the MIDD mutation (six with diabetes mellitus (DM) and fi ve non-DM) 
and eight healthy subjects, phosphocreatine (PCr) and inorganic phosphate (Pi) in the vastus 
medialis muscle was measured immediately after exercise using 31P-magnetic resonance 
spectroscopy (MRS). The half-time of recovery (t1/2) of monoexponentially fi tted (PCr+Pi)/PCr 
was calculated from spectra obtained every 4 seconds after cessation of exercise. A multiple 
linear regression model was used for statistical analysis.
Results 
Patients with the MIDD mutation showed a signifi cantly prolonged t1/2 (PCr+Pi)/PCr after ex-
ercise as compared to controls (13.6 ± 3.0 vs. 8.7 ± 1.3 sec, p = 0.01). No association between 
the presence of DM and t1/2 (PCr + Pi)/PCr was found (p = 0.382).
Conclusion 
MIDD patients showed impaired mitochondrial oxidative phosphorylation in skeletal muscle 
shortly after exercise, irrespective of the presence of DM.
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INTRODUCTION 
The maternally inherited diabetes and deafness (MIDD) syndrome is known as a phenotype 
of the adenosine to guanine mutation at position 3243 (A3243G) in the tRNA gene (1,2). The 
key identifying features of MIDD patients are characterized by a triad of diabetes mellitus 
(DM), developing in 80% of patients with the MIDD mutation carriers, sensorineural deafness, 
and a history of these conditions in maternal relatives (3-6). Diagnosis of the MIDD syndrome 
is based on the pattern of inheritance, the presence of clinical features, and DNA analysis. 
Although MIDD is often unrecognized, it is estimated that MIDD aff ects between 0.6-1.5% of 
DM patients (7).
Besides the characteristic triad, MIDD patients may present with other symptoms such as 
renal disease, cardiomyopathy, gastrointestinal complaints, and muscle cramps or muscle 
weakness (3). A transition of adenosine to guanine at nucleotide position 3243 aff ects the 
encoding of mitochondrial proteins. This mutation causes the formation of dysfunctional mi-
tochondria and subsequently reduced mitochondrial oxidative adenosinetriphosphate (ATP) 
energy production (4). The striated skeletal muscle depends largely on mitochondrial oxida-
tive phosphorylation for generation of high-energy phosphates. Associations have been 
suggested between (sub)clinical myopathies and mitochondrial dysfunction in the MIDD 
syndrome (5,6). 
Phosphorus-31 magnetic resonance spectroscopy (31P-MRS) is a sensitive and specifi c 
noninvasive method for the assessment of skeletal muscle mitochondrial ATP production. 
Observations at rest are not specifi c for mitochondrial disorders. During exercise patients 
with mitochondrial myopathies will display rapid phosphocreatine (PCr) depletion. During 
recovery, 31P-MRS measurements are the most sensitive and the most specifi c indices used to 
assess skeletal muscle mitochondrial ATP production (8-11). To our knowledge, only a limited 
number of MIDD patients have been studied by skeletal muscle 31P-MRS and the potential 
confounding eff ect of the presence of DM has not been systematically evaluated before (12-
14). As the A3243G mutation potentially results in decreased oxidative phosphorylation and 
some MIDD patients show signs of muscle involvement, we hypothesized that alterations in 
phosphate energy metabolism of the striated muscles can be detected in these patients after 
exercise. 
Accordingly, the objective of the current study was to investigate with 31P-MRS whether the 
presence of the A3243G mitochondrial mutation in the MIDD phenotype aff ects high-energy 
phosphate metabolism in the striated skeletal muscle of patients with the A3243G MIDD 
mutation. As alterations in phosphate metabolism in MIDD patients may be attributed to DM 





The local medical ethics committee approved the study and informed consent was obtained 
from all participants prior to enrolment in the study.
A 31P-MRS examination was performed in 11 MIDD patients (fi ve male; age 36 ± 10 years; 
six with DM and fi ve non-DM) and eight healthy control subjects (fi ve male; age 35 ± 8 years), 
matched for age, height, and body weight. Patients were recruited from the local MIDD 
database of the DM outpatient clinic of our institution. A standard oral glucose tolerance test 
(OGTT) was performed in the MIDD patient group - except for the DM patients - to diff erenti-
ate between DM and patients with normal glucose tolerance (non-DM). The patient group 
showed no signs of increased muscle weakness or fatigue during normal daily activities. 
Control subjects and patients were not actively engaged in sports or training activities. Other 
exclusion criteria comprised general contraindications to MRI.
MR spectroscopy protocol
In order to apply an individually adjusted exercise load, the maximal isokinetic potential of 
the leg muscles was measured prior to MRS in a standardized setting with a dynamometer 
(EnKnee, Enraf Nonius, Delft, The Netherlands). Subjects were positioned in the test chair with 
the lower leg secured above the ankle, and hip and thigh strapped down to avoid involuntary 
movements. After extending the knee 15 times in rapid succession the isokinetic muscle 
strength was expressed as the maximum peak torque produced in these knee extensions. 
The subjects were subsequently instructed to exercise by leg extension in the scanner with 
a weight attached to the ankle of the dominant leg. The weight consisted of lead-containing 
rubber strips and corresponded to 25% of the individually assessed maximal isokinetic po-
tential. The knee of the subject was supported to enable extension. Exercise was performed 
by repeated extension once per second during 3 minutes to reach a steady state, which was 
validated in a pilot study before onset of this study, depicted in Figure 1. During exercise the 
subjects were in a supine position in a 1.5 T MRI-system (Gyroscan ACS/NT15; Philips, Best, The 
Netherlands, Philips Medical Systems). A 6 cm diameter circular surface coil was positioned at 
the anatomical localization of the vastus medialis muscle. After exercise the subject kept the 
leg immobilized for 3 minutes, in which the spectra were obtained. The whole procedure was 
repeated after 15 minutes of rest.
Immediately after cessation of the exercise, 31P-MRS from the vastus medialis muscle were 
obtained every 4 seconds (sweep width 2000 Hz, 1024 samples, fl ip angle 20°, 6 cm diameter 
circular surface coil, four signal averages obtained at TR = 1 sec). Shimming of the magnetic 
fi eld was performed with the proton imaging body coil, yielding a water resonance of 0.2-0.3 
parts/million full-width at half-maximum. Relative concentrations of high-energy phosphates 
(PCr and inorganic phosphate (Pi)) were measured.
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Data analysis
Ratios of (PCr+Pi)/PCr were calculated from spectra obtained during the recovery period 
using time-domain spectral fi tting (MRUI-software, AMARES) (20). Recovery rate, refl ecting 
effi  ciency and rate of oxidative phosphorylation (21), was characterized by the half-time of 
recovery (t1/2) of monoexponential fi tted (PCr+Pi)/PCr (22).
As each subject performed exercise twice in the scanner, we obtained two phosphorus 
spectra from each individual. From each obtained phosphorus spectrum the half-time of PCr 
recovery was calculated. Subsequently the average of the two measurements in each subject 
was used for statistical analysis.
Laboratory assessment
Venous blood samples were obtained prior to and after exercise to determine blood glucose, 
insulin, connecting-peptide (C-peptide), glycated hemoglobin (HbA1c), creatine-phosphoki-
nase (CPK), and lactate levels.
Statistical analysis
Multiple linear regression analysis and one-way analysis of variance (ANOVA) were used for 
statistical evaluation. Results are expressed as mean ± standard deviation. A multiple linear 
regression analysis was performed for analysis of the 31P-MRS results. To identify independent 
predictors of skeletal phosphorus-metabolism, t1/2 (PCr+Pi)/PCr was entered as a dependent 
variable and MIDD mutation (yes/no) and DM (yes/no) were subsequently entered as inde-
pendent variables into the model. For comparison of isokinetic potentials and laboratory 
measurements between groups one-way ANOVA analysis was used, with post-hoc Bonfer-
Figure 1. 31P-MRS derived phosphor-curve during exercise in a healthy volunteer, showing a steady state of 
phosphor metabolism at 3 minutes.




















roni correction when comparing healthy subjects with patients both with DM and without 
DM. Statistical signifi cance was indicated by a p-value less than 0.05.
RESULTS
The results of patients and healthy subjects are summarized in Table 1.











Gender (male/female) 5 / 3 3 / 3 3 / 2 6 / 5
Age (years) 35 ± 6 39 ± 6 36 ± 5 38 ± 5
Body mass Index (kg/m2) 23.7 ± 2.4 22.6 ± 3.6 24.4 ± 3.1 23.4 ± 3.3
HbA1c (%) 4.5 ± 0.4 7.2 ± 2.5* 5.0 ± 0.2* 6.2 ± 2.1*
Max isokinetic potential (Newton) 103 ± 27 88 ± 47 137 ± 70 110 ± 61
Ankle load (kg) 6.6 ± 1.3 5.6 ± 2.7 7.3 ± 2.0 6.4 ± 2.5
31P-MRS result
t½ (PCr+Pi)/PCr 8.7 ± 1.3 14.2 ± 3.8* 12.9 ± 1.9* 13.6 ± 3.0*
Laboratory measurements
Glucose prior exercise (mmol/l) 5.0 ± 0.8 6.7 ± 2.1 4.7 ± 0.4 5.8 ± 1.9
Glucose after exercise (mmol/l) 5.2 ± 1.0 6.4 ± 1.8 5.8 ± 1.3 6.1 ± 1.5
Insulin prior exercise (mU/l) 17 ± 19 12 ± 8 15 ± 6 13 ± 7
Insulin after exercise (mU/l) 13 ± 18 37 ± 60 19 ± 18 29 ± 45
C-Peptide prior exercise (nmol/l) 1.05 ± 0.71 0.61 ± 0.43 1.06 ± 0.24 0.81 ± 0.41
C-Peptide after exercise (nmol/l) 0.79 ± 0.67 0.67 ± 0.53 1.36 ± 1.07 0.97 ± 0.84
Lactate prior exercise (mmol/l) 1.1 ± 0.3 1.5 ± 0.4 1.9 ± 1.4 1.7 ± 1.0
Lactate after exercise (mmol/l) 1.6 ± 0.7 2.1 ± 0.9 2.5 ± 2.2 2.3 ± 1.5
CPK prior exercise (U/l) 99 ± 29 239 ± 191 210 ± 134 226 ± 159
CPK after exercise (U/l) 95 ± 31 221 ± 183 191 ± 131 208 ± 153
Data are expressed as mean ± standard deviation.* Results were signifi cantly diff erent from healthy subjects 
(p < 0.05). A3243G: adenosine to guanine mutation at position 3243; MIDD: maternally inherited diabetes and 
deafness; DM: diabetes mellitus; HbA1c: glycated hemoglobin; Max: maximal; 31P-MRS: 31-phosphorus magnetic 
resonance spectroscopy; t½: recovery half time; Pi: inorganic phosphate; PCr: phosphocreatine; C-peptide: 
connecting-peptide; CPK: creatine-phosphokinase
Patient characteristics
Comparison of the study groups shows similar age and body mass index (BMI) due to match-
ing (Table 1). Four of the DM patients used insulin, one of them in combination with an oral 
glucose-lowering sulfonylurea derivate; the other two DM patients showed abnormal glu-
cose levels on OGTT. HbA1C levels were signifi cantly higher in the MIDD group, refl ecting the 
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inclusion of MIDD patients diagnosed with DM in this group. Diff erences in values of maximal 
isokinetic potential in exercise and the subsequently used ankle loads were nonsignifi cant. 
All subjects tolerated the exercise well.
Skeletal muscle mitochondrial function
31P-MRS was performed successfully and a steady state was reached in all participants. Figure 
2 shows typical examples of skeletal muscle 31P-MRS recovery curves of an MIDD patient and 
a healthy subject from which PCr recovery t1/2 was calculated. The MIDD mitochondrial muta-
tion showed a statistically signifi cant association with half-time of PCr recovery after exercise 
(beta: 0.611, p = 0.01). In the multiple linear regression model no association of the presence 
of DM was found with t1/2 (PCr + Pi)/PCr (p = 0.382).
Figure 2. Phosphorus metabolite ratio recovery curves. Example of an MIDD patient (t1/2 = 18.0 sec) and a 
healthy control subject (t1/2 = 6.9 sec). Solid lines indicate fi tted curves.





















Glucose, insulin, and C-peptide measurements before and after exercise did not signifi cantly 
diff er between all groups. Lactate levels were normal in all subjects, before and after exercise. 
High baseline CPK levels were seen in A3243G MIDD mutation carriers (borderline signifi cance 
with controls, p = 0.058), but in both groups CPK levels did not increase after the exercise.
DISCUSSION
This study revealed that mitochondrial function is impaired in the skeletal muscle in carriers 
of the MIDD mutation compared to healthy subjects. Furthermore, in the mutation carriers 
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no additional eff ect of DM on mitochondrial function was demonstrated. The latter observa-
tion, however, could be due to insuffi  cient statistical power in the small study sample size of 
this rare mutation.
In the present study PCr recovery half-time was signifi cantly prolonged in the MIDD muta-
tion carriers as compared to healthy controls. During recovery from exercise, PCr is resynthe-
sized as a consequence of oxidative ATP synthesis (23). Therefore, t1/2 (PCr+Pi)/PCr provides 
information about mitochondrial function. Our results support the studies of Chinnery et 
al, who observed mitochondrial dysfunction in the calf muscle in a case report (13) and in 
A3243G mutation families (14). However, in their study not all A3243G mutation carriers 
were of the MIDD phenotype, in contrast to our carefully selected MIDD patient population. 
Furthermore, those authors speculated that physical training or the use of coenzyme Q (12) 
or dichloracetate contributed to the 31P-MRS detected impaired oxidative phosphorylation 
rather than the mutation itself. In our study none of the participants used this medication and 
none were actively engaged in sports or training activities, excluding for the potential con-
founding eff ect of these factors. In the current study all participants performed individually 
adjusted exercise to equal the exercise level. Similar maximal isokinetic potentials at a suc-
cession of knee extensions were seen, which confi rms comparable baseline physical exercise 
capacity between the groups. So we suggest that MIDD patients show subclinical muscular 
impaired mitochondrial phosphorylation. This is supported by the high CPK baseline levels in 
the patient group, without clinical signs of muscle weakness.
We did not fi nd an association of DM and PCr recovery values, as no eff ect of DM in our MIDD 
patient population on skeletal oxidative phosphorylation was observed. Recently, Schrauwen-
Hinderling et al (18) applied 31P-MR spectroscopy in the vastus lateralis muscle to study 
mitochondrial function in overweight type 2 DM patients and BMI-matched control subjects. 
They reported a longer PCr recovery half-time in the type 2 diabetes group when compared 
to the control group. On the basis of their results we expected an additional eff ect of DM in 
the MIDD patient group with DM as compared to the non-DM MIDD subgroup, which was not 
confi rmed by our results. The recently published results of de Feyter et al (15) did not show an 
eff ect of insulin resistance or type 2 DM on mitochondrial function when compared to healthy 
normoglycemic controls, which is in accordance with our study results. In the current study we 
did not perform proton MRS to further evaluate mitochondrial dysfunction and the associa-
tion with insulin resistance, as shown in previous studies (15,18). Thus, the exact relationship 
between DM per se and skeletal muscle phosphate metabolism remains to be clarifi ed, but our 
results clearly indicate an eff ect of the MIDD mutation itself on phosphate metabolism.
Our study has limitations. We studied a limited number of patients and controls, although 
the MIDD phenotype of the A3243G mutation is a very rare entity and previous reports in 
the literature described mainly case reports. As the mutation is not a common entity, inter-
national collaboration is required to collect larger numbers of MIDD subjects, including DM 
and non-DM patients.
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In conclusion, the present study demonstrates subclinical mitochondrial dysfunction of 
the skeletal muscle in MIDD patients. The presence of DM does not seem to aff ect the mito-
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Seven Tesla (T) MR imaging is potentially promising for the morphologic evaluation of coro-
nary arteries because of the increased signal-to-noise ratio compared to lower fi eld strengths, 
in turn allowing improved spatial resolution, improved temporal resolution, or reduced 
scanning times. However, there are a large number of technical challenges, including the 
commercial 7 T systems not being equipped with homogeneous body radiofrequency coils, 
conservative specifi c absorption rate constraints, and magnifi ed sample-induced amplitude 
of radiofrequency fi eld inhomogeneity. In the present study, an initial attempt was made 
to address these challenges and to implement coronary MR angiography at 7 T. A single-
element radiofrequency transmit and receive coil was designed and a 7 T specifi c imaging 
protocol was implemented, including signifi cant changes in scout scanning, contrast genera-
tion, and navigator geometry compared to current protocols at 3 T. With this methodology, 
the fi rst human coronary MR images were successfully obtained at 7 T, with both qualitative 
and quantitative fi ndings being presented.
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INTRODUCTION 
Coronary magnetic resonance angiography (MRA) has been shown to be a promising tool 
for the noninvasive identifi cation of signifi cant proximal coronary artery disease (1,2). The 
most commonly used magnetic fi eld strength for coronary MRA is 1.5 Tesla (T), involving 
many years of sequence, parameter, and radiofrequency (RF) coil optimization. In common 
with many MRI applications, the use of higher magnetic fi eld strengths for coronary MRA 
is attractive, with advantages arising from increases in signal-to-noise ratio (SNR), smaller 
voxel sizes, a higher temporal resolution, and/or shortened scanning times. Individually or 
in combination, these improvements are likely to result in improved image quality and ulti-
mately better access to small diameter and branching vessels. As a fi rst step in this direction, 
implementation of coronary MRA at 3 T has been found to result in increased SNR, increased 
contrast-to-noise ratio, and increased measured coronary vessel lengths compared to 1.5 T 
(3-5). Voxel sizes as low as 0.35 × 0.35 × 1.5 mm3 have been obtained at 3 T (6) in selected 
cases. Although initial studies comparing 1.5 T coronary MRA with 3 T coronary MRA and the 
gold standard x-ray coronary angiography showed little advantage of 3 T for the identifi cation 
of signifi cant luminal coronary artery disease, a more recent report (4) appears much more 
promising, and other studies that take advantage of new high-fi eld specifi c improvements 
are ongoing. Notably, the increase in magnetic fi eld strength between 1.5 and 3 T produces 
a series of challenges, including adequate electrocardiograph (ECG) triggering (7), sophisti-
cated higher-order shimming (8) to account for increased magnetic fi eld susceptibility, and 
spatially homogeneous magnetization preparation for contrast generation (9).
Given the promising indicators at 3 T, the recent availability of commercial human whole-
body high-fi eld 7 T MR systems might off er great potential for cardiovascular imaging in 
general (10). However, because of the large resonance frequency increase between 3 T and 
7 T, roughly three times that between 1.5 T and 3 T, considerable challenges are expected 
for cardiovascular studies at 7 T. Initial feasibility for cardiac MRI at 7 T has been demon-
strated by Snyder et al. (10), who showed a series of very promising anatomic and functional 
cardiac scans in normal volunteers, using a highly sophisticated multiple-transmit array. In 
the present paper, we investigated the feasibility of coronary MRA in humans at 7 T. The 
methodology adopted was to use a custom-built RF transmit and receive surface coil, a 7 T 
specifi c scout scanning approach, specifi c navigator adaptations, and segmented gradient 





All imaging protocols were approved by the Leiden University Medical Center medical 
ethics committee. Ten healthy adult volunteers (seven men, age 32.7 ± 8.1 years) without 
known history of cardiovascular disease, were studied on a commercial human whole-body 
7 T MR system (Philips Achieva; Philips Healthcare, Best, The Netherlands). The MR system is 
equipped with a commercial vector ECG module (7). The electrodes of the vector ECG were 
placed at the anterior chest wall, with two electrodes on the sternum, one electrode on the 
left thorax, and one below the sternum, as shown in Figure 1a. All subjects were positioned 
head fi rst and in the supine position in the magnet.
Figure 1. Electrocardiogram at 7 T. The position of the four ECG electrodes (dots) on the thorax is shown in 
(a). A normal ECG signal from outside (b) and inside (c) the 7 T magnet is shown with enhanced T-wave 
(arrow) due to the magneto-hydrodynamic eff ect. Despite the amplifi ed artifactual signal on the T-wave, 
R-wave triggering was reliable, as demonstrated by the vertical black lines that indicate the computer-














For coronary imaging, a 13-cm-diameter RF transmit and receive surface coil was developed 
for operation at 298.1 MHz. The coil was constructed using copper tape with a width of 1.6 cm 
(3M, Minneapolis, MN). Eight segments, with a length of 4.3 cm each, were segmented by 5.1-
pF nonmagnetic capacitors (ATC, Series B, Huntington Station, NY). Three variable capacitors 
(1-40 pF; Johansson, Camarillo, CA) were used for fi ne tuning and impedance matching in a 
balanced confi guration. A lattice balun was used to improve the balancing of the coil. The coil 
was constructed in an end-on confi guration to reduce electric fi eld coupling to the patient 
(11). In addition, short lengths of copper foil were placed on the plastic former between 
the capacitors and the patient to reduce the conservative electric fi elds within the patient. 
Finally, a 1-cm-diameter gap between the coil and patient was introduced using foam rubber 
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to reduce patient-induced losses (12). The RF coil was connected via an RG-58 cable to the 
interface box of the scanner. The patient loading of the coil was dominant, with a loaded-
to-unloaded Q-ratio of 1:10, and the coil was well matched to 50 ohm for all of the subjects 
irrespective of body size. Therefore, there was no need for manual adjustment for individual 
subjects, although the use of variable capacitors does leave the option open. Amplitude of 
RF fi eld (B1) homogeneity was tested using a phantom that was fi lled with mineral oil: the 
sensitivity pattern usual for this coil size was obtained (data not shown). Specifi c absorption 
rate (SAR) calculations were based upon previous work by Collins and Smith (13), using the 
appropriate scaling factors outlined in the publication. The RF pulses were calibrated by 
measuring the fl ip angle averaged over an aligned slice through the center of the imaging 
volume, which results in a more accurate fl ip angle calibration than the standard scheme 
where the fl ip angle is measured in a transverse plane through the isocenter of the magnet.
Coronary MR angiography
Coronary MR angiography was performed as follows: one low-resolution scout scan preceded 
a two-dimensional (2D) axial multislice cine scout scan and volume-targeted 3D coronary 
MRA.
Scout scans
Two scout scans were acquired to localize the navigator volume for identifi cation of the 
period of minimal coronary motion and for anatomic localization of the right coronary artery 
(RCA).
The fi rst scout scan was a multistack, 2D, segmented, k-space, gradient-echo acquisition 
obtained in coronal, axial, and sagittal orientations. The images were collected without ECG 
triggering during free breathing of the volunteers (pulse repetition time = 4.0 ms, echo time 
= 1.82 ms, RF excitation angle = 20°, acquisition matrix = 192 × 96, reconstruction matrix = 
256 × 256, fi eld of view = 450 × 450 mm2, slice thickness = 10 mm, no slice gap, 20 slices per 
stack, scan duration ~25 sec). This scout scan was utilized for scan plane localization of the 
subsequent cine scout scan and for the localization of the 2D selective navigator.
After the fi rst scout scan, an ECG-triggered, multislice, 2D, axial cine scout scan (Figure 2) 
was localized using the coronal images of the fi rst scout. This scan replaces the low-resolution 
whole-heart 3D scout scan that is commonly used for the identifi cation and volume targeting 
of the coronaries at 3 T. However, since the use of standard T2 preparation (9,14) was im-
practical at 7 T due to conservative SAR constraints, an alternative mechanism for improved 
visualization of the coronaries was required. This was accomplished by taking advantage of 
the in-fl ow contrast on 2D cine images. Therefore, the second scout was performed using 
a retrospectively ECG-gated, segmented, k-space, gradient-echo, cine imaging sequence. 
Thirty-three cine acquisitions per RR interval were obtained, resulting in a temporal resolu-
tion of ~25-35 ms, dependent on individual heart rate. Ten 8-mm-thick slices with a slice gap 
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of 4 mm covered the whole heart from base to apex in an axial plane (pulse repetition time = 
4.0 ms, echo time = 2.4 ms, RF excitation angle = 15°, breath-hold duration ~15 sec per slice). 
This scan was utilized for the identifi cation of the period of minimal coronary motion needed 
for identifying the acquisition time delay (= trigger delay) and for volume targeting of the 
subsequent 3D stack in parallel to the RCA.
Figure 2. Multislice 2D axial cine scout scans. Multislice cine scout scans were acquired in an axial plane 
covering the whole heart. The fi gure shows selected images at multiple anatomic levels: basal (a), 
midventricular (b), and closer to the apex (c). The RCA (arrows) was visually identifi ed at the period of 
minimal coronary motion in these slices. Subsequently, a three-point-plan-scan tool was used for volume 
targeting in parallel to the RCA.
3D coronary MRA
Scan plane localization for volume-targeted 3D MRA of the RCA was performed on the 
multislice cine scout scans. In cine slices at multiple anatomic levels (basal (Figure 2a), mid-
ventricular (Figure 2b) and closer to the apex (Figure 2c)), the RCA was identifi ed at time 
point trigger delay. Subsequently, a previously described three-point-plan-scan tool (15) 
was used for volume targeting of the stack in parallel to the RCA. A 3D segmented k-space 
gradient-echo sequence was used with prospective ECG triggering. In total, 15 slices with a 
slice thickness of 4 mm were acquired and reconstructed to thirty 2-mm-thick slices. A fi eld of 
view of 420 × 269 mm2 and a scan matrix of 512 × 312 led to an in-plane voxel size of 0.82 × 
0.86 mm2. The RF excitation angle was 15°, pulse repetition time = 4.3 ms, echo time = 1.4 ms, 
signal readout bandwidth = 335 Hz/pixel, and the duration of the acquisition window was 
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116 ms. The 3D volume-targeted coronary MRA data were acquired during free breathing, 
using prospective navigator gating and tracking. The 2D selective navigator was localized at 
the anterior wall of the left ventricle (16), as identifi ed in the coronal (Figure 3a) and sagittal 
images of the fi rst scout scan. To minimize T2*-related susceptibility artifacts on the navigator 
signal, the duration of the 2D selective navigator RF pulse was shortened from 7 ms in the 3 T 
protocol to 4.4 ms by reducing the number of cycles in k-space from 16 to eight. The naviga-
tor gating window was 3-5 mm, and both RF excitation and signal reception for the navigator 
were obtained with the local RF transmit and receive surface coil. Since the navigator was 
localized at the heart and not at the lung-liver interface, a correction factor of 1.0, rather than 
the conventional 0.6 (17), was used. 
Contrast enhancement between the coronary lumen blood pool and the epicardial fat was 
obtained by using a spectrally selective adiabatic RF inversion pulse for fat suppression. The 
duration of this pulse was 18 ms, the B1 was 7.3 μT, and the center frequency was -850 Hz 
relative to the water resonance frequency (f0). The pulse was adiabatic over a range of B1 
values, with a lower limit of 60% of the expected B1. The bandwidth was 800 Hz, which repre-
sents a tradeoff  between the measured line width of the water and fat peaks after shimming 
and the adiabaticity of the pulse. In a few initial volunteers, the time delay between this fat 
saturation prepulse and data acquisition at the center of k-space that leads to the best visual 
fat suppression was experimentally determined. A spectrally selective adiabatic RF inversion 
pulse with an inversion time of 200 ms was found to null the signal from fat eff ectively. The fat 
saturation prepulse preceded the navigator not only to reduce the fat signal for the navigator 
signal readout but also to minimize the time delay between the navigator and the imaging 
part of the sequence (18). First-order local volume shimming in a volume of 50 × 140 × 50 mm 
localized at the level of the RCA was performed in all cases. The off -center and angulations of 
the shim volume were identical to that of the imaged volume.
Figure 3. Navigator gating at 7 T. a: A coronal scout scan with the navigator (rectangle) positioned at the left 
heart-lung interface is shown. The scan plane (contiguous slices) localized in parallel to the RCA is visible. 
The navigator signal received from the 2D selective excitation is shown in (b). The navigator window 




3D coronary MRAs were reformatted using the “Soapbubble” tool (19). Measurements of 
vessel length, diameter, and sharpness (19) of the fi rst 4 cm of the RCA were subsequently 
performed. SNR of the blood was measured for the RCA and the left main coronary artery 
(LM) as described before (20) if it could be identifi ed on the image. The diff erence in SNR 
between RCA and LM was compared using a paired Student’s t test. A p value of <0.05 was 
considered statistically signifi cant.
RESULTS
Images of the RCA were successfully obtained in nine of the 10 subjects, with a total 3D 
coronary MRA scan duration of 232 ± 36 sec. In one volunteer, data collection could not be 
completed due to navigator failure related to insuffi  cient SNR of the navigator signal. Quan-
titative coronary length, diameter, and vessel sharpness measurements could be performed 
in all 3D coronary MRA. However, the LM could only successfully be identifi ed and used for 
subsequent SNR analysis in six out of the nine available datasets because of rapid signal 
drop-off  more distant from the surface coil. The average contiguous length of the RCA was 
66 ± 38 mm, and the average diameter of the fi rst 4 cm of the RCA was 2.8 ± 0.4 mm, with 
an average vessel sharpness of 49 ± 10%. The SNR of the RCA was 18.1 ± 3.4, and that of the 
LM 8.3 ± 1.5 (p< 0.001). Representative examples of MR images of the RCA obtained at 7 T 
are displayed in Figure 4, which shows sharply delineated contiguous segments with good 
contrast between the coronary lumen blood pool and the epicardial fat.
The 13-cm-diameter RF transmit and receive surface coil was suffi  cient to cover the heart 
in the superior-inferior and left-right direction, but the coverage was limited in the anterior-
Figure 4. Representative examples of MR images of the RCA obtained at 7 T. Proximal (a,c) and more distal (b) 
segments of the RCA are visualized. The 13-cm RF transmit and receive coil provides suffi  cient penetration 
depth to visualize a considerable RCA segment length. Sharply delineated contiguous coronary segments 
with good contrast between the coronary lumen blood pool and the epicardial fat are shown.
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posterior direction. The coil coverage supported adequate scan planning, navigator gating 
and tracking, and 3D data acquisition of the RCA. The RF penetration depth of the surface 
coil was also suffi  cient to follow the RCA for a considerable distance, as shown in Figure 4. 
The coil coverage was not large enough for the simultaneous visualization of the RCA, LM, 
left anterior descending, and the left circumfl ex coronary arteries. Although the eff ects of B1 
inhomogeneity were visible in the scout images and in certain areas of the coronary MRA, 
this did not adversely aff ect the regions in which the RCA was visible.
Despite a signifi cantly amplifi ed magneto-hydrodynamic eff ect at 7 T that led to consider-
able artifi cial augmentation of the T-wave of the ECG, the vector ECG algorithm allowed reli-
able R-wave triggering in all subjects. Representative ECG traces are shown in Figure 1, where 
the recordings from outside (Figure 1b) and inside (Figure 1c) the magnet are displayed. In 
Figure 1c, the artifactual T-wave augmentation is clearly visible, as indicated by the arrow.
With the navigator volume localized at the anterior wall of the left ventricle, the navigator 
could adequately track breathing motion, resulting in a navigator effi  ciency between 36 and 
82% (mean 70 ± 16%). In Figure 2b the navigator signal received by the surface coil is shown.
DISCUSSION
This initial report demonstrates that in vivo human right coronary MRA is feasible on a com-
mercial high-fi eld 7 T scanner equipped with a custom-built RF transmit and receive cardiac 
surface coil. The present study, to our knowledge, is the fi rst to report on coronary MRA at 
this fi eld strength. These fi ndings complement those from a recently published study by 
Snyder et al. (10), in which successful in vivo human anatomic and cardiac cine imaging was 
demonstrated at 7 T.
The 7 T coronary MR images allowed quantitative measurements of RCA length and 
diameter, as well as vessel sharpness. While we did not perform a direct comparison with 
lower-fi eld-strength coronary MRA, the 7 T scanning time was similar to that of earlier reports 
performed at lower fi eld strength (21,22) and without parallel imaging. However, and using 
the present 7 T approach, an increased visible vessel length and a higher image quality may 
be expected at both 1.5 T (20) and 3 T (5). Nevertheless, measurements of RCA diameter and 
vessel sharpness were similar to those reported in an early study on in vivo human coronary 
MRA at 3 T (23).
When compared to contemporary 1.5 T or 3 T protocols, the current 7 T methodology was 
diff erent in that a local RF transmit and receive surface coil with limited volumetric cover-
age was utilized, and in that both the scout scanning approach and the coronary MRA data 
collection had to be adapted, primarily due to SAR constraints. These conservative SAR con-
straints at 7 T limit the use of more common cardiac pulse sequences and certainly remove 
fl exibility for pulse sequence design. The use of steady state free precession sequences with 
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T2-preparation considerably augments image quality in comparison to 3D gradient echo 
sequences (24) at 1.5 T and is currently the most commonly used technique at 1.5 T. However, 
implementation of steady state free precession sequences at higher fi eld strength is chal-
lenging due to increased magnetic susceptibility, banding artifacts, and SAR constraints that 
limit the use of minimal pulse repetition time. While sophisticated higher-order shimming 
approaches have helped to improve image quality for steady state free precession at 3 T 
(8), most of the research with (25) and without contrast agents at 3 T is currently done with 
more conventional segmented k-space gradient echo imaging sequences. Since amplitude 
of static fi eld inhomogeneity and SAR constraints are already limiting factors for steady 
state free precession at 3 T, its adoption for 7 T use is currently not straightforward. For these 
reasons, a segmented k-space gradient echo technique similar to that described in this article 
will most likely be the method of choice for future coronary MRA implementations at 7 T. 
Successful contrast enhancement mechanisms at 1.5 T include T2-preparation (14,26) and in-
version recovery (27), in combination with contrast agents. While inversion recovery in com-
bination with slow contrast infusion was very successful at 3 T (25), the use of conventional 
T2-preparation is more challenging and an adiabatic version of the T2-preparation had to be 
developed to account for amplitude of static fi eld and B1 inhomogeneities at 3 T. However, at 
7 T, the SAR constraints on our system did not permit the use of an adiabatic T2-preparation 
for contrast generation. Therefore, the slow infusion approach described by Liu et al. (4) holds 
great promise at 7 T but remains to be explored. Similarly, spin labeling techniques that do 
not depend on two acquisitions and subtraction, as that described by Katoh et al. (28), may 
be valuable alternatives that deserve further investigation.
The RF penetration depth of the surface coil was suffi  cient for coverage of the proximal 
segments of the RCA, but more distal segments may not easily be visualized. The coil cover-
age was also not large enough for the simultaneous visualization of the left coronary arterial 
system. The lower SNR of the LM when compared to the RCA confi rms a signal loss in the 
region of the left coronary arterial system that is more distant from the surface coil. This is 
attributable to both limited RF penetration and coil sensitivity of the small-diameter transmit 
and receive coil. Therefore, the development of larger surface coils or coil arrays will be criti-
cal to improve volumetric coverage (10). The RF coil setup used in these initial experiments is 
extremely simple. This has both advantages and disadvantages. Recent studies have shown 
that homogeneous transmit fi elds can be produced using transmit arrays and sophisticated 
B1 shimming routines (29). Although this represents the optimum strategy, it does require 
hardware that is not yet standard on most commercial MRI scanners, and it currently neces-
sitates the development of sophisticated hardware and software interfaces. No doubt, such 
hardware will become more widely available on commercial systems. However, the aim of 
this article was to demonstrate feasibility of motion-compensated 3D coronary MRA data 
acquisition at 7 T with an RF transmit and receive surface coil architecture that is relatively 
straightforward to construct and which can be easily interfaced with a commercial 7-T system.
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Both intrinsic cardiac and extrinsic respiratory motion suppression was eff ective at 7 T. 
Augmented T-waves of the ECG were observed in all subjects while positioned in the magnet. 
However, with careful positioning of the ECG leads, the vector ECG module enabled reliable 
R-wave detection, despite the high magnetic fi eld strength. A reduction in the duration of the 
navigator RF pulse compared to that used at 3 T helped to minimize T2*-related susceptibility 
artifacts on the navigator signal and improved navigator performance. While the diameter 
of the 2D selective RF pulse remained unchanged, increased aliasing of the navigator signal 
may be expected. However, due to the limited sensitivity of the surface coil outside the heart, 
this is a minor concern. Nevertheless, this will have to be revisited if larger coils or coil arrays 
will be used, and dedicated navigator signal receive coils (23) may have to be exploited to 
account for that problem. Because of the relatively small fi eld of view of the 13-cm surface 
coil, the right hemidiaphragm was outside the fi eld of view, and therefore navigator localiza-
tion at the lung-liver interface was not practical. With the navigator localized at the anterior 
wall of the left ventricle, a workaround was found and adequate respiratory motion suppres-
sion was ensured. However, this strategy works only for 2D selective excitations with small 
RF excitation angles. Navigators that consist of echoes obtained from intersecting planes 
may not be useful since the presence of local signal voids has to be considered. Finally, the 
navigator effi  ciency was quite high when compared to that commonly reported at lower 
magnetic fi eld strength. However, in the present report, the navigator was localized directly 
at the heart-lung interface where the respiration-induced motion in the foot-head direction 
is reduced when compared to that at the lung-liver interface. This may have contributed to 
improved navigator effi  ciency.
The use of 3D-segmented gradient echo sequences with relatively short echo times and 
spectrally selective adiabatic RF inversion pulses for fat suppression enabled this initial 
feasibility study of coronary MRA at 7 T. No direct comparison with data obtained at lower 
magnetic fi eld strength was performed and no patient data were collected.
Neither a higher spatial resolution, temporal resolution, nor an abbreviated scanning 
time was obtained when compared to lower fi eld strengths. However, the purpose of this 
initial study was to test feasibility of coronary MR angiography at 7 T. To fully benefi t from 
the potential for improved image quality at 7 T, the limits of spatial resolution and temporal 
resolution remain to be explored as methodology advances. Nevertheless, signifi cant chal-
lenges have been addressed, and it has been demonstrated that coronary MRA at 7 T can be 
successfully obtained. Future steps include the design of improved RF transmit/receive coils 




This initial report demonstrates feasibility of 3D motion compensated in vivo human right 
coronary MRA at 7 T while quantitative measurements of RCA length, diameter, vessel sharp-
ness, and SNR could successfully be obtained. The combination of a home-built RF transmit 
and receive surface coil, vector ECG hardware, navigator adaptations, specifi cally designed 
scout scanning procedures, segmented k-space gradient echo imaging, and adiabatic inver-
sion of the magnetization for fat suppression was critical to address some of the 7 T specifi c 
challenges. Further improvements in coil design and a strong focus on contrast enhancement 
mechanisms will critically support continued progress.
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To objectively compare parameters related to image quality of coronary magnetic resonance 
angiography (MRA) of the right coronary artery (RCA) obtained with 7 Tesla (T) and 3 T MRI.
Materials and Methods
Approval from our institutional review board was obtained, and participants gave informed 
consent. Ten healthy adult subjects (mean age 25 ± 4 years, 7 men) underwent navigator-
gated 3D MRA of the RCA at 7 T and 3 T. For 7 T, a custom-built quadrature radiofrequency 
(RF) transmit/receive surface coil was utilized. At 3 T, a commercial body RF transmit coil and 
a cardiac coil array for signal reception were used. Segmented k-space gradient echo imaging 
with spectrally selective adiabatic fat suppression was performed and scan parameters were 
similar at both fi eld strengths. Contrast-to-noise ratio (CNR) between blood and epicardial 
fat, signal-to-noise ratio (SNR) of the blood-pool, RCA vessel sharpness, diameter and length 
as well as navigator effi  ciency were quantifi ed at both fi eld strengths and compared using 
Mann-Whitney-U test.
Results
The CNR between blood and epicardial fat was signifi cantly improved at 7 T when compared 
to 3 T (87 ± 34 versus 52 ± 13, p=0.01). SNR of the blood-pool was increased at 7 T (109 ± 47 
versus 67 ± 19, p=0.02). Vessel sharpness obtained at 7 T was also higher (58 ± 9 % versus 50 
± 5 %, p=0.04). Simultaneously RCA vessel diameter, length and navigator effi  ciency showed 
no signifi cant fi eld strength dependent diff erence.
Conclusion 
In our quantitative and qualitative study comparing in vivo human imaging of the RCA at 7 
T and 3 T in young healthy volunteers, parameters related to image quality obtained at 7 T 
equal or surpass those from 3 T.
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INTRODUCTION 
Currently, relatively few (~40) seven Tesla (T) magnetic resonance imaging (MRI) systems 
are available for human use to our knowledge, most of them situated in research centers. 
High fi eld cardiac MRI was initially thought to be very problematic due to magnetic fi eld 
inhomogeneity and specifi c absorption rate (SAR) constraints. Further, contemporary com-
mercial 7 T units are not routinely equipped with body radiofrequency (RF) transmit coils 
or surface RF receive coils. Despite these major challenges, a number of research groups 
have already demonstrated the feasibility of cardiac imaging at 7 T and beyond (1-5). Initial 
attempts focusing on coronary artery imaging at 7 T have shown that these barriers can suc-
cessfully be removed and initial in vivo human images were very promising (6). While these 
early 7 T studies were conducted using single channel RF transmit/receive coil architecture, 
recent advances in surface coil technology seem particularly promising. However, and while 
an improvement in image quality may be expected at higher magnetic fi eld strength (7), 
there have been no reports to our knowledge on cardiac MR imaging studies that directly 
and objectively compare parameters related to image quality at 7 T with those obtained at 
lower fi eld strength.
Therefore, the purpose of our study was to objectively compare quantitative parameters 
related to image quality of coronary MRA of the right coronary artery (RCA) obtained at 7 T 
and 3 T.
MATERIALS AND METHODS
Our study was approved by our institutional review board and all volunteers signed informed 
consent. Three-dimensional MRA of the right coronary system was performed in 10 healthy 
adult young subjects (mean age 25 ± 4 years, 3 women) scanned at 7 T and 3 T (Philips 
Achieva; Philips Healthcare, Best, NL) in a prospective study design. For practical reasons, 7 
T scanning always occurred prior to 3 T MRI. Coronary MRA were acquired with prospective 
navigator technology and vector ECG-triggering (8). All volunteers were studied in head-fi rst 
and supine position. None of the volunteers received nitroglycerin before MRI. The interval 
between the two examinations was 8 ± 5 weeks on average.
7 T imaging
A quadrature transmit/receive surface coil consisting of two overlapping loops (13 cm diam-
eter each) was constructed in-house (Figure 1). The coil size is larger than described previ-
ously (4,6) to improve volumetric coverage. First, a non-ECG triggered scout scan in coronal, 
axial and sagittal orientations was acquired to plan subsequent scans and to localize the 2D 
selective navigator. At 7 T, the navigator was placed at the lung-heart interface because of the 
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limited sensitive volume of the surface coil. Secondly, an ECG-triggered, breath-hold multi-
slice axial cine scout scan was performed for both the determination of the period of minimal 
coronary motion (=trigger delay) and volume targeting of the 3D stack in parallel to the mid-
diastolic RCA. Finally, volume-targeted coronary MRA was obtained using a 3D segmented 
k-space gradient echo imaging technique (parameters Table 1) combined with a spectrally 
selective adiabatic inversion recovery (SPAIR) pulse (TI=200 ms) for fat saturation. First-order 
local volume shimming at the anatomical level of the RCA was performed in all cases.
3 T imaging
On the 3 T system, the body coil was used for RF transmission, with a commercial six-element 
cardiac coil array for signal reception. Scout scanning included a free-breathing, retro-
spectively ECG-gated, 2D cine balanced turbo-gradient echo scan in a horizontal long-axis 
view (4-chamber) to determine the trigger delay. Further, an ECG-triggered free-breathing 
navigator gated and corrected 3D gradient echo whole heart scan was obtained for the ana-
tomical localization of the RCA. After scout scanning, two coronary imaging sequences were 
performed at 3 T with diff erent navigator localization in random order; 1.) with navigator 
localization at the lung-heart interface (navigator at heart), 2.) with navigator localization at 
the lung-liver interface (navigator at liver). Both 3 T coronary imaging sequences consisted of 
a 3D segmented k-space gradient echo technique with SPAIR (TI=150 ms) for fat saturation. 
The coronary MRA scan parameters were very similar (Table 1) at both fi eld strengths to sup-
port a fair quantitative comparison.
Figure 1. The custom-built quadrature RF transmit/receive surface coil consisting of two 13 cm elements 
used for our study at 7 T is shown.
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Data analysis
Images were processed and analyzed using the Soap bubble tool (9). Both a visual qualitative 
description and a direct quantitative comparison between 7 T and 3 T images were performed. 
All data analyses were performed by one physician (S.G.C.v.E., 4 years of experience in cardiac 
MRI) with supervision of a senior researcher (M.S, 18 years of experience in cardiac MRI).
The following parameters were measured: contrast-to-noise ratio (CNR) between the 
blood-pool and the epicardial fat, signal-to-noise ratio (SNR) of the blood-pool, RCA vessel 
sharpness and diameter of the fi rst 4cm and visible vessel length. The CNR was defi ned as the 
diff erence in signal intensity between a manually placed region of interest (ROI) in the aortic 
root (mean ROI area 1.80 ± 0.60 cm2) near the off spring of the RCA, and that of a ROI placed 
in the epicardial fat adjacent to the proximal RCA (mean ROI area 0.90 ± 0.61 cm2), divided by 
the standard deviation (SD) of the background signal from a ROI positioned anterior to the 
chest wall (=noise) (mean ROI area: 9.95 ± 3.98 cm2). The SNR was calculated for the blood 
signal in the above-described ROI localized in the aortic root. The average signal intensity 
from this ROI was divided by the noise. Vessel sharpness was measured using signal intensity 
gradients perpendicular to the 3D course of the RCA, and was calculated for the proximal 
4cm of the RCA (9). The RCA vessel length was measured manually and both vessel sharpness 
and diameter for the proximal 4 cm of the RCA were automatically calculated by the software. 
Statistical analysis
Data are presented as mean ± SD. Comparisons were made between the results obtained 
at 7 T and 3 T, and between those obtained with the diff erent navigator positions at 3 T. 
Table 1. Scan parameters of the coronary MRA sequences at 7 T and 3 T
Field strength 7 Tesla 3 Tesla 3 Tesla
Sequence 3D gradient echo 3D gradient echo 3D gradient echo
Navigator position / correction 
factor
Lung-heart interface / 1.0 Lung-heart interface / 1.0 Lung-liver interface / 0.6
Coil Quadrature two-element 
surface coil transmit/receive
Body coil transmit / six-
element phased array receive
Body coil transmit / six-
element phased array receive
Fat suppression Adiabatic SPIR Adiabatic SPIR Adiabatic SPIR
TR (ms) 4.3 4.3 4.3
TE (ms) 1.38 1.38 1.38
TI (ms) 200 150 150
Acquired voxel size (mm3) 0.82x0.86x2.00 0.82x0.86x2.00 0.82x0.86x2.00
Reconstructed voxel size (mm3) 0.82x0.82x1.00 0.82x0.82x1.00 0.82x0.82x.1.00
Number of slices 30 30 30
Field of view (mm2) 420x268 420x269 420x269
Matrix 512x312 512x312 512x312
Flip angle (˚) 15 15 15
Acquisition window (ms) 107 108 108
Abbreviations; SPIR: spectrally selective inversion recovery; TR: repetition time; TE: echo time; TI: inversion time
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For comparisons, a nonparametric Mann-Whitney-U test was used. P<0.05 was considered 
statistically signifi cant.
RESULTS
Coronary MRA was successfully performed in all volunteers at both fi eld strengths. At 7 T, 
one study participant complained about vertigo while the table was moving. All quantitative 
fi ndings are listed in Table 2. Total time in the magnet was on average 30 minutes at 7 T and 
20 minutes at 3 T.
Table 2. Quantitative results obtained from ten healthy volunteers
7 Tesla, navigator on lung-heart 
interface
3 Tesla, navigator on lung-heart 
interface
3 Tesla, navigator on lung-liver 
interface
CNR blood-pool – epicardial 
fat
87.5 ± 33.9* 51.7 ± 12.7 47.8 ± 15.2
SNR blood-pool 109.2 ± 46.9* 66.9 ± 19.4 67.2 ± 24.9
RCA vessel sharpness (%) 58.3 ± 8.9* 49.7 ± 5.1 48.9 ± 7.5
RCA vessel length (cm) 7.24 ± 2.34 8.21 ± 2.19 7.99 ± 2.73
RCA diameter, fi rst 4 cm (mm) 2.97 ± 0.27 3.07 ± 0.38 3.07 ± 0.37
Navigator effi  ciency (%) 54 ± 20 53 ± 20 46 ± 14
Acquisition time (sec) 469 ± 225 410 ± 180 470 ± 191
Heart rate (beats/min) 70 ± 15 67 ± 10 69 ± 10
All data are expressed as mean ± SD; * signifi cantly diff erent from 3 T (p<0.05); 
Abbreviations; CNR: contrast-to-noise ratio between blood-pool and epicardial fat surrounding the proximal 
right coronary artery; RCA: right coronary artery; SNR: signal-to-noise ratio
Figure 2, 3 and 4 illustrate example coronary MRA reformations obtained at 7 T and at 3 T. All 
images show high signal intensity of the coronary artery lumen while that of the surrounding 
epicardial fat is suppressed. At 7 T, suppression of the epicardial fat appears visually improved 
when compared to 3 T (Figure 2).
Consistent with these fi ndings, quantitative CNR between the blood-pool and epicardial fat 
was signifi cantly improved at 7 T (7 T vs. 3 T navigator at heart: p=0.013, 7 T vs. 3 T navigator 
at liver: p=0.009). Visually, the contrast between the myocardium and the blood-pool in the 
left ventricle is rather shallow at 7 T as shown in Figures 3 and 4. When compared to 3 T, the 
SNR of the blood-pool measured on the 7 T images was 60% higher (7 T vs. 3 T navigator at 
heart: p=0.023, 7 T vs. 3 T navigator at liver: p=0.027). Improved delineation of the RCA at 7 
T is visible in Figure 3, with good depiction of RCA branches and distal segments. Consistent 
with these fi ndings, objective vessel sharpness analysis demonstrated improved quantitative 
vessel conspicuity at 7 T (vs. 3 T navigator at heart p=0.038, vs. 3 T navigator at liver p=0.031).
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Figure 2. An example of a coronary magnetic resonance angiogram of the RCA obtained at 7 T (a) and at 3 
T (b) in the same healthy 18 year old male volunteer is illustrated (double oblique volume targeted plane 
parallel to the right coronary artery). Improved suppression of the epicardial fat (dotted arrows) with high 
contrast between the blood and epicardial fat is visible at 7 T. At both fi eld strengths a number of small 
branching vessels can be depicted (larger hatched arrows). Also, at 7 T a long portion of the RCA can be 
visualized. The solid arrow indicates the distal part of the RCA.
Abbreviations; Ao: aortic root; LV: Left ventricle; RCA: right coronary artery; RV: Right ventricle; TW: thoracic wall
Figure 3. These right coronary artery (RCA) images (double oblique volume targeted plane parallel to 
the right coronary artery) from a healthy 26 year old male subject display a high visual vessel defi nition 
(dotted arrows with small arrow heads) in the 7 T image (a) compared to 3 T (b). At 7 T there is limited 
contrast between the myocardium (2 dots) and the blood pool (1 dot). Multiple RCA side-branches 
(squared arrows) and distal parts of the RCA (plain arrow) are clearly depicted at both fi eld strengths.
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Even though constraints related to the B1 fi eld and coil sensitivity adversely aff ect the signal 
more distant to the surface transmit/receive coil at 7 T (Figures 2-4), there was no signifi cant 
diff erence in vessel length (7 T vs. 3 T navigator at heart; p=0.233, 7 T vs. 3 T navigator at liver: 
p=0.414) or vessel diameter (7 T vs. 3 T navigator at heart; p=0.653, 7 T vs. 3 T navigator at 
liver: p=0.567) measurements among the images from the diff erent fi eld strengths. Navigator 
effi  ciency (7 T vs. 3 T navigator at heart: p=0.970, 7 T vs. 3 T navigator at liver: p=0.272) and the 
total data acquisition time (7 T vs. 3 T navigator at heart: p=0.520, 7 T vs. 3 T navigator at liver: 
p=0.821) were also not fi eld strength dependent. 
No signifi cant diff erence in CNR between the blood-pool and epicardial fat, SNR of the blood-
pool, RCA vessel sharpness, vessel length, vessel diameter, navigator effi  ciency or acquisition 
time was found between the 3 T scans acquired with diff erent navigator localization.
DISCUSSION
In our study comparing 7 T and 3 T RCA coronary MRA in young healthy volunteers, we 
found an improved CNR between the blood-pool and the epicardial fat, enhanced SNR of 
Figure 4. The SN and a proximal branch of the RCA (image obtained in a double oblique volume targeted 
plane parallel to the right coronary artery) from a healthy 28 year old male subject is depicted. At 7 T (a), 
there is not much diff erence in signal between the blood pool (dot) and the myocardium (2 dots). At 3 T 
(b), this contrast is slightly improved. On the 3 T image, the GCV can easily be identifi ed but this structure 
is less visible on the 7 T counterpart likely due to shortened T2* at 7 T as well as limited surface coil RF 
penetration. The squared arrow points out a RCA side-branch.
Abbreviations; Ao: aortic root; GCV: great cardiac vein; RCA: right coronary artery; SN: sinoatrial nodal artery; RF: 
radiofrequency
133
7 Tesla versus 3 Tesla coronary MRA comparison
the blood-pool and increased vessel sharpness at 7 T. These fi ndings may have implications 
since vessel conspicuity and well-defi ned borders of the coronary arteries support improved 
identifi cation of signifi cant coronary artery stenoses.
Considering the results of a most recent multicenter study, multi detector computed 
tomography (CT) is highly promising and superior to MRA for the non-invasive evaluation of 
signifi cant proximal coronary stenoses (10). However, most recent data from a coronary MRA 
multicenter trial (11) demonstrate signifi cant progress, and with a further improvement in 
SNR diagnostic quality approaching that of CTA may soon be expected. Therefore, the devel-
opment of new MRI methodology at higher magnetic fi eld strength is of particular interest. 
Approximately a two-fold increase in SNR is predicted at 7 T when compared to 3 T (7,12) 
while a 60% SNR improvement was found in our study. This may be explained with the pro-
longed T1 at 7 T and the depth penetration of the RF transmit/receive coil, which was clearly 
inferior to that at 3 T. However, a signifi cant 60% increase in SNR with a simple coil design is 
encouraging and emphasizes the need for further developments in coil technology. Recent 
advances in RF transmit arrays (2,3) are a step in this direction. Previous studies comparing 
1.5 T and 3 T coronary MRA (13-15) clearly demonstrated that the expected 100% improve-
ment in SNR could not be obtained. At 7 T the lack of commercially available RF coils and 
the only recent availability of 7 T for whole body human use comprise additional 7 T specifi c 
limitations. Despite these limitations, the reported 60% improvement in SNR, when going 
from 3 T to 7 T, is consistent with that reported for direct 1.5 T vs. 3 T comparisons.
Our fi ndings of increased vessel sharpness at 7 T suggest that motion suppression works 
eff ectively at 7 T since vessel sharpness depends on the performance of ECG-triggering 
and the respiratory navigator. Two similar scans with diff erent navigator localizations were 
performed at 3 T to exclude the infl uence of navigator localization on the quantitative param-
eters related to image quality. Consistent with earlier fi ndings (16), no navigator-dependent 
quantitative diff erences were observed.  
The results from the RCA vessel length and diameter measurements were similar for both 
fi eld strengths. This suggests that coverage and RF penetration of the surface coil at 7 T may 
not be limiting factors for visualization of the RCA.
The situation for the left coronary system (LCS) is diff erent. On the one hand, the pen-
etration depth of the current transmit/receive coil is limited and therefore, parts of the LCS 
may not easily be visualized. On the other hand, an enhancement of the contrast between 
myocardium and the blood-pool is mandatory for the visualization of the LCS. At 3 T, such 
contrast enhancement has been obtained with adiabatic T2 preparation (T2Prep) (17) or by 
the combination of extracellular contrast agents and inversion-recovery (18). However, at 7 
T, SAR constraints preclude the use of T2Prep and alternative 7 T-specifi c solutions with or 
without contrast agents remain to be explored. Finally, and even though a 60% increase in 
SNR was obtained at 7 T, we have not used this gain for an increased spatial resolution. How-
ever, the objective of our work was a direct, quantitative and objective comparison with 3 T.
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In conclusion, while there are substantial challenges associated with 7 T cardiac MRI, a 
number of these have been successfully addressed. In our study directly comparing in vivo 
human imaging of the right coronary artery at 7 T and 3 T in young healthy volunteers, 
quantitative parameters related to image quality obtained at 7 T equal or surpass those from 
3 T. Our results clearly warrant further evaluation in patients with coronary artery disease to 
assess the potential of our 7 T approach for the visualization of luminal RCA disease. Future 
work will concentrate on refi nements in coil technology and contrast generation to support 
concomitant imaging of the left coronary system.
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The aim of this thesis was to evaluate MRI assessed end-organ damage, and the role of aortic 
pulse wave velocity in diabetes mellitus and hypertensive patients.
Increased aortic stiff ness is an important risk factor for adverse cardiovascular outcome in 
various disease states including diabetes mellitus and hypertension. Chapter 2 studies the 
independent and synergistic eff ect of type 1 diabetes mellitus and hypertension on MRI as-
sessed aortic pulse wave velocity, as a marker of aortic stiff ness. Aortic pulse wave velocity 
measurements were compared between 4 groups, all free from established cardiovascular 
disease and on treatment for diabetes (insulin use) respectively hypertension (antihyperten-
sive medication): 20 type 1 diabetes mellitus patients, 31 hypertensive patients, 28 patients 
with type 1 diabetes mellitus and hypertension, 32 healthy controls. This study revealed that 
the independent eff ect of type 1 diabetes mellitus on aortic stiff ness is minor, whereas hyper-
tension in itself or hypertension in type 1 diabetes mellitus patients is a major determinant 
of increased aortic stiff ness.
In chapter 3 the infl uence of aortic pulse wave velocity on cardiac and cerebral end-organ 
damage is evaluated in hypertensive patients using a comprehensive MRI protocol. Fifty 
patients with hypertension underwent MR examination to assess aortic arch pulse wave 
velocity, left ventricular (LV) mass, LV systolic and diastolic function, lacunar brain infarcts 
and cerebral white matter hyperintensities. Aortic arch PWV was associated with LV mass and 
the presence of lacunar brain infarcts, independent of age, gender and hypertension dura-
tion, and not with diastolic and systolic LV function and white matter hyperintensities. The 
associations between aortic stiff ness, LV mass and cerebral damage found in our study may 
be indirect through shared vascular risk factors or causative in nature due to aortic stiff ness, 
increasing cardiac afterload and transmission of high pulsatile fl ow to the brain.
In chapter 4 a similar MR evaluation of the eff ect of aortic pulse wave velocity on cardiac 
function and cerebral small vessel disease is assessed in eighty-six type 1 diabetes mellitus 
patients. Aortic PWV was associated with parameters of systolic LV function; LV ejection 
fraction, LV stroke volume, LV cardiac output, and with cerebral white matter hyperinten-
sities after correction for age, gender, mean arterial pressure, heart rate, body mass index, 
smoking, diabetes mellitus disease duration and the presence of hypertension. In contrast 
to the results in hypertensive patients in the before mentioned chapter 2, no independent 
association was found between aortic pulse wave velocity and LV mass, lacunar brain infarcts 
or cerebral microbleeds in type 1 diabetes mellitus patients. These study results suggest that 
aortic stiff ness is a marker or an independent risk factor for cardiac and cerebral end-organ 
damage, with diff erent eff ects in type 1 diabetes mellitus and hypertension.
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The study described in chapter 5 aimed to explore the eff ect of type 1 diabetes mellitus on 
aortic stiff ness, independent of the possible confounding eff ect of renal dysfunction that 
may aggravate reduction in vascular elasticity. Type 1 diabetes mellitus patients without mi-
croalbuminuria and with an estimated glomerular fi ltration rate > 60 ml/min/1.73m2 showed 
slight increased MRI assessed aortic pulse wave velocity compared to age and renal function 
matched healthy controls. Furthermore, this study showed an inverse relationship between 
aortic pulse wave velocity and estimated glomerular fi ltration rate in normal range in type 1 
diabetes mellitus patients as well as in healthy controls. Therefore, this study demonstrates 
interaction between aortic stiff ness and renal function which is apparently physiological to 
some extent, and provides additional insight into the potential mechanism of aortic stiff en-
ing in renal failure. Diabetic nephropathy is one of the major complications of type 1 diabetes 
mellitus. Gradual progressive aortic stiff ening, decreasing renal function and their interaction 
can accordingly be assumed in type 1 diabetes mellitus disease appearing before onset of 
clinically detectable renal failure.
In chapter 6 we evaluated vascular mechanisms of brain atrophy in type 1 diabetes mellitus 
patients by investigating the relationship between brain volumes and cerebral perfusion and 
aortic stiff ness using MRI. Type 1 diabetes mellitus patients with a mean diabetes disease 
duration of 23 years and without hypertension showed grey matter and white matter brain 
atrophy compared to age and gender matched healthy controls, with concomitant increased 
brain perfusion (expressed in ml/min/100ml brain tissue). Aortic pulse wave velocity was 
similar in type 1 diabetes mellitus and healthy controls. Total cerebral blood fl ow measured 
at the level of the internal carotid arteries and basilar artery and aortic pulse wave velocity 
both independently predicted white matter brain atrophy. The current fi ndings suggest two 
separate vascular mechanisms operating on white matter brain atrophy. Also, the results of 
this study imply increased susceptibility of the brain of type 1 diabetes mellitus patients for 
relative small changes in aortic pulse wave velocity, even when aortic pulse wave velocity 
appears to be normal.
Chapter 7 reports accelerated progression of brain atrophy with cognitive consequences 
in type 2 diabetes mellitus patients in a population of non-demented elderly subjects, aged 
70-82 years, with vascular disease or at increased vascular risk. Subjects were included for 
brain MRI scanning and cognitive function testing at baseline and re-examination after 
3-years. Changes in brain atrophy, white matter hyperintensities, number of infarctions and 
cognitive function test results were determined in diabetes mellitus and non-diabetes mel-
litus subjects. Diabetes mellitus patients showed increased progression of brain atrophy and 
increased decline in cognitive performance on selective attention and recent memory after 
follow-up compared to control subjects. Furthermore, in diabetes mellitus patients, brain 
atrophy at baseline was a predictor for a decline in recent memory. These fi ndings add fur-
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ther evidence to the hypothesis that diabetes mellitus exerts deleterious eff ects on neuronal 
integrity by showing that non-demented elderly diabetes mellitus patients have accelerated 
progression of brain atrophy with signifi cant consequences in cognition.
Chapter 8 evaluates the metabolic eff ect of diabetes mellitus on the skeletal muscle in 
patients carrying the mitochondrial Maternally Inherited Diabetes and Deafness (MIDD) 
mutation, present in approximately 1% of all diabetes mellitus patients, using the Phospho-
rus-31 MR spectroscopy technique. Phosphocreatine (PCr) and inorganic phosphate (Pi) were 
measured in the vastus medialis muscle immediately after exercise in 11 MIDD patients (six 
with diabetes mellitus and fi ve non-diabetes mellitus) and eight healthy controls similar 
in age, height, and body weight. Half-time of PCr recovery after exercise was prolonged in 
MIDD patients compared to controls. No association of the presence of diabetes mellitus 
was found with PCr recovery half-time. Thus, subclinical mitochondrial dysfunction of the 
skeletal muscle in MIDD patients is demonstrated without additional eff ect of the presence 
of diabetes mellitus.
New developments in high magnetic fi eld MRI, with the introduction of human 7 Tesla MRI 
scanners, potentially contribute to imaging of end-organ damage at early states of the dis-
ease. In the fi nal two chapters of this thesis, implementation of coronary magnetic resonance 
angiography (MRA) at high fi eld 7 Tesla MRI is described, relevant for studying coronary artery 
disease causing myocardial end-organ damage.
The use of higher magnetic fi eld strengths for coronary MRA is attractive, with advantages 
arising from increases in signal-to-noise ratio, smaller voxel sizes, a higher temporal reso-
lution, and/or shortened scanning times, likely to result in improved image quality for the 
noninvasive identifi cation of signifi cant proximal coronary artery disease. However, because 
of the large resonance frequency increase, the increase in magnetic fi eld strength produces 
a series of challenges. In chapter 9 we show feasibility of right coronary MRA at 7 Tesla by 
applying a home-built radiofrequency transmit and receive surface coil, vector electrocardi-
ography hardware, navigator adaptations, specifi cally designed scout scanning procedures, 
segmented k-space gradient echo imaging and adiabatic inversion of the magnetization for 
fat suppression. With this methodology, the fi rst human coronary MR images were success-
fully obtained at 7 Tesla.
Chapter 10 demonstrates a study comparing image quality of coronary MRA at 7 Tesla with 
lower fi eld strength 3 Tesla. Ten healthy volunteers underwent navigator-gated 3 dimensional 
MRA of the right coronary artery at 7 Tesla and 3 Tesla using comparable imaging protocols. 
We found an improved contrast-to-noise ratio between the blood-pool and the epicardial fat, 
enhanced signal-to-noise ratio of the blood-pool, and increased vessel sharpness at 7 Tesla. 
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These fi ndings may have important implications for the use of MRA images since vessel con-
spicuity and well-defi ned borders of the coronary arteries support improved identifi cation 
of signifi cant coronary artery stenoses. This study shows the benefi ts of imaging at higher 
magnetic fi eld strengths.
CONCLUSIONS
Our studies have shown MRI assessed aortic stiff ness to be an integrated marker of cardiac 
function, cerebral small vessel disease and atrophy, as well as of renal function in type 1 
diabetes mellitus patients. Aortic stiff ness already in normal range is related to end-organ 
damage in type 1 diabetes mellitus, suggesting increased organ-susceptibility for vascular 
alterations in diabetes mellitus. Structural changes in the brain as a manifestation of end-
organ damage has shown to be clinical relevant to elderly with diabetes mellitus predicting 
accelerated cognitive decline.
Hypertension is a major contributor to increased aortic stiff ness. There is a clear eff ect of 
aortic stiff ness on cardiac and cerebral end-organ damage in hypertensive patients, which is 
diff erent from type 1 diabetes mellitus.
The results of our cross-sectional studies suggest that MRI assessment of aortic pulse wave 
velocity could function as a marker or risk factor for generalized vascular disease and end-
organ damage that might potentially be treated. Our fi ndings may therefore have implica-
tions for cardiovascular risk stratifi cation and optimization of therapy in diabetes mellitus 
and hypertensive patients beyond classical risk factors.
Finally, this thesis describes the technical implementation and benefi ts of right coronary 
artery MRA at high fi eld 7 Tesla. This is a promising step towards improved MRI detection of 
coronary artery disease.





In dit proefschrift worden MRI technieken beschreven om eind-orgaan schade te bestuderen, 
en wordt de relatie tussen eind-orgaan schade en de polsgolfsnelheid van de aorta beschre-
ven bij patiënten met diabetes mellitus en hypertensie.
Verminderde elasticiteit van de aorta is een belangrijke risicofactor voor cardiovasculaire 
morbiditeit en mortaliteit bij verschillende ziekten zoals diabetes mellitus en hypertensie. 
Hoofdstuk 2 beschrijft het onafhankelijke en synergistische eff ect van type 1 diabetes mel-
litus en hypertensie op de met MRI gemeten polsgolfsnelheid van de aorta, als een maat 
voor aorta-elasticteit. De polsgolfsnelheid van de aorta werd vergeleken tussen 4 groepen: 
20 type 1 diabetes mellitus patiënten, 31 hypertensie patiënten, 28 patiënten met type 1 
diabetes mellitus èn hypertensie, en 32 gezonde controles. Andere cardiovasculaire ziekten 
in deze groepen werden uitgesloten en de patiënten werden adequaat behandeld voor 
respectievelijk diabetes (insuline gebruik) of hypertensie (bloeddrukverlagende medicatie). 
De resultaten van deze studie lieten zien dat het onafhankelijke eff ect van type 1 diabetes 
mellitus op een verminderde aorta-elasticiteit klein is. Hypertensie blijkt een belangrijke fac-
tor te zijn bij type 1 diabetes mellitus patiënten, hetgeen tot uiting komt in een verminderde 
aorta-elasticiteit.
In hoofdstuk 3 wordt door middel van MRI de relatie tussen polsgolfsnelheid van de aorta 
en cardiale en cerebrale eind-orgaan schade geëvalueerd bij hypertensie patiënten. Vijftig 
hypertensie patiënten ondergingen een MRI onderzoek voor het meten van de polsgolfsnel-
heid van de aortaboog, de cardiale linkerventrikel (LV) massa, de systolische en diastolische 
LV functie, lacunaire infarcten en wittestofafwijkingen in de hersenen. De polsgolfsnelheid 
van de aortaboog was geassocieerd met de LV massa en de aanwezigheid van lacunaire 
infarcten, onafhankelijk van leeftijd, geslacht en hypertensie ziekteduur. Er werden geen 
signifi cante associaties gevonden tussen polsgolfsnelheid van de aortaboog en systolische 
en diastolische LV functie of cerebrale wittestofafwijkingen. De aangetoonde relaties in deze 
studie tussen aorta-elasticiteit, LV massa en cerebrale schade zouden indirect het gevolg 
kunnen zijn van gedeelde vasculaire risicofactoren, of causaal doordat een verminderde 
aorta-elasticiteit de afterload van het LV verhoogt en een drukgolf zich met hoge snelheid en 
verminderde demping naar de hersenen voortplant.
In hoofdstuk 4 wordt een zelfde MRI protocol gebruikt om de relatie te bestuderen tus-
sen de polsgolfsnelheid van de aorta en cardiale en cerebrale eind-orgaan schade bij 86 
type 1 diabetes mellitus patiënten. Er werden signifi cante relaties gevonden tussen de 
aorta-polsgolfsnelheid, systolische LV parameters (LV ejectiefractie, LV slagvolume, LV cardiac 
output) en cerebrale wittestofafwijkingen, onafhankelijk van leeftijd, geslacht, gemiddelde 
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arteriële polsdruk, hartslag, body mass index, roken, diabetes ziekteduur en de aanwezigheid 
van hypertensie. In tegenstelling tot de hierbovengenoemde resultaten van hoofdstuk 2 bij 
hypertensie patiënten werden er bij type 1 diabetes mellitus patiënten geen signifi cante 
associaties gevonden tussen de aorta-polsgolfsnelheid en LV massa, cerebrale lacunaire 
infarcten of microbloedingen. De resultaten van deze studie suggereren dat aorta-elasticiteit 
een marker en/of een onafhankelijke risicofactor is voor cardiale en cerebrale eind-orgaan 
schade, met een verschillende werking bij type 1 diabetes mellitus en hypertensie.
Het doel van de studie beschreven in hoofdstuk 5 was om het eff ect van type 1 diabetes 
mellitus op aorta-elasticiteit te evalueren onafhankelijk van nierfalen dat op zichzelf kan 
bijdragen aan een verminderde vasculaire elasticiteit. Type 1 diabetes mellitus patiënten 
zonder de aanwezigheid van microalbuminurie en met een nierklaring (eGFR) > 60 ml/
min/1.73m2 lieten een licht verhoogde aorta-polsgolfsnelheid zien ten opzichte van op leef-
tijd en nierfunctie gematchte gezonde controles. Bovendien toonden we in deze studie aan 
dat er zowel bij type 1 diabetes mellitus patiënten als bij gezonde controles een omgekeerde 
relatie bestaat tussen de aorta-polsgolfsnelheid en de nierklaring (eGFR), in geval er sprake 
is van een normale nierfunctie bij zowel de patiënten als bij de vrijwilligers. Er is blijkbaar 
een fysiologische interactie tussen aorta-elasticiteit en de nierfunctie hetgeen kan bijdra-
gen aan het begrip van de pathofysiologie van verminderde aorta-elasticiteit bij nierfalen. 
Diabetische nefropathie is een van de meest voorkomende complicaties bij type 1 diabetes 
mellitus. Het is denkbaar dat bij type 1 diabetes mellitus de geleidelijke vermindering van 
aorta-elasticiteit, nierschade en de interactie tussen beide reeds plaats vindt vóór de klini-
sche manifestatie van nierfalen.
In hoofdstuk 6 worden vasculaire mechanismen van hersenatrofi e bij type 1 diabetes 
mellitus onderzocht. De relatie tussen hersenvolumina en cerebrale perfusie en aorta-
elasticiteit wordt in dit hoofdstuk nader bestudeerd. Type 1 diabetes mellitus patiënten met 
een gemiddelde diabetes ziekteduur van 23 jaar en zonder hypertensie vertoonden atrofi e 
van de grijze en witte stof en toegenomen cerebrale perfusie (uitgedrukt in ml/min/100ml 
hersenweefsel) in vergelijking met op leeftijd en geslacht gematchte gezonde controles. 
De aorta-polsgolfsnelheid was niet signifi cant verschillend tussen type 1 diabetes mellitus 
patiënten en gezonde controles. Onafhankelijke voorspellers voor hersenatrofi e van de witte 
stof waren zowel de cerebrale perfusie (gemeten door middel van fl ow metingen in de arte-
ria carotis interna beiderzijds en arteria basilaris), als de aorta-polsgolfsnelheid. De resultaten 
van deze studie geven aanwijzingen voor de aanwezigheid van twee verschillende vasculaire 
mechanismen voor hersenatrofi e bij type 1 diabetes mellitus. Mogelijk speelt hierin ook een 
rol dat er een verhoogde gevoeligheid van het hersenweefsel voor fysiologische waarden 
van de aorta-polsgolfsnelheid bestaat.
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Hoofdstuk 7 rapporteert een versnelde progressie van hersenatrofi e bij type 2 diabetes 
mellitus patiënten met cognitieve achteruitgang. Een niet-demente oudere populatie in de 
leeftijd tussen 70-82 jaar met manifestaties van vasculaire ziekte of een verhoogd vasculair 
risico werd onderzocht. De deelnemers aan deze studie ondergingen bij start van de studie 
en na een follow-up duur van 3 jaar een MRI scan van de hersenen en cognitieve functie-
testen. Er werden veranderingen vastgesteld in hersenatrofi e, wittestofafwijkingen, aantal 
infarcten en resultaten van de cognitieve functietest voor diabetes mellitus patiënten en 
voor deelnemers zonder diabetes mellitus (controles). De patiënten in de diabetes mellitus 
groep toonden versnelde progressie van hersenatrofi e en een versnelde achteruitgang in 
cognitie in het gebied van selectieve aandacht en korte termijn geheugen ten opzichte van 
controles. Bovendien was de mate van hersenatrofi e bij start van de studie een signifi cante 
voorspeller van verslechtering in korte termijn geheugen in de diabetes mellitus groep.
Hoofdstuk 8 evalueert door middel van de Phosphor-31 MR spectroscopie techniek het me-
tabole eff ect van diabetes mellitus op de skeletspier bij dragers van de mitochrondiale ‘Ma-
ternally Inherited Diabetes and Deafness’ (MIDD) mutatie. Een groep van 11 MIDD patiënten 
(waarvan 6 met diabetes mellitus, en 5 zonder diabetes mellitus) werd op leeftijd, lengte en 
lichaamsgewicht gematcht met een groep van 8 gezonde controles. Phosphocreatinine (PCr) 
en inorganisch phosphaat (Pi) werden direct na inspanning gemeten in de vastus medialis 
spier. De halfwaardetijd van PCr herstel na inspanning was toegenomen bij MIDD patiënten 
ten opzichte van controles. Er werd geen associatie gevonden met de aanwezigheid van 
diabetes mellitus en halfwaardetijd van PCr herstel. De aanwezigheid van subclinische mi-
tochondriale dysfunctie in de skeletspier werd aangetoond bij MIDD patiënten, zonder dat 
een additioneel eff ect werd gezien tengevolge van de aanwezigheid van diabetes mellitus.
Nieuwe ontwikkelingen in hoge veldsterkte MRI, door de introductie van de 7 Tesla MRI scan-
ners voor humane toepassingen, kunnen potentieel een bijdrage leveren aan het opsporen 
van eind-orgaan schade in een vroegtijdig stadium tijdens de manifestatie van de ziekte. 
De volgende twee hoofdstukken van dit proefschrift beschrijven de ontwikkelingen in mag-
netische resonantie angiografi e (MRA) van de coronairen met hoge veldsterkte 7 Tesla MRI, 
hetgeen van belang is bij de bestudering van coronairziekten als oorzaak van eind-orgaan 
schade in het myocard.
Het gebruik van een hoge magnetische veldsterkte biedt potentiële voordelen voor het 
afbeelden van de coronairen met behulp van MRA vanwege de mogelijke toename in 
signaal-ruis-verhouding, het gebruik van kleinere voxels, een hogere temporele resolutie en/
of kortere scantijden. Uiteindelijk kunnen deze verbeteringen bijdragen aan een verbeterde 
beeldkwaliteit voor het non-invasief identifi ceren van coronairziekten. De toename in mag-
netische veldsterkte gaat echter ook gepaard met technische uitdagingen. In hoofdstuk 9 
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beschrijven we de implementatie van MRA met 7 Tesla voor het afbeelden van de rechter 
coronair arterie door middel van de toepassing van in ons ziekenhuis ontwikkelde spoelen, 
vector electrocardiografi e hardware, aanpassingen in de navigator technologie, speciaal 
ontwikkelde scout procedures, gesegmenteerde k-space gradient echo imaging en adiaba-
tische inversie van de magnetisatie voor vet-suppressie. Door middel van deze ontwikkelde 
methodologie werden voor het eerst succesvol coronair MRA afbeeldingen met een 7 Tesla 
MRI verkregen bij gezonde vrijwilligers.
Hoofdstuk 10 beschrijft een studie waarin beeldkwaliteit van MRA van de rechter coronair 
arterie verkregen met 7 Tesla wordt vergeleken met 3 Tesla. Tien gezonde vrijwilligers onder-
gingen een 3D MRA van de rechter coronair arterie met 7 Tesla en met 3 Tesla gebruikmakend 
van vergelijkbare scan-protocollen. Met 7 Tesla werd een hogere contrast-ruis-verhouding 
tussen bloed en epicardiaal vet gemeten, een verhoogde signaal-ruis verhouding van bloed, 
en een scherpere defi nitie van het lumen van de rechter coronair arterie, ten opzichte van de 
3 Tesla afbeeldingen. Deze bevindingen hebben belangrijke implicaties voor het gebruik van 
MRA beelden omdat een verbeterde signaal intensiteit van bloed in de beelden van de coro-
nair arterie en een goede defi nitie van de vaatwand van belang zijn om vernauwingen in de 
coronair arterie nauwkeurig vast te kunnen stellen. De studie toont de potentiële voordelen 
van MRA technieken op hoge magnetische veldsterkte aan.
CONCLUSIES
De studies beschreven in dit proefschrift tonen aan dat met MRI gemeten aorta-elasticiteit 
een integrale marker is voor de hartfunctie, cerebrale ‘small vessel disease’ en atrofi e, als ook 
voor de nierfunctie bij type 1 diabetes mellitus patiënten. Schommelingen reeds binnen 
normale waarden van aorta-elasticteit zijn gerelateerd aan eind-orgaan schade bij type 1 
diabetes mellitus, wat een toegenomen gevoeligheid voor arteriële (hemodynamische) 
veranderingen suggereert van de eind-organen, zoals het hart, de hersenen en de nieren. 
Het proefschrift toont aan dat structurele veranderingen in de hersenen een signifi cante 
cognitieve verslechtering tot gevolg hebben bij oudere diabetes mellitus patiënten. 
Hypertensie is een belangrijke oorzaak van een verslechterde aorta-elasticiteit. Er is een 
duidelijk eff ect van verminderde aorta-elasticiteit op cardiale en cerebrale eind-orgaanscha-
de bij hypertensie patiënten.
De resultaten van onze observationele studies suggereren dat aorta-elasticiteit kan functio-
neren als marker en/of risicofactor voor algemene vasculaire ziekte en eind-orgaanschade. 
Onze bevindingen hebben potentieel implicaties voor de cardiovasculaire risico-screening 




Ten slotte behandelt dit proefschrift de voordelen en technische implementatie van MRA 
van de rechter coronair arterie met gebruikmaking van MRI bij een veldsterkte van 7 Tesla. De 
studies beschreven in het proefschrift leggen de grondslag voor een verbeterde diagnostiek 
van coronairziekten met MRI.
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